

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: February 24, 2005, 03:24:47 ; Search time 75 Seconds
(without alignments)
2171.015 Million cell updates/sec

Title: US-09-037-657-44

Perfect score: 2290
Sequence: 1.MPAGRRGPAQASARPPPLT.....NODEGILPSGRGTARGPAR 421

Scoring table: BLOSUM62
Gapop 10.0, Gapext 0.5

Searched: 2105692 seqs, 386760381 residues

Total number of hits satisfying chosen parameters: 2105692

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%

Listing first 45 summaries

Database :

1: A_Geneseq_16Dec04:*
2: geneseqp1980s:*
3: geneseqp1990s:*
4: geneseqp2000s:*
5: geneseqp2001s:*
6: geneseqp2002s:*
7: geneseqp2003as:*
8: geneseqp2003bs:*
9: geneseqp2004s:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	2290	100.0	421	4	AAE00826 Murine ha
2	2279.5	99.5	422	2	AAV05782 Human typ
3	2279.5	99.5	422	2	AAV06479 Human tum
4	2279.5	99.5	422	2	AAV17825 Human PRO
5	2279.5	99.5	422	2	AAV26339 Human U4
6	2279.5	99.5	422	3	AAV26339 Human PRO
7	2279.5	99.5	422	3	AAV26339 Human PRO
8	2279.5	99.5	422	3	AAV26339 Human PRO
9	2279.5	99.5	422	3	AAV26339 Human PRO
10	2279.5	99.5	422	3	AAV26339 Human PRO
11	2279.5	99.5	422	3	AAV26339 Human PRO
12	2279.5	99.5	422	3	AAV26339 Human PRO
13	2279.5	99.5	422	3	AAV26339 Human PRO
14	2279.5	99.5	422	3	AAV26339 Human PRO
15	2279.5	99.5	422	3	AAV26339 Human PRO
16	2279.5	99.5	422	3	AAV26339 Human PRO
17	2279.5	99.5	422	3	AAV26339 Human PRO
18	2279.5	99.5	422	3	AAV26339 Human PRO
19	2279.5	99.5	422	3	AAV26339 Human PRO
20	2279.5	99.5	422	3	AAV26339 Human PRO
21	2279.5	99.5	422	3	AAV26339 Human PRO
22	2279.5	99.5	422	3	AAV26339 Human PRO
23	2279.5	99.5	422	3	AAV26339 Human PRO
24	2279.5	99.5	422	3	AAV26339 Human PRO
25	2279.5	99.5	422	3	AAV26339 Human PRO

26	2279.5	99.5	422	8	ADN04232
27	2279.5	99.5	422	8	ADN00411
28	2279.5	99.5	422	8	ADN08851
29	2279.5	99.5	422	2	AAV70860
30	2208.5	96.4	408	2	AAV59805
31	2208.5	96.4	408	2	AAV59805
32	2208.5	96.4	408	2	AAV59805
33	2196	95.9	425	2	AAV70861
34	2188	95.5	410	2	AAV29779
35	2188	95.5	410	3	AAV19588
36	2188	95.5	410	4	AAV36647
37	2188	95.5	410	7	ADN07179
38	2188	95.5	410	8	ADN0844
39	2188	95.5	410	8	ADN0844
40	2188	95.5	457	8	ADN0844
41	2185.5	95.4	426	2	AAV28281
42	2185.5	95.4	445	4	AAV63544
43	2178	95.1	425	3	AAV55012
44	2178	95.1	425	3	AAV3659
45	2178	95.1	425	4	AAV00821

ALIGNMENTS

RESULT 1
AAE00826 standard; protein, 421 AA.
ID AAE00826;
AC AAE00826;
AD AAE00826;
AE AAE00826;
AF AAE00826;
AG AAE00826;
AH AAE00826;
AI AAE00826;
AJ AAE00826;
AK AAE00826;
AL AAE00826;
AM AAE00826;
AN AAE00826;
AO AAE00826;
AP AAE00826;
AQ AAE00826;
AR AAE00826;
AS AAE00826;
AT AAE00826;
AU AAE00826;
AV AAE00826;
AW AAE00826;
AX AAE00826;
AY AAE00826;
AZ AAE00826;
BA AAE00826;
BB AAE00826;
BC AAE00826;
BD AAE00826;
BE AAE00826;
BF AAE00826;
BG AAE00826;
BH AAE00826;
BI AAE00826;
BJ AAE00826;
BK AAE00826;
BL AAE00826;
BM AAE00826;
BN AAE00826;
BO AAE00826;
BP AAE00826;
BQ AAE00826;
BR AAE00826;
BS AAE00826;
BT AAE00826;
BU AAE00826;
BV AAE00826;
BW AAE00826;
BX AAE00826;
BY AAE00826;
BZ AAE00826;
CA AAE00826;
CB AAE00826;
CC AAE00826;
CD AAE00826;
CE AAE00826;
CF AAE00826;
CG AAE00826;
CH AAE00826;
CI AAE00826;
CJ AAE00826;
CK AAE00826;
CL AAE00826;
CM AAE00826;
CN AAE00826;
CO AAE00826;
CP AAE00826;
CQ AAE00826;
CR AAE00826;
CS AAE00826;
CT AAE00826;
CU AAE00826;
CV AAE00826;
CW AAE00826;
CX AAE00826;
CY AAE00826;
CZ AAE00826;
DA AAE00826;
DB AAE00826;
DC AAE00826;
DD AAE00826;
DE AAE00826;
DF AAE00826;
DG AAE00826;
DH AAE00826;
DI AAE00826;
DJ AAE00826;
DK AAE00826;
DL AAE00826;
DM AAE00826;
DN AAE00826;
DO AAE00826;
DP AAE00826;
DQ AAE00826;
DR AAE00826;
DS AAE00826;
DT AAE00826;
DU AAE00826;
DV AAE00826;
DW AAE00826;
DX AAE00826;
DY AAE00826;
DZ AAE00826;
EA AAE00826;
EB AAE00826;
EC AAE00826;
ED AAE00826;
EE AAE00826;
EF AAE00826;
EG AAE00826;
EH AAE00826;
EI AAE00826;
EJ AAE00826;
EK AAE00826;
EL AAE00826;
EM AAE00826;
EN AAE00826;
EO AAE00826;
EP AAE00826;
EQ AAE00826;
ER AAE00826;
ES AAE00826;
ET AAE00826;
EU AAE00826;
EV AAE00826;
EW AAE00826;
EX AAE00826;
EY AAE00826;
EZ AAE00826;
FA AAE00826;
FB AAE00826;
FC AAE00826;
FD AAE00826;
FE AAE00826;
FF AAE00826;
FG AAE00826;
FH AAE00826;
FI AAE00826;
FJ AAE00826;
FK AAE00826;
FL AAE00826;
FM AAE00826;
FO AAE00826;
FP AAE00826;
FQ AAE00826;
FR AAE00826;
FS AAE00826;
FT AAE00826;
FU AAE00826;
FV AAE00826;
FW AAE00826;
FX AAE00826;
FY AAE00826;
FZ AAE00826;
GA AAE00826;
GB AAE00826;
GC AAE00826;
GD AAE00826;
GE AAE00826;
GF AAE00826;
GG AAE00826;
GH AAE00826;
GI AAE00826;
GJ AAE00826;
GK AAE00826;
GL AAE00826;
GM AAE00826;
GN AAE00826;
GO AAE00826;
GP AAE00826;
GQ AAE00826;
GR AAE00826;
GS AAE00826;
GT AAE00826;
GU AAE00826;
GV AAE00826;
GW AAE00826;
GX AAE00826;
GY AAE00826;
GZ AAE00826;
HA AAE00826;
HB AAE00826;
HC AAE00826;
HD AAE00826;
HE AAE00826;
HF AAE00826;
HG AAE00826;
HH AAE00826;
HI AAE00826;
HJ AAE00826;
HK AAE00826;
HL AAE00826;
HM AAE00826;
HN AAE00826;
HO AAE00826;
HP AAE00826;
HQ AAE00826;
HR AAE00826;
HS AAE00826;
HT AAE00826;
HU AAE00826;
HV AAE00826;
HW AAE00826;
HX AAE00826;
HY AAE00826;
HZ AAE00826;
IA AAE00826;
IB AAE00826;
IC AAE00826;
ID AAE00826;
IE AAE00826;
IF AAE00826;
IG AAE00826;
IH AAE00826;
II AAE00826;
IJ AAE00826;
IK AAE00826;
IL AAE00826;
IM AAE00826;
IN AAE00826;
IO AAE00826;
IP AAE00826;
IQ AAE00826;
IR AAE00826;
IS AAE00826;
IT AAE00826;
IU AAE00826;
IV AAE00826;
IW AAE00826;
IX AAE00826;
IY AAE00826;
IZ AAE00826;
JA AAE00826;
JB AAE00826;
JC AAE00826;
JD AAE00826;
JE AAE00826;
JF AAE00826;
JG AAE00826;
JH AAE00826;
JI AAE00826;
JJ AAE00826;
JK AAE00826;
JL AAE00826;
JM AAE00826;
JN AAE00826;
JO AAE00826;
JP AAE00826;
JQ AAE00826;
JR AAE00826;
JS AAE00826;
JT AAE00826;
JU AAE00826;
JV AAE00826;
JW AAE00826;
JX AAE00826;
JY AAE00826;
JZ AAE00826;
KA AAE00826;
KB AAE00826;
KC AAE00826;
KD AAE00826;
KE AAE00826;
KF AAE00826;
KG AAE00826;
KH AAE00826;
KI AAE00826;
KJ AAE00826;
KK AAE00826;
KL AAE00826;
KM AAE00826;
KN AAE00826;
KO AAE00826;
KP AAE00826;
KQ AAE00826;
KR AAE00826;
KS AAE00826;
KT AAE00826;
KU AAE00826;
KV AAE00826;
KW AAE00826;
KX AAE00826;
KY AAE00826;
KZ AAE00826;
LA AAE00826;
LB AAE00826;
LC AAE00826;
LD AAE00826;
LE AAE00826;
LF AAE00826;
LG AAE00826;
LH AAE00826;
LI AAE00826;
LJ AAE00826;
LK AAE00826;
LM AAE00826;
LN AAE00826;
LO AAE00826;
LP AAE00826;
LQ AAE00826;
LR AAE00826;
LS AAE00826;
LT AAE00826;
LU AAE00826;
LV AAE00826;
LW AAE00826;
LX AAE00826;
LY AAE00826;
LZ AAE00826;
MA AAE00826;
MB AAE00826;
MC AAE00826;
MD AAE00826;
ME AAE00826;
MF AAE00826;
MG AAE00826;
MH AAE00826;
MI AAE00826;
MJ AAE00826;
MK AAE00826;
ML AAE00826;
MN AAE00826;
MO AAE00826;
MP AAE00826;
MQ AAE00826;
MR AAE00826;
MS AAE00826;
MT AAE00826;
MU AAE00826;
MV AAE00826;
MW AAE00826;
MX AAE00826;
MY AAE00826;
MZ AAE00826;
NA AAE00826;
NB AAE00826;
NC AAE00826;
ND AAE00826;
NE AAE00826;
NF AAE00826;
NG AAE00826;
NH AAE00826;
NI AAE00826;
NJ AAE00826;
NK AAE00826;
NL AAE00826;
NM AAE00826;
NO AAE00826;
NP AAE00826;
NQ AAE00826;
NR AAE00826;
NS AAE00826;
NT AAE00826;
NU AAE00826;
NV AAE00826;
NW AAE00826;
NX AAE00826;
NY AAE00826;
NZ AAE00826;
OA AAE00826;
OB AAE00826;
OC AAE00826;
OD AAE00826;
OE AAE00826;
OF AAE00826;
OG AAE00826;
OH AAE00826;
OI AAE00826;
OJ AAE00826;
OK AAE00826;
OL AAE00826;
OM AAE00826;
ON AAE00826;
OO AAE00826;
OP AAE00826;
OQ AAE00826;
OR AAE00826;
OS AAE00826;
OT AAE00826;
OU AAE00826;
OV AAE00826;
OW AAE00826;
OX AAE00826;
OY AAE00826;
OZ AAE00826;
PA AAE00826;
PB AAE00826;
PC AAE00826;
PD AAE00826;
PE AAE00826;
PF AAE00826;
PG AAE00826;
PH AAE00826;
PI AAE00826;
PJ AAE00826;
PK AAE00826;
PL AAE00826;
PM AAE00826;
PN AAE00826;
PO AAE00826;
PP AAE00826;
PQ AAE00826;
PR AAE00826;
PS AAE00826;
PT AAE00826;
PU AAE00826;
PV AAE00826;
PW AAE00826;
PX AAE00826;
PY AAE00826;
PZ AAE00826;
QA AAE00826;
QB AAE00826;
QC AAE00826;
QD AAE00826;
QE AAE00826;
QF AAE00826;
QG AAE00826;
QH AAE00826;
QI AAE00826;
QJ AAE00826;
QK AAE00826;
QL AAE00826;
QM AAE00826;
QN AAE00826;
QO AAE00826;
QP AAE00826;
QQ AAE00826;
QR AAE00826;
QS AAE00826;
QT AAE00826;
QU AAE00826;
QV AAE00826;
QW AAE00826;
QX AAE00826;
QY AAE00826;
QZ AAE00826;
RA AAE00826;
RB AAE00826;
RC AAE00826;
RD AAE00826;
RE AAE00826;
RF AAE00826;
RG AAE00826;
RH AAE00826;
RI AAE00826;
RJ AAE00826;
RK AAE00826;
RL AAE00826;
RM AAE00826;
RN AAE00826;
RO AAE00826;
RP AAE00826;
RQ AAE00826;
RR AAE00826;
RS AAE00826;
RT AAE00826;
RU AAE00826;
RV AAE00826;
RW AAE00826;
RX AAE00826;
RY AAE00826;
RZ AAE00826;
SA AAE00826;
SB AAE00826;
SC AAE00826;
SD AAE00826;
SE AAE00826;
SF AAE00826;
SG AAE00826;
SH AAE00826;
SI AAE00826;
SJ AAE00826;
SK AAE00826;
SL AAE00826;
SM AAE00826;
SN AAE00826;
SO AAE00826;
SP AAE00826;
SQ AAE00826;
SR AAE00826;
SS AAE00826;
ST AAE00826;
SU AAE00826;
SV AAE00826;
SW AAE00826;
SX AAE00826;
SY AAE00826;
SZ AAE00826;
TA AAE00826;
TB AAE00826;
TC AAE00826;
TD AAE00826;
TE AAE00826;
TF AAE00826;
TG AAE00826;
TH AAE00826;
TI AAE00826;
TJ AAE00826;
TK AAE00826;
TL AAE00826;
TM AAE00826;
TN AAE00826;
TO AAE00826;
TP AAE00826;
TQ AAE00826;
TR AAE00826;
TS AAE00826;
TU AAE00826;
TV AAE00826;
TW AAE00826;
TX AAE00826;
TY AAE00826;
TZ AAE00826;
UA AAE00826;
UB AAE00826;
UC AAE00826;
UD AAE00826;
UE AAE00826;
UF AAE00826;
UG AAE00826;
UH AAE00826;
UI AAE00826;
UJ AAE00826;
UK AAE00826;
UL AAE00826;
UM AAE00826;
UN AAE00826;
UO AAE00826;
UP AAE00826;
UQ AAE00826;
UR AAE00826;
US AAE00826;
UT AAE00826;
UU AAE00826;
UV AAE00826;
UW AAE00826;
UX AAE00826;
UY AAE00826;
UZ AAE00826;
VA AAE00826;
VB AAE00826;
VC AAE00826;
VD AAE00826;
VE AAE00826;
VF AAE00826;
VG AAE00826;
VH AAE00826;
VI AAE00826;
VJ AAE00826;
VK AAE00826;
VL AAE00826;
VM AAE00826;
VN AAE00826;
VO AAE00826;
VP AAE00826;
VQ AAE00826;
VR AAE00826;
VS AAE00826;
VT AAE00826;
VU AAE00826;
VV AAE00826;
VW AAE00826;
VX AAE00826;
VY AAE00826;
VZ AAE00826;
WA AAE00826;
WB AAE00826;
WC AAE00826;
WD AAE00826;
WE AAE00826;
WF AAE00826;
WG AAE00826;
WH AAE00826;
WI AAE00826;
WJ AAE00826;
WK AAE00826;
WL AAE00826;
WM AAE00826;
WN AAE00826;
WO AAE00826;
WP AAE00826;
WQ AAE00826;
WR AAE00826;
WS AAE00826;
WT AAE00826;
WU AAE00826;
WV AAE00826;
WW AAE00826;
WX AAE00826;
WY AAE00826;
WZ AAE00826;
XA AAE00826;
XB AAE00826;
XC AAE00826;
XD AAE00826;
XE AAE00826;
XF AAE00826;
XG AAE00826;
XH AAE00826;
XI AAE00826;
XJ AAE00826;
XK AAE00826;
XL AAE00826;
XM AAE00826;
XN AAE00826;
XO AAE00826;
XP AAE00826;
XQ AAE00826;
XR AAE00826;
XS AAE00826;
XT AAE00826;
XU AAE00826;
XV AAE00826;
XW AAE00826;
XX AAE00826;
XY AAE00826;
XZ AAE00826;
YA AAE00826;
YB AAE00826;
YC AAE00826;
YD AAE00826;
YE AAE00826;
YF AAE00826;
YG AAE00826;
YH AAE00826;
YI AAE00826;
YJ AAE00826;
YK AAE00826;
YL AAE00826;
YM AAE00826;
YN AAE00826;
YO AAE00826;
YP AAE00826;
YQ AAE00826;
YR AAE00826;
YS AAE00826;
YT AAE00826;
YU AAE00826;
YV AAE00826;
YW AAE00826;
YX AAE00826;
YY AAE00826;
YZ AAE00826;
ZA AAE00826;
ZB AAE00826;
ZC AAE00826;
ZD AAE00826;
ZE AAE00826;
ZF AAE00826;
ZG AAE00826;
ZH AAE00826;
ZI AAE00826;
ZJ AAE00826;
ZK AAE00826;
ZL AAE00826;
ZM AAE00826;
ZN AAE00826;
ZO AAE00826;
ZP AAE00826;
ZQ AAE00826;
ZR AAE00826;
ZS AAE00826;
ZT AAE00826;
ZU AAE00826;
ZV AAE00826;
ZW AAE00826;
ZX AAE00826;
ZY AAE00826;
ZZ AAE00826;

```
CC Revised record issued on 09-SEP-2004 : Correction to Organism field
XX Sequence 421 AA:
SQ Query Match 100.0%; Score 2290; DB 4; Length 421;
Best Local Similarity 100.0%; Pred. No. 4,4e-185;
Matches 421; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MPAGRGPAAGSARPPPLP-LTLLCVLGAPRAGSGAHTAVISPDPPTLLIGSSLLATCS 60
DB 1 MPAGRGPAAGSARPPPLP-LTLLCVLGAPRAGSGAHTAVISPDPPTLLIGSSLLATCS 60
QY 61 VHGDPGATAGLTYWTNGRRLPELSRVYLNASTLALANLNGSRSGDNLYCHARDG 120
DB 61 VHGDPGATAGLTYWTNGRRLPELSRVYLNASTLALANLNGSRSGDNLYCHARDG 120
QY 121 SIILAGSCLYVGLPEPEKPVNISCSKMKDILTCRWTPGAHGETFLHTNYSILKYLKRWYGO 180
DB 121 SIILAGSCLYVGLPEPEKPVNISCSKMKDILTCRWTPGAHGETFLHTNYSILKYLKRWYGO 180
QY 181 NTCEBYHTVGPBHSCHIPKDLALFTPYEITWEATNRLGSARSDVLTLDILDVYTTDPPDY 240
DB 181 NTCEBYHTVGPBHSCHIPKDLALFTPYEITWEATNRLGSARSDVLTLDILDVYTTDPPDY 240
QY 241 HVSHVGLIEDQLSVRWVSPALKDPLFOAKYQIRYVEDSDVKVYDDVSNQTSCLAGL 300
DB 241 HVSHVGLIEDQLSVRWVSPALKDPLFOAKYQIRYVEDSDVKVYDDVSNQTSCLAGL 300
QY 301 KPGTVYVYQVRCNPFGIYSGSKAGIWESEHPTAASPRSERPGGACPRGGEPSSG 360
DB 301 KPGTVYVYQVRCNPFGIYSGSKAGIWESEHPTAASPRSERPGGACPRGGEPSSG 360
QY 361 PVRRRLKQFLGWLKHAHCNSLSPFLYDQWRAMWQSKHKTNRNDEGLIPSGRGRTAGPA 420
DB 361 PVRRRLKQFLGWLKHAHCNSLSPFLYDQWRAMWQSKHKTNRNDEGLIPSGRGRTAGPA 420
QY 421 R 421
DB 421 R 421

RESULT 2
ID AAY05782 standard; protein; 422 AA.
XX AC AAY05782;
XX DT 02-AUG-1999 (first entry)
XX DE Human type 1 cytokine receptor GBRI-ILR.
XX KW GBRI-ILR; hGBR-ILR; cytokine receptor; human; cancer; obesity;
XX inflammation; septic shock; AIDS; embryo development; lung infection;
XX cytoskeletal; anorectic; immunosuppressive; antibacterial; antiviral;
XX antiinflammatory; therapy.
XX OS Homo sapiens.
XX FH Key 1.37 Location/Qualifiers
XX FT Peptide /note="signal peptide"
XX FT Protein /note="mature protein; a polypeptide comprising amino
FT acids 38-422 is also claimed in Claim 1a"
XX PN MO9920755-A2.
XX PD 29-APR-1999.
XX PF 14-OCT-1998; 98WO-EP006497.
XX PR 16-OCT-1997; 97GB-00021961.
```

```
XX (GLAXO ) GLAXO GROUP LTD.
PA Elson G, Gauchat J, Kosco-Vilbois M;
XX WPI; 1999-288305/24.
XX DR N-PSDB; AAX25489.
XX PT Novel human or mouse type I cytokine receptors hGBRI-ILR or mGBRI-ILR,
XX useful for treating e.g. cancer, immune disorders, obesity and AIDS.
XX PS Claim 1a; Fig 4; 41pp; English.
XX CC The present sequence represents a novel type 1 cytokine receptor that has
XX been termed human GBRI-ILR as it is believed to be an interleukin
XX receptor, or at least a substantial part of such a receptor. The sequence
XX is predicted from an isolated full-length cDNA clone (see AAX25489)
XX obtained from a human placental cDNA library. GBRI-ILR mRNA is expressed
XX most strongly in spleen, thymus, lymph node, appendix, bone marrow,
XX thymoid, adrenal cortex, stomach, heart, placenta and skeletal muscle,
XX suggesting a role for GBRI-ILR in the immune system. In human foetal
XX tissue, strong expression is seen in the lung, but not in brain, kidney
XX or liver. A GBRI-ILR receptor has also been identified in mice (see
XX AAY05783). The high degree of conservation of amino acids between the
XX human and murine polypeptides indicates that this receptor is
XX functionally important. GBRI-ILR polypeptides, nucleic acids, antibodies,
XX agonists and antagonists can be used to treat e.g. cancer, immune
XX disorders, obesity (in view of homology to the leptin receptor),
XX embryonic developmental disorders, AIDS, septic shock and lung infection
XX (claimed)
SQ Sequence 422 AA;
```

```
Query Match 99.5%; Score 2279.5; DB 2; Length 422;
Best Local Similarity 99.8%; Pred. No. 3,4e-184;
Matches 421; Conservative 0; Mismatches 0; Indels 1; Gaps 1;

QY 1 MPAGRGPAAGSARPPPLP-LTLLCVLGAPRAGSGAHTAVISPDPPTLLIGSSLLATC 59
DB 1 MPAGRGPAAGSARPPPLP-LTLLCVLGAPRAGSGAHTAVISPDPPTLLIGSSLLATC 60
QY 60 VHGDPGATAGLTYWTNGRRLPELSRVYLNASTLALANLNGSRSGDNLYCHARD 119
DB 61 VHGDPGATAGLTYWTNGRRLPELSRVYLNASTLALANLNGSRSGDNLYCHARD 120
QY 120 GSILAGSCLYVGLPEPEKPVNISCSKMKDILTCRWTPGAHGETFLHTNYSILKYLKRWYGO 179
DB 121 GSILAGSCLYVGLPEPEKPVNISCSKMKDILTCRWTPGAHGETFLHTNYSILKYLKRWYGO 180
QY 180 DNTCEBYHTVGPBHSCHIPKDLALFTPYEITWEATNRLGSARSDVLTLDILDVYTTDPPDY 239
DB 181 DNTCEBYHTVGPBHSCHIPKDLALFTPYEITWEATNRLGSARSDVLTLDILDVYTTDPPDY 240
QY 240 VHSRVGGLIEDQLSVRWVSPALKDPLFOAKYQIRYVEDSDVKVYDDVSNQTSCLAG 299
DB 241 VHSRVGGLIEDQLSVRWVSPALKDPLFOAKYQIRYVEDSDVKVYDDVSNQTSCLAG 300
QY 300 LKPGTVYVYQVRCNPFGIYSGSKAGIWESEHPTAASPRSERPGGACPRGGEPSSG 359
DB 301 LKPGTVYVYQVRCNPFGIYSGSKAGIWESEHPTAASPRSERPGGACPRGGEPSSG 360
QY 360 GPVRRRLKQFLGWLKHAHCNSLSPFLYDQWRAMWQSKHKTNRNDEGLIPSGRGRTAGPA 419
DB 361 GPVRRRLKQFLGWLKHAHCNSLSPFLYDQWRAMWQSKHKTNRNDEGLIPSGRGRTAGPA 420
QY 420 AR 421
DB 421 AR 422

RESULT 3
ID AAY06479 standard; protein; 422 AA.
```

```

XX AC AAY06479;
XX AC 27-SEP-1999 (first entry)
XX DT Human tumour-associated protein PRO327.
XX DE PRO327; UNQ288; cancer; tumour; diagnosis; therapy; human.
XX KM Homo sapiens.
XX OS MO9935170-A4.
XX PN 15-JUL-1999.
XX PD 05-JAN-1999; 99MO-US000106.
XX PF 05-JAN-1998/ 98US-0070440P.
XX PR 29-APR-1998/ 98US-0083500P.
XX PR 22-MAY-1998/ 98US-0086414P.
XX PR 10-JUN-1998/ 98US-0088742P.
XX PR 10-NOV-1998/ 98US-0107783P.
XX PR 20-NOV-1998/ 98US-0109304P.
XX PA (GETH ) GENENTECH INC.
XX PI Botstein D, Goddard A, Gurney AL, Hillan KJ, Lawrence DA, Roy MA;
XX PI Wood WI;
XX DR MPI; 1999-430385/36.
XX DR N-PSDB; AAX87256.
XX PT Antibody against proteins expressed in neoplastic cells, useful for tumor
XX PT diagnosis and treatment.
XX PS Example 1; Fig 6; 162pp; English.
XX PS This sequence represents human PRO327 (UNQ288), a 46.3 kDa protein (pI
XX CC 9.42) encoded by the novel cDNA clone DNA38113 (see AAX87256).
XX CC Amplification of DNA38113 occurs in various lung and colon tumours and
XX CC cell lines, suggesting a significant role in tumour formation and growth.
XX CC Antagonists (e.g. antibodies) directed against PRO327 are expected to
XX CC have utility in cancer therapy. The invention identifies 14 genes (see
XX CC AAX87254-67) that are amplified in the genome of tumour cells. Such
XX CC amplification is expected to be associated with overexpression of the
XX CC gene product and to contribute to tumorigenesis. The encoded proteins
XX CC (see AAY06477-90) may be useful targets for the diagnosis and/or
XX CC treatment (including prevention) of certain cancers, and may act as
XX CC predictors of the prognosis of tumour treatment. Antibodies that bind the
XX CC proteins are claimed and used in claimed cancer diagnostic kits
XX SO Sequence 422 AA;

Query Match          99.5%; Score 2279.5; DB 2; Length 422;
Best Local Similarity 99.8%; Pred. No. 3,4e-184;
Matches 421; Conservative 0; Mismatches 0; Indels 1; Gaps 1;

```

```

QY 1 MPAGRRGPAQAQARRPPPLP-LLLLCVLAGAPAGSAGHTAVTSPQDPILLIGSSILATC 59
DB 1 MPAGRRGPAQAQARRPPPLP-LLLLCVLAGAPAGSAGHTAVTSPQDPILLIGSSILATC 60
QY 60 SVHGDPPGATAEGLVMTLNRRRLPPELSRTIANSTLALANLNGSRQSGDNLVCHARD 119
DB 61 SVHGDPPGATAEGLVMTLNRRRLPPELSRTIANSTLALANLNGSRQSGDNLVCHARD 120
QY 120 GSILASCLVYGLPPEKPVNISCSKMKDLCRTWTPGAGETFLHTNYSLKYLAWYQ 179
DB 121 GSILASCLVYGLPPEKPVNISCSKMKDLCRTWTPGAGETFLHTNYSLKYLAWYQ 180
QY 180 DNTCEHYHTVGPISHCHIKDIALFTPEYIWEATNRLGARSVDLTLDLIVVTTDPPD 239
DB 181 DNTCEHYHTVGPISHCHIKDIALFTPEYIWEATNRLGARSVDLTLDLIVVTTDPPD 240

QY 240 VHSRVGLEDQSLVHSPSPALKDFLFOAKYQIRRVEDSVDMKYVDVSNQTSCLAG 299
DB 241 VHSRVGLEDQSLVHSPSPALKDFLFOAKYQIRRVEDSVDMKYVDVSNQTSCLAG 300
QY 300 LKPGTYVYVQVRCNPFGIYGSKKAGIWESEWHPSTAATSPRSEPPGCGACEPRGEPSS 359
DB 301 LKPGTYVYVQVRCNPFGIYGSKKAGIWESEWHPSTAATSPRSEPPGCGACEPRGEPSS 360
QY 360 GPVRRRLKQFLGMLKKHAYCSNLSFRLYDQWRAMQKSHKTRNODGILPSGRGRTARGP 419
DB 361 GPVRRRLKQFLGMLKKHAYCSNLSFRLYDQWRAMQKSHKTRNODGILPSGRGRTARGP 420
QY 420 AR 421
DB 421 AR 422

RESULT 4
AAY17825
ID AAY17825 standard; protein; 422 AA.
AC AAY17825;
XX 12-AUG-1999 (first entry)
XX DT Human PRO327 protein sequence.
XX DE Human; PRO protein; tumour necrosis factor family; TNF; cytokine;
XX KM secreted protein; transmembrane protein; inflammation disorder.
XX OS Homo sapiens.
XX PN MO9928462-A2.
XX PD 10-JUN-1999.
XX PF 01-DEC-1998; 98MO-US025108.
XX PR 03-DEC-1997; 97US-0067411P.
XX PR 11-DEC-1997; 97US-0069278P.
XX PR 11-DEC-1997; 97US-0069334P.
XX PR 12-DEC-1997; 97US-0069425P.
XX PR 16-DEC-1997; 97US-0069594P.
XX PR 16-DEC-1997; 97US-0069596P.
XX PR 16-DEC-1997; 97US-0069702P.
XX PR 17-DEC-1997; 97US-0069870P.
XX PR 17-DEC-1997; 97US-0069873P.
XX PR 18-DEC-1997; 97US-0068017P.
XX PR 05-JAN-1998; 98US-0070440P.
XX PR 09-FEB-1998; 98US-0074086P.
XX PR 09-FEB-1998; 98US-0074092P.
XX PR 25-FEB-1998; 98US-0075945P.
XX PA (GETH ) GENENTECH INC.
XX PI Wood WI, Goddard A, Gurney AL, Yuan J, Baker KP, Chen J;
XX DR MPI; 1999-371118/31.
XX DR N-PSDB; AAX80050.
XX PT Nucleic acids encoding PRO secreted and transmembrane proteins.
XX PS Claim 12; Fig 17; 123pp; English.
XX CC The present invention describes nucleic acids encoding PRO secreted and
XX CC transmembrane proteins used therapeutically. The PRO proteins have
XX CC cytostatic, anti-inflammatory, anti-proliferative and immunosuppressive
XX CC activity. The proteins and polynucleotides can be used in therapy,
XX CC identification of homologues, raising antibodies and design of probes and
XX CC primers. They can be used in a range of diseases related to proteins that
XX CC they have homology with, e.g. a PRO protein having homology to complement
XX CC proteins may be used in inflammatory responses

```

```
XX Sequence 422 AA:
SQ Query Match 99.5%; Score 2279.5; DB 2; Length 422;
Best Local Similarity 99.8%; Pred. No. 3.4e-184;
Matches 421; Conservative 0; Mismatches 0; Indels 1; Gaps 1;

QY 1 MPAGRRGPAAGARRPPPLP-LLLLCYLGAPRAGSGAHTAVISPODPTLLIGSSILATC 59
DB 1 MPAGRRGPAAGARRPPPLP-LLLLCYLGAPRAGSGAHTAVISPODPTLLIGSSILATC 60
QY 60 SVHGDPPGATABGLWYTLNGRRLPELSRVLNASTLALANLNGSRGSDNLYCHARD 119
DB 61 SVHGDPPGATABGLWYTLNGRRLPELSRVLNASTLALANLNGSRGSDNLYCHARD 120
QY 120 GSIIAGSCLYVGLPPEKPVNISCSKMKDLTCRWTPGAHGETFLHTNYSLKYLKWYGQ 179
DB 121 GSIIAGSCLYVGLPPEKPVNISCSKMKDLTCRWTPGAHGETFLHTNYSLKYLKWYGQ 180
QY 180 DNTCEHYHTVGHSHCHIPKDLALFTPYEITWVATNRLGSARSDVLTLLIDVVTTPPPD 239
DB 181 DNTCEHYHTVGHSHCHIPKDLALFTPYEITWVATNRLGSARSDVLTLLIDVVTTPPPD 240
QY 240 VHSRVGGLLEDQLSVWVSPPALKDPLFOAKYQIRYVEDSVDMKYVDVSNQTSCLAG 299
DB 241 VHSRVGGLLEDQLSVWVSPPALKDPLFOAKYQIRYVEDSVDMKYVDVSNQTSCLAG 300
QY 300 LKPGTYFVQVRCNPFGIYGSKKAGIWEWSHPTAASPRSERPGGGAACEPRGGEPS 359
DB 301 LKPGTYFVQVRCNPFGIYGSKKAGIWEWSHPTAASPRSERPGGGAACEPRGGEPS 360
QY 360 GPRREELKQFLGWLKKHAYCSNLSFRLYDQWRAMQKSHKTRNODGILPSGRGTARGP 419
DB 361 GPRREELKQFLGWLKKHAYCSNLSFRLYDQWRAMQKSHKTRNODGILPSGRGTARGP 420
QY 420 AR 421
DB 421 AR 422

RESULT 5
AA26339
ID AAY26339 standard; protein; 422 AA.
AC AAY26339;
DT 13-JAN-2000 (first entry)
XX
DE Human U4 haematopoietin receptor superfamily chain-2.
XX
KW Human U4 protein; haematopoietin receptor superfamily;
KW biological activity; cytokine; cell proliferation; cell differentiation;
KW immune stimulation; immune suppression; haematopoiesis regulation;
KW immune disorder; immune deficiency; autoimmune disorder; allergy; cancer;
KW myeloid cell; lymphoid cell deficiency; platelet disorder.
XX
OS Homo sapiens.
XX
PN WO953066-A1.
XX
PD 21-OCT-1999.
XX
PE 09-APR-1999; 99WO-US007882.
XX
PR 10-APR-1998; 98US-00058660.
XX
PA (GEMV ) GENETICS INST INC.
XX
PI Donaldson D, Collins M, Whitters M, Neben T;
XX
DR WPI; 1999-611303/52.
XX
DR N-PSDB; AAX90754.
XX
```

```
PT Novel polypeptides and polynucleotides used for treatment of human
PT diseases and disorders e.g. immune disorders or deficiencies caused by
PT fungal, parasitic or viral infections.
XX
XX Claim 9; Page 36-38; 43pp; English.
XX
PS The present sequence is a human U4 protein which is predicted to have the
CC haematopoietin receptor superfamily. The protein is predicted to have the
CC following biological activities: cytokine, cell
CC proliferation/differentiation, immune stimulating or suppressing and
CC haematopoiesis regulating. The U4 protein can be used to treat immune
CC disorders and deficiencies, autoimmune disorders, allergies, cancer,
CC myeloid or lymphoid cell deficiencies and platelet disorders
XX
SQ Sequence 422 AA:
Query Match 99.5%; Score 2279.5; DB 2; Length 422;
Best Local Similarity 99.8%; Pred. No. 3.4e-184;
Matches 421; Conservative 0; Mismatches 0; Indels 1; Gaps 1;

QY 1 MPAGRRGPAAGARRPPPLP-LLLLCYLGAPRAGSGAHTAVISPODPTLLIGSSILATC 59
DB 1 MPAGRRGPAAGARRPPPLP-LLLLCYLGAPRAGSGAHTAVISPODPTLLIGSSILATC 60
QY 60 SVHGDPPGATABGLWYTLNGRRLPELSRVLNASTLALANLNGSRGSDNLYCHARD 119
DB 61 SVHGDPPGATABGLWYTLNGRRLPELSRVLNASTLALANLNGSRGSDNLYCHARD 120
QY 120 GSIIAGSCLYVGLPPEKPVNISCSKMKDLTCRWTPGAHGETFLHTNYSLKYLKWYGQ 179
DB 121 GSIIAGSCLYVGLPPEKPVNISCSKMKDLTCRWTPGAHGETFLHTNYSLKYLKWYGQ 180
QY 180 DNTCEHYHTVGHSHCHIPKDLALFTPYEITWVATNRLGSARSDVLTLLIDVVTTPPPD 239
DB 181 DNTCEHYHTVGHSHCHIPKDLALFTPYEITWVATNRLGSARSDVLTLLIDVVTTPPPD 240
QY 240 VHSRVGGLLEDQLSVWVSPPALKDPLFOAKYQIRYVEDSVDMKYVDVSNQTSCLAG 299
DB 241 VHSRVGGLLEDQLSVWVSPPALKDPLFOAKYQIRYVEDSVDMKYVDVSNQTSCLAG 300
QY 300 LKPGTYFVQVRCNPFGIYGSKKAGIWEWSHPTAASPRSERPGGGAACEPRGGEPS 359
DB 301 LKPGTYFVQVRCNPFGIYGSKKAGIWEWSHPTAASPRSERPGGGAACEPRGGEPS 360
QY 360 GPRREELKQFLGWLKKHAYCSNLSFRLYDQWRAMQKSHKTRNODGILPSGRGTARGP 419
DB 361 GPRREELKQFLGWLKKHAYCSNLSFRLYDQWRAMQKSHKTRNODGILPSGRGTARGP 420
QY 420 AR 421
DB 421 AR 422

RESULT 6
AAB01316
ID AAB01316 standard; protein; 422 AA.
AC AAB01316;
DT 25-SEP-2000 (first entry)
XX
DE Human PRO327 polypeptide.
XX
KW PRO, membrane bound protein; secreted protein; PRO357; PRO327; PRO243;
KW PRO715; PRO241; PRO323; PRO299; PRO344; PRO347; PRO355; PRO353;
KW PRO361; PRO365; transmembrane polypeptide; antibody; screening;
KW detection; inhibition; probe; primer; human.
XX
XX Homo sapiens.
XX
XX Key Location/Qualifiers
XX FT 1..30
XX FT /label=Signal peptide
```


PT	Modified-site	3. .7	/note= "Amidation site"
PT	Modified-site	30. .36	/note= "N-myristoylation site"
PT	Modified-site	37. .43	/note= "N-myristoylation site"
PT	Modified-site	44. .61	/note= "N-myristoylation site"
PT	Domain	/label=	Transmembrane domain
PT	Modified-site	73. .79	/note= "N-myristoylation site"
PT	Modified-site	79. .83	/note= "Amidation site"
PT	Modified-site	92. .96	/note= "N-glycosylation site"
PT	Modified-site	104. .108	/note= "N-glycosylation site"
PT	Modified-site	121. .127	/note= "N-myristoylation site"
PT	Modified-site	140. .144	/note= "N-glycosylation site"
PT	Modified-site	168. .172	/note= "N-glycosylation site"
PT	Modified-site	179. .185	/note= "N-myristoylation site"
PT	Modified-site	218. .224	/note= "N-myristoylation site"
PT	Modified-site	292. .296	/note= "N-glycosylation site"
PT	Modified-site	300. .306	/note= "N-myristoylation site"
PT	Modified-site	317. .323	/note= "N-myristoylation site"
PT	Modified-site	320. .326	/note= "N-myristoylation site"
PT	Modified-site	325. .331	/label= Growth factor/cytokine receptor family signature
PT	Modified-site	347. .353	/note= "N-myristoylation site"
PT	Modified-site	355. .361	/note= "N-myristoylation site"
PT	Modified-site	382. .386	/note= "N-glycosylation site"
PT	Modified-site	407. .413	/note= "N-myristoylation site"
PT	Modified-site	413. .417	/note= "cAMP and cGMP-dependent protein kinase phosphorylation site"
PT	Modified-site		
PN	WO200032776-A2.		
XX	08-JUN-2000.		
XX	01-DEC-1999;	99WC-US028301.	
XX	01-DEC-1998;	98WO-US025108.	
XX	16-DEC-1998;	98US-0112850P.	
XX	22-DEC-1998;	98US-0113296P.	
PA	(GETH) GENENTECH INC.		
PI	Baker KP, Botstein D, Eaton DL, Ferrara N, Flvayroff E;		
PI	Gerltsen ME, Goddard A, Godowski PJ, Grimaldi CU, Gurney AU;		
PI	Hallan KJ, Kljgvin ID, Napier MA, Roy MA, Tumas D, Wood WI;		
DR	WPI: 2000-412324/35.		
DR	N-PSDB; AAA49558.		
XX	New human nucleic acids encoding secreted and transmembrane polypeptides		
PT	designated as PRO polypeptides, useful as pharmaceutical and diagnostic		
PT	agents.		
XX	Claim 12; Fig 14; 187pp; English.		

CC	New human nucleic acids encoding secreted and transmembrane polypeptides which are designated as PRO polypeptides and are described. The membrane-bound proteins have various industrial applications, including as pharmaceutical and diagnostic agents. The membrane-bound proteins can also be employed for screening of potential peptide or small molecule inhibitors of the relevant receptor/ligand interaction. Anti-PRO antibodies are useful for the affinity purification of PRO from recombinant cell culture or natural sources
CC	Sequence 422 AA;
XX	Query Match 99.5%; Score 2279.5; DB 3; Length 422; Best Local Similarity 99.8%; Pred. No. 3.4e-184; Matches 421; Conservative 0; Mismatches 0; Indels 1; Gaps 1;
QY	1 MPAGRRPAAQASARRPPLLP-LLLLCVLGAPRAGSANTAVISPDPPTLLIGSSLATC 59
DB	1 MPAGRRPAAQASARRPPLLP-LLLLCVLGAPRAGSANTAVISPDPPTLLIGSSLATC 60
QY	60 SVHGDPPGATAEGLYMTLNGRRLPPELSRYLNASTLALANLNGSRQSGDNLVCHARD 119
DB	61 SVHGDPPGATAEGLYMTLNGRRLPPELSRYLNASTLALANLNGSRQSGDNLVCHARD 120
QY	120 GSILAGSLVYGLPPEKPVNISCSKMKDLCRWTPGAGHGFTHNNYSLKLYLRWYGO 179
DB	121 GSILAGSLVYGLPPEKPVNISCSKMKDLCRWTPGAGHGFTHNNYSLKLYLRWYGO 180
QY	180 DNTCEEHTVYSPHSCHIKPOLALFTPEYIWEATNRLGARSVDLTLDIVVTDDPPD 239
DB	181 DNTCEEHTVYSPHSCHIKPOLALFTPEYIWEATNRLGARSVDLTLDIVVTDDPPD 240
QY	240 VHSRVSGLEDQSLVSRWVSPALKDLFPAQKQIQRVVEDSVDMKVVDVVSNOTSCRLAG 299
DB	241 VHSRVSGLEDQSLVSRWVSPALKDLFPAQKQIQRVVEDSVDMKVVDVVSNOTSCRLAG 300
QY	300 LKRGTYVYVQVRCNPFGIYGSXKAGIWEASHPTAASPSEKPGGACPEKPGEPSS 359
DB	301 LKRGTYVYVQVRCNPFGIYGSXKAGIWEASHPTAASPSEKPGGACPEKPGEPSS 360
QY	360 GPVAREIKQFLGWLKKAIVCSNLSFRLYDQWRAMQKSHTRNDQEGILPSGRGRTARGP 419
DB	361 GPVAREIKQFLGWLKKAIVCSNLSFRLYDQWRAMQKSHTRNDQEGILPSGRGRTARGP 420
QY	420 AR 421
DB	421 AR 422
RESULT 7	
ID	AAV93686
AAV93686	standard; protein; 422 AA.
XX	AAV93686;
AC	03-OCT-2000 (first entry)
DT	
XX	
DE	Amino acid sequence of novel polypeptide PRO327.
XX	
KW	PRO201; PRO292; PRO327; PRO1265; PRO344; PRO343; PRO347; PRO357; PRO715; PRO1017; PRO1112; PRO309; PRO853; PRO862; tumour cell; tumorigenesis;
KM	cancer; neoplastic cell growth; cell proliferation.
XX	
OS	Homo sapiens.
XX	
FH	Key
FT	Peptide
FT	Location/Qualifiers
FT	1..30
FT	/note= "signal sequence"
FT	3..7
FT	/note= "amidation site"
FT	30..36
FT	/note= "N-myristoylation site"
FT	37..43
FT	/note= "N-myristoylation site"

PT	Modified-site	44..48	/note= "casein kinase II phosphorylation site"
FT	Modified-site	73..79	/note= "N-myristoylation site"
FT	Modified-site	79..83	/note= "amidation site"
FT	Modified-site	92..96	/note= "N-glycosylation site"
FT	Modified-site	104..108	/note= "N-glycosylation site"
FT	Modified-site	121..127	/note= "N-glycosylation site"
FT	Modified-site	140..144	/note= "N-myristoylation site"
FT	Modified-site	168..172	/note= "N-glycosylation site"
FT	Modified-site	179..185	/note= "N-glycosylation site"
FT	Modified-site	183..187	/note= "N-myristoylation site"
FT	Modified-site	205..209	/note= "casein kinase II phosphorylation site"
FT	Modified-site	218..224	/note= "casein kinase II phosphorylation site"
FT	Modified-site	292..296	/note= "N-myristoylation site"
FT	Modified-site	300..306	/note= "N-glycosylation site"
FT	Modified-site	317..323	/note= "N-myristoylation site"
FT	Modified-site	320..326	/note= "N-myristoylation site"
FT	Modified-site	325..332	/note= "N-myristoylation site"
FT	Modified-site	347..353	/note= "Growth factor and cytokines receptor family signature 2"
FT	Modified-site	355..361	/note= "N-myristoylation site"
FT	Modified-site	382..386	/note= "N-myristoylation site"
FT	Modified-site	407..413	/note= "N-glycosylation site"
FT	Modified-site	411..415	/note= "N-myristoylation site"
FT	Modified-site	413..417	/note= "amidation site"
FT	Modified-site	413..417	/note= "cAMP- and cGMP-dependent protein kinase phosphorylation site"
XX			
PN	WO200037640-A2.		
XX			
PD	29-JUN-2000.		
XX			
PF	16-DEC-1999;	99WO-US030095.	
XX			
PR	22-DEC-1998;	98US-0113296P.	
PR	08-MAR-1999;	99WO-US005028.	
PR	02-JUN-1999;	99WO-US012252.	
PR	01-SEP-1999;	99WO-US020111.	
PR	15-SEP-1999;	99WO-US021090.	
PR	30-NOV-1999;	99WO-US028313.	
PR	30-NOV-1999;	99WO-US028409.	
PR	01-DEC-1999;	99WO-US028301.	
PR	02-DEC-1999;	99WO-US028565.	
XX			
PA	(GETH) GENENTECH INC.		
XX			
PI	Botstein D, Goddard A, Gurney AL, Hillan K, Lawrence DA, Roy MA, Wood WI;		
XX			
DR	WPI, 2000-452188/39.		
XX	N-PSDB; AAA46902.		

Query Match	99.5%	Score 2279.5	DB 3	Length 422
Best Local Similarity	99.8%	Pred. No. 3.4e-184		
Matches 421	Conservative 0	Mismatches 0	Indels 1	Gaps 1
QY	1	MPAGRRGPAASARPPPLLP-LILLVLAGAPRAGSGAHTAVISPODPFTLLIGSSLATC	59	
Db	1	MPAGRRGPAASARPPPLLP-LILLVLAGAPRAGSGAHTAVISPODPFTLLIGSSLATC	60	
QY	60	SVHGDPGATAEGLYWTNGRRLLPELSRVYNASTLALANLANSRORSQDNLYCHARD	119	
Db	61	SVHGDPGATAEGLYWTNGRRLLPELSRVYNASTLALANLANSRORSQDNLYCHARD	120	
QY	120	GSLLAGSLCYGLPPEKPVNISCSKNNKDLTCRWTPGAHGTFPLHTNYSLKXKLRWYGO	179	
Db	121	GSLLAGSLCYGLPPEKPVNISCSKNNKDLTCRWTPGAHGTFPLHTNYSLKXKLRWYGO	180	
QY	180	DNTCEEYHTVGFHSHCHIPKDLALFTYEIWEATNRLGARSVDVLTLLDLYVTDDPPD	239	
Db	181	DNTCEEYHTVGFHSHCHIPKDLALFTYEIWEATNRLGARSVDVLTLLDLYVTDDPPD	240	
QY	240	VHVSRYVGLLEDOLSVRWVSPPAKDLPLFOAKQIIRYVEDSDVMKRVNDVSNQTSCLRAG	299	
Db	241	VHVSRYVGLLEDOLSVRWVSPPAKDLPLFOAKQIIRYVEDSDVMKRVNDVSNQTSCLRAG	300	
QY	300	LKRGIVYVQVRCNPFGIYGSKKAGIWSMESHPTAASPRSPRGGACPRGGEPS	359	
Db	301	LKRGIVYVQVRCNPFGIYGSKKAGIWSMESHPTAASPRSPRGGACPRGGEPS	360	
QY	360	GFVRRELKQFLGMLKKHAYCSNLSFRLYDQWRAMQKSHKTBNODEGILPSGRGTARGP	419	
Db	361	GFVRRELKQFLGMLKKHAYCSNLSFRLYDQWRAMQKSHKTBNODEGILPSGRGTARGP	420	
QY	420	AR 421		
Db	421	AR 422		
QY	422	AR 422		
Db	422	AR 422		

RESULT 8
AAG63545 ID AAG63545 standard; protein; 422 AA.

XX AAG63545;
XX
XX 15-OCT-2001 (first entry)
XX
XX Amino acid sequence of a human CLP-1 protein.
XX NNT-1; CLP-1; SCNFALPHA; nervous system; neuron; nervous system;
XX neuro-muscular function; tumour; immune system; haematopoietic system;
XX reproductive system; liver; skeletal muscle; neurodegenerative disease;
XX amyotrophic lateral sclerosis; Parkinson's disease; Huntington's disease;
XX muscular mass; paralysis; cancer; obesity; fertility; endometriosis;
XX blastocyst implantation; thrombosis; retinal disease;
XX retinal pigmentosis.
XX

OS Homo sapiens.
 XX WO200155172-A2.
 XX
 XX 02-AUG-2001.
 PD
 XX 26-JAN-2001; 2001WO-FR000253.
 XX
 XX 27-JAN-2000; 2000FR-00001035.
 PR 12-OCT-2000; 2000FR-00013089.
 XX
 XX (FABR) FABRE MEDICAMENT SA PIERRE.
 PA (INRM) INSERM INST NAT SANTE & RECH MEDICALE.
 XX
 PI Elson G, Gauchat J, Plun-Favreau H, Chevalier S, Gaecan H;
 XX WPI; 2001-48877/53.
 DR N-PSDB; AAH74486.
 XX
 PT A complex comprising a NNT-1 protein and a CLF-1 and/or SCNTFRalpha
 PT protein useful to treat neurodegenerative disease including Parkinson's
 PT and Huntington's, obesity and cancer.
 XX
 XX Claim 2; Page 63-64; 67pp; French.
 XX
 CC The present sequence represents a human CLF-1 protein. The specification
 CC describes a complex comprising a NNT-1 protein and a CLF-1 and/or
 CC SCNTFRalpha protein. The NNT-1/CLF-1 complex is used to modulate activity
 CC of the SCNTFRalpha/gp130/LIFbeta receptor complex, or to induce
 CC phosphorylation of the tyrosine of gp130 and LIFbeta, particularly where
 CC cells expressing the receptor complex are in the central or peripheral
 CC nervous system, in neurons implicated in neuro-muscular function or in
 CC skeletal muscle. The complex or antibodies are also used to decrease the
 CC survival, growth or proliferation of tumour cells or to facilitate the
 CC proliferation and/or inhibit differentiation of cells stocks. The complex
 CC is also used to modulate activity of the gp130/LIFbeta receptor or cells
 CC expressing that receptor, particularly those cells implicated in the
 CC immune, haematopoietic, nervous or reproductive system, the liver or
 CC skeletal muscle. Molecules of the invention may be used to prevent or
 CC treat neurodegenerative diseases including amyotrophic lateral sclerosis,
 CC Parkinson's and Huntington's disease, to repair or regenerate nervous or
 CC muscular tissue or to maintain muscular mass in paralysis patients. They
 CC may also be used to treat cancer, obesity and associated diseases, and to
 CC improve fertility, particularly to avoid endometriosis and/or assist
 CC blastocyst implantation, thrombosis, or retinal disease, particular
 CC retinal pigmentosis
 CC
 CC
 XX
 XX Sequence 422 AA;
 SQ
 Query Match 99.5%; Score 2279.5; DB 4; Length 422;
 Best Local Similarity 99.8%; Pred. No. 3,4e-184;
 Matches 421; Conservative 0; Mismatches 0; Indels 1; Gaps 1;

QY 300 LKPGTVYFVQRCNPFGIYSKKAGIWEWSHPAASTPSPERPDCGACPEPGCEPSS 359
 DB 301 LKPGTVYFVQRCNPFGIYSKKAGIWEWSHPAASTPSPERPDCGACPEPGCEPSS 360
 QY 360 GPVAREIKQPLGWLKKAAYCSNLSFRLYDQWRAMQSKHTRNDEGILPSGRRTARGP 419
 DB 361 GPVAREIKQPLGWLKKAAYCSNLSFRLYDQWRAMQSKHTRNDEGILPSGRRTARGP 420
 QY 420 AR 421
 DB 421 AR 422
 RESULT 9
 ABUS5925
 ID ABUS5925 standard; protein; 422 AA.
 XX
 XX ABUS5925;
 AC
 XX
 DT 26-MAR-2003 (first entry)
 XX
 DE Human secreted/transmembrane protein PRO327.
 XX
 XX Human; PRO; secreted protein; transmembrane protein; anti-HIV;
 KW cytosolic; antiarteriosclerotic; antiinflammatory; antidiabetic;
 KW candida; AIDS; acquired immunodeficiency syndrome; cancer;
 KW atherosclerosis; inflammatory disease; diabetic complication;
 KW cardiac injury; organ failure.
 XX
 OS Homo sapiens.
 XX
 XX US2002142959-A1.
 PN
 XX
 PD 03-OCT-2002.
 XX
 XX 31-AUG-2001; 2001US-00944654.
 XX
 PR 16-SEP-1998; 98WO-US019330.
 PR 01-DEC-1998; 98WO-US025108.
 PR 22-JUN-1999; 99WO-US012252.
 PR 15-SEP-1999; 99WO-US021090.
 PR 30-NOV-1999; 99WO-US028313.
 PR 30-NOV-1999; 99WO-US028409.
 PR 01-DEC-1999; 99WO-US028301.
 PR 16-DEC-1999; 99WO-US030095.
 PR 11-FEB-2000; 2000WO-US003565.
 PR 22-FEB-2000; 2000WO-US004414.
 PR 02-MAR-2000; 2000WO-US008439.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 28-JUL-2000; 2000WO-US020710.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 25-MAY-2001; 2001US-00866028.
 XX
 XX (GETH) GENENTECH INC.
 PA
 XX Baker KP, Botstein D, Eaton DL, Ferrara N, Filvaroff E;
 PI Gerritsen ME, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL;
 PI Hillan KJ, Kijavlin IV, Napier MA, Roy MA, Tumas D, Wood WI;
 XX
 DR WPI; 2003-174141/17.
 DR N-PSDB; ABX75462.
 XX
 PT New isolated PRO polypeptide and encoding nucleic acid, useful for the
 PT diagnosis and treatment of disorders associated with the PRO polypeptide,
 PT such as AIDS, cancer, atherosclerosis, inflammatory disease and diabetes.
 XX
 XX Claim 12; Fig 14; 17pp; English.
 PS
 CC The invention relates to an isolated PRO polypeptide (a secreted or
 CC transmembrane protein) comprising: (a) at least 80% sequence identity or
 CC positives when compared to any of 15 sequences, fully defined in the

CC specification, lacking or with its associated signal peptide; or (b) at
CC least 80% sequence identity to a sequence encoded by the full-length
CC coding sequence of a DNA deposited in the American Type Culture
CC Collection (ATCC). Also included are: (1) an isolated nucleic acid
CC comprising: (a) at least 80% sequence identity to a nucleotide sequence
CC that encodes a PRO protein; (b) at least 80% sequence identity to a
CC nucleotide sequence or full-length coding sequence with any of 15 fully
CC defined sequences of 957-3441 base pairs, given in the specification; or
CC (c) at least 80% sequence identity to a full-length coding sequence of a
CC DNA deposited under ATCC Accession No. 209526, 209524, 209528,
CC 209530, 209523, 209492, 209532, 209529, 209527, 209570, 209618,
CC 209621 or 209619; (2) a vector comprising the nucleic acid; (3) a host
CC cell comprising the vector which, when cultured under conditions suitable
CC for expression of the PRO polypeptide, produces the PRO protein; (4) a
CC chimeric molecule comprising PRO fused to a heterologous amino acid
CC sequence; and (5) an anti-PRO antibody. The methods and compositions of
CC the present invention are useful for the diagnosis and treatment of
CC disorders associated with the PRO polypeptide, such as AIDS (acquired
CC immunodeficiency syndrome), cancer, atherosclerosis, inflammatory
CC disease, diabetic complications, cardiac injury and organ failure. The
CC antibodies can also be used in the different screening, therapeutic and
CC biological assays. The present sequence represents a PRO protein
XX
XX
SQ Sequence 422 AA;

Query Match 99.5%; Score 2279.5; DB 6; Length 422;
Best Local Similarity 99.8%; Pred. No. 3,4e-184;
Matches 421; Conservative 0; Mismatches 0; Indels 1; Gaps 1;

QY 1 MPAGRGPAAGARRRRPPLLP-LLLCVAGAPAGAGATPAVSPDPFTLLISSLLATC 59
DB 1 MPAGRGPAAGARRRRPPLLP-LLLCVAGAPAGAGATPAVSPDPFTLLISSLLATC 60
QY 60 SVHGDPPGATAGELTYTLNGRRLLPPELSRYLNASTLALANLNGSRGSDNLVCHAD 119
DB 61 SVHGDPPGATAGELTYTLNGRRLLPPELSRYLNASTLALANLNGSRGSDNLVCHAD 120
QY 120 GSTIASSCLYGLPPEKPNVISCWSKMDLTCRWTPGANGEFLLTNTSLKTKLAWYQ 179
DB 121 GSTIASSCLYGLPPEKPNVISCWSKMDLTCRWTPGANGEFLLTNTSLKTKLAWYQ 180
QY 180 DNTCEETHVGPSSCHIPKDLAFTPEIWEATNRLGARSVDLTLDIDVYTTDPPD 239
DB 181 DNTCEETHVGPSSCHIPKDLAFTPEIWEATNRLGARSVDLTLDIDVYTTDPPD 240
QY 240 VHSVSVGLLEDQLSVWVSPPALKDFLQAKYQIRYREVDSDVMKVVDDVNSQTSCLAG 299
DB 241 VHSVSVGLLEDQLSVWVSPPALKDFLQAKYQIRYREVDSDVMKVVDDVNSQTSCLAG 300
QY 300 LKRGTYFVQVRNCPGIYSSKKAGIWESEHPTASTPSSRPGCGGACERGGEPSS 359
DB 301 LKRGTYFVQVRNCPGIYSSKKAGIWESEHPTASTPSSRPGCGGACERGGEPSS 360
QY 360 GPVRRRELKQFLGWLKKAHACSNLSFRLYDQWRAMQKSHKTRNODGILLPSGRGTARGP 419
DB 361 GPVRRRELKQFLGWLKKAHACSNLSFRLYDQWRAMQKSHKTRNODGILLPSGRGTARGP 420
QY 420 AR 421
DB 421 AR 422

RESULT 10
ABU60235
ID ABU60235 standard; protein; 422 AA.
XX
AC ABU60235;

DT 24-APR-2003 (first entry)
XX
XX Human PRO polypeptide #6.
XX
XX Human; PRO; secreted polypeptide; transmembrane polypeptide; cancer;

KW inflammatory disease; atherosclerosis; cardiac injury; AIDS; infertility;
KW birth defect; premature aging; diabetes; dog; cat; horse;
KW acquired immunodeficiency syndrome; cow; sheep; pig; goat; rabbit;
KW industry; cytostatic; antiinflammatory; cardiac; antiinfertility;
KW anti-HIV; antiarteriosclerotic; antidiabetic.

OS Homo sapiens.

XX US2002132768-A1.

XX 19-SEP-2002.

XX 31-AUG-2001; 2001US-00945015.

XX 03-DEC-1997; 97US-0067411P.
XX 11-DEC-1997; 97US-0069278P.
XX 11-DEC-1997; 97US-0069334P.
XX 11-DEC-1997; 97US-0069335P.
XX 12-DEC-1997; 97US-0069425P.
XX 16-DEC-1997; 97US-0069694P.
XX 16-DEC-1997; 97US-0069696P.
XX 16-DEC-1997; 97US-0069702P.
XX 17-DEC-1997; 97US-0069870P.
XX 17-DEC-1997; 97US-0068017P.
XX 05-JAN-1998; 98US-0070440P.
XX 09-FEB-1998; 98US-0074086P.
XX 25-FEB-1998; 98US-0075945P.
XX 16-SEP-1998; 98WO-US019330.
XX 01-DEC-1998; 98WO-US025108.
XX 16-DEC-1998; 98US-00216021.
XX 16-DEC-1998; 98US-0112850P.
XX 22-DEC-1998; 98US-0021851P.
XX 22-DEC-1998; 98US-0113296P.
XX 03-MAR-1999; 99US-00254311.
XX 22-JUN-1999; 99US-0146222P.
XX 28-JUL-1999; 99US-0146222P.
XX 15-SEP-1999; 99WO-US02109P.
XX 30-NOV-1999; 99WO-US028313.
XX 30-NOV-1999; 99WO-US028409.
XX 01-DEC-1999; 99WO-US028301.
XX 16-DEC-1999; 99WO-US030095.
XX 11-FEB-2000; 2000WO-US003565.
XX 22-FEB-2000; 2000WO-US004414.
XX 02-MAR-2000; 2000WO-US005841.
XX 30-MAR-2000; 2000WO-US008439.
XX 22-MAY-2000; 2000WO-US014042.
XX 28-JUL-2000; 2000WO-US020710.
XX 01-DEC-2000; 2000WO-US032678.
XX 28-FEB-2001; 2001WO-US006520.
XX 25-MAY-2001; 2001US-00866028.

XX (GENTH) GENENTECH INC.

XX Baker KP, Bostein D, Baton DL, Ferrara N, Filvaroff E;

PI Gerritsen ME, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL,
PI Hillan KJ, Kijavlin IO, Napier MA, Roy MA, Tumas D, Wood WI;

DR WPI; 2003-174088/17.

DR N-PSDB; ABX89453.

XX New secreted and transmembrane polypeptides (e.g. PRO241, for use in
PT pharmaceuticals, diagnostics or bioreactors, particularly for detecting
PT or treating e.g. cancers, infertility or acquired immunodeficiency
XX syndrome in mammals.

PS Claim 1, Fig 14; 173pp; English.

XX The invention relates to a human secreted and transmembrane polypeptide
CC (PRO) and the polynucleotide encoding it. The PRO polypeptide or
CC polynucleotide is useful in pharmaceuticals, diagnostics, biosensors or
CC bioreactors. These are particularly useful for detecting or treating

DB 241 VHSRVGGLLEDQLSVWVSPALKDPLFOAKYQIRRVSDVDMKVVDVSNQTSRLAG 300
QY 300 LKRGTYFVQVRCNPFIGYSSKAGIWSWSHPTAASRPSRPGGACBPRGGEPS 359
DB 301 LKRGTYFVQVRCNPFIGYSSKAGIWSWSHPTAASRPSRPGGACBPRGGEPS 360
QY 360 GPRRRLKQFLGMLKKHAYCSNLSFRLYDQWRAMWQKSHKTRNODGILPSGRGTARGP 419
DB 361 GPRRRLKQFLGMLKKHAYCSNLSFRLYDQWRAMWQKSHKTRNODGILPSGRGTARGP 420
QY 420 AR 421
DB 421 AR 422

RESULT 12
ABU64921
ID ABU64921 standard; protein; 422 AA.
AC ABU64921;
DE 15-MAY-2003 (first entry)
XX Human secreted/transmembrane protein PRO327.
XX Human; PRO; secreted protein; transmembrane protein;
XX Cornelia de Lange syndrome; gene therapy; immune disorder;
XX inflammatory disease; organ failure; atherosclerosis; cardiac injury;
XX infertility; birth defect; premature aging; cardiac injury; AIDS; cancer;
XX diabetic complication.
XX Homo sapiens.
XX US2002173463-A1.
PD 21-NOV-2002.
PF 31-ANG-2001; 2001US-00944944.
XX 03-DEC-1997; 97US-0067411P.
XX 11-DEC-1997; 97US-0069278P.
XX 11-DEC-1997; 97US-0069334P.
XX 12-DEC-1997; 97US-0069425P.
XX 16-DEC-1997; 97US-0069696P.
XX 16-DEC-1997; 97US-0069702P.
XX 17-DEC-1997; 97US-0069870P.
XX 18-DEC-1997; 97US-0069873P.
XX 05-JAN-1998; 98US-0070440P.
XX 09-FEB-1998; 98US-0074086P.
XX 25-FEB-1998; 98US-0075945P.
XX 16-FEB-1998; 98US-0075945P.
XX 01-DEC-1998; 98US-0075945P.
XX 16-DEC-1998; 98US-0112850P.
XX 22-DEC-1998; 98US-0112850P.
XX 02-JUN-1999; 99US-00812252.
XX 28-JUL-1999; 99US-0146222P.
XX 15-SEP-1999; 99US-00812252.
XX 30-NOV-1999; 99US-00812252.
XX 01-DEC-1999; 99US-00812252.
XX 16-DEC-1999; 99US-00812252.
XX 11-FEB-2000; 2000US-00003655.
XX 22-FEB-2000; 2000US-00004414.
XX 02-MAR-2000; 2000US-00005841.
XX 30-MAR-2000; 2000US-00008439.
XX 22-MAY-2000; 2000US-0014042.
XX 28-JUL-2000; 2000US-0020710.
XX 01-DEC-2000; 2000US-0032678.

PR 28-FEB-2001; 2001US-0006520.
PR 25-MAY-2001; 2001US-00866028.
XX (GETH) GENENTECH INC.
XX Baker KD, Boetstein D, Bacon DL, Ferrara N, Filvaroff E;
XX Gertsen ME, Goddard A, Godowski PJ, Grimaldi JC, Gunney AL;
XX Hillan KJ, Kijavir IU, Napier MA, Roy MA, Tumas D, Wood WI;
XX WPI; 2003-311003/30.
XX N-PSDB; ABX96790.
XX New transmembrane polypeptides and polynucleotides useful for chromosome
XX identification, tissue typing, gene therapy, in chromosome and gene
XX mapping, or as molecular weight markers.
XX Claim 12; Fig 14; 172pp; English.
XX The invention relates to an isolated nucleic acid encoding a secreted/
XX transmembrane polypeptide (designated as PRO protein). 15 PRO
XX polypeptides and their encoding polynucleotides are disclosed. Also
XX included are a vector comprising the PRO nucleic acid, a host cell
XX comprising the vector, a process for producing a PRO polypeptide (by
XX culturing the host cell under conditions for the expression of the PRO
XX polypeptide, and recovering the PRO polypeptide from the cell culture, an
XX isolated polypeptide having at least 80% amino acid sequence identity to
XX the PRO polypeptides), a chimeric molecule comprising PRO fused to a
XX heterologous amino acid sequence and an antibody which specifically binds
XX to PRO. The PRO nucleotide sequences are useful as hybridisation probes,
XX in chromosome and gene mapping, in generating sense and antisense RNA or
XX DNA, in generating transgenic or knock-out animals which can be used in
XX the development and screening of therapeutically useful reagents, and in
XX gene therapy. The polypeptides may be used as molecular weight markers
XX for protein electrophoresis purposes. The PRO polypeptides and nucleic
XX acids may also be used for chromosome identification, and tissue typing.
XX PRO241 (identified as Chordin) is a candidate gene for Cornelia de Lange
XX syndrome. Other PRO proteins are variously implicated in immune
XX disorders, inflammatory disease, organ failure, atherosclerosis, cardiac
XX injury, infertility, birth defects, premature aging, cardiac injury,
XX AIDS, cancer and diabetic complications. The present sequence represents
XX a PRO protein
XX
SQ Sequence 422 AA;
Query Match 99.5%; Score 2279.5; DB 6; Length 422;
Best Local Similarity 99.8%; Pred. No. 3,4e-184;
Matches 421; Conservative 0; Mismatches 0; Indels 1; Gaps 1;
QY 1 MPAGRRGPAQASRRPPLLP-LLLLCVLAGPRAGGATTAATVSPDPTLLIGSSLLATC 59
DB 1 MPAGRRGPAQASRRPPLLP-LLLLCVLAGPRAGGATTAATVSPDPTLLIGSSLLATC 60
QY 60 SVHGDPPGATAGLYVTLNGRLPPELSRVNASTLALALAMNGSRSGDNLVCHARD 119
DB 61 SVHGDPPGATAGLYVTLNGRLPPELSRVNASTLALALAMNGSRSGDNLVCHARD 120
QY 120 GSILAGSCLYVGLPEPKPVNISCWKNMDLTCRTWPGHAGFTLHTNYSLKTKLAWYQ 179
DB 121 GSILAGSCLYVGLPEPKPVNISCWKNMDLTCRTWPGHAGFTLHTNYSLKTKLAWYQ 180
QY 180 DNTCEHYHTVGPSPCHIPKDLALFTPYEIVWEATNRIGSARSBDVLTLDLIVTTDPPD 239
DB 181 DNTCEHYHTVGPSPCHIPKDLALFTPYEIVWEATNRIGSARSBDVLTLDLIVTTDPPD 240
QY 240 VHSRVGGLLEDQLSVWVSPALKDPLFOAKYQIRRVSDVDMKVVDVSNQTSRLAG 299
DB 241 VHSRVGGLLEDQLSVWVSPALKDPLFOAKYQIRRVSDVDMKVVDVSNQTSRLAG 300
QY 300 LKRGTYFVQVRCNPFIGYSSKAGIWSWSHPTAASRPSRPGGACBPRGGEPS 359
DB 301 LKRGTYFVQVRCNPFIGYSSKAGIWSWSHPTAASRPSRPGGACBPRGGEPS 360
QY 360 GPRRRLKQFLGMLKKHAYCSNLSFRLYDQWRAMWQKSHKTRNODGILPSGRGTARGP 419

Db 361 GPRREIKQFLGMLKKHAYCSNLSFRLYDQWRAMQKSHKTRNQDEGILPSGRGTARGP 420
QY 420 AR 421
Db 421 AR 422

RESULT 13
ABUS8355
ID ABUS8355 standard; protein; 422 AA.
XX
AC ABUS8355;
XX
DT 14-APR-2003 (first entry)
XX
DE Novel human secreted protein PRO327.

XX Human; antiinflammatory; antiarteriosclerotic; cardiac; gynecological;
KM anti-HIV; cytostatic; antidiabetic; BMP-agonist; BMP-Antagonist;
KM cytokine-agonist; cytokine-antagonist; gene-Therapy;
KM inflammatory disease; organ failure; atherosclerosis; cardiac injury;
KM infertility; birth defect; premature aging; AIDS; cancer;
XX diabetic complication.

XX Homo sapiens.

XX US2002150976-A1.

XX 17-OCT-2002.

XX 30-AUG-2001; 2001US-00943851.

XX 03-DEC-1997; 97US-0067411P.
PR 11-DEC-1997; 97US-0069278P.
PR 11-DEC-1997; 97US-0069334P.
PR 12-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 16-DEC-1997; 97US-0069684P.
PR 16-DEC-1997; 97US-0069686P.
PR 16-DEC-1997; 97US-0069702P.
PR 17-DEC-1997; 97US-0069870P.
PR 17-DEC-1997; 97US-0068073P.
PR 18-DEC-1997; 97US-0068017P.
PR 05-JAN-1998; 98US-0070440P.
PR 09-FEB-1998; 98US-0074086P.
PR 09-FEB-1998; 98US-0074092P.
PR 16-SEP-1998; 98US-0075945P.
PR 16-SEP-1998; 98US-0075945P.
PR 01-DEC-1998; 98US-0075945P.
PR 16-DEC-1998; 98US-0075945P.
PR 16-DEC-1998; 98US-0075945P.
PR 22-DEC-1998; 98US-0075945P.
PR 22-DEC-1998; 98US-0075945P.
PR 03-MAR-1999; 99US-00254311.
PR 02-JUN-1999; 99US-00254311.
PR 28-JUL-1999; 99US-0146222P.
PR 15-SEP-1999; 99US-0146222P.
PR 30-NOV-1999; 99US-0146222P.
PR 30-NOV-1999; 99US-0146222P.
PR 01-DEC-1999; 99US-0146222P.
PR 16-DEC-1999; 99US-0146222P.
PR 11-FEB-2000; 2000US-0003565.
PR 22-FEB-2000; 2000US-0003565.
PR 02-MAR-2000; 2000US-0003565.
PR 30-MAR-2000; 2000US-0003565.
PR 22-MAY-2000; 2000US-0003565.
PR 28-JUL-2000; 2000US-0003565.
PR 01-DEC-2000; 2000US-0003565.
PR 28-FEB-2001; 2001US-0003565.
PR 25-MAY-2001; 2001US-0003565.

XX (GETH) GENENTECH INC.

XX Baker KP, Botstein D, Eaton DL, Ferrara N, Filvaroff E;
PI Gerritsen ME, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL;
PI Hillan KU, Kijavini IO, Napier MA, Roy MA, Tamas D, Wood WT;
XX WPI; 2003-198285/19.
DR N-PSDB; ABX78444.

PT New isolated PRO polypeptide and encoding nucleic acids, useful for the
PT diagnosis and treatment of disorders such as inflammatory disease,
PT atherosclerosis, cardiac injury, infertility, AIDS, cancer and diabetic
PT complications.

PS Claim 12; Fig 14; 171pp; English.

CC The invention describes a novel isolated PRO polypeptide. The methods and
CC compositions of the present invention are useful for the diagnosis and
CC treatment of disorders such as inflammatory disease, organ failure,
CC atherosclerosis, cardiac injury, infertility, birth defects, premature
CC aging, AIDS, cancer, diabetic complications and mutations in general.
CC This is the amino acid sequence of a novel human secreted PRO protein

XX Sequence 422 AA;

Query Match 99.5%; Score 2279.5; DB 6; Length 422;
Best Local Similarity 99.8%; Pred. No. 3,4e-184;
Matches 421; Conservative 0; Mismatches 0; Indels 1; Gaps 1;

QY 1 MPAGRRGPAQAQARRPPPLP-LLLLCVLAGPAGSGAHTAVISPODPTLLIGSSLLATC 59

Db 1 MPAGRRGPAQAQARRPPPLP-LLLLCVLAGPAGSGAHTAVISPODPTLLIGSSLLATC 60

QY 60 SVHGDPGATAEGLVYTLNRRLLPPELSRVLANSTLALANLNGSRGSDNIVCHARD 119

Db 61 SVHGDPGATAEGLVYTLNRRLLPPELSRVLANSTLALANLNGSRGSDNIVCHARD 120

QY 120 GSIIAGSCLVYGLPPEKPVNISCSKMKMDLTCRWMPGAGETPLHTNYSLKTKLRVYGO 179

Db 121 GSIIAGSCLVYGLPPEKPVNISCSKMKMDLTCRWMPGAGETPLHTNYSLKTKLRVYGO 180

QY 180 DNTCEHYHTVSPHSCHIPKDLALFTPEIWEATNRLSGARSVDLTLDVYTTDPPD 239

Db 181 DNTCEHYHTVSPHSCHIPKDLALFTPEIWEATNRLSGARSVDLTLDVYTTDPPD 240

QY 240 VHSRVGGLDQSVWVSPSPALKDPLFOAKYIIRRVEDSVWVYDVVSNQSCILAG 299

Db 241 VHSRVGGLDQSVWVSPSPALKDPLFOAKYIIRRVEDSVWVYDVVSNQSCILAG 300

QY 300 LKPGTYFPVQVRCNPGIYSGKAGIWMESHPTASTPSSRRPGGCGACEPPGSPSS 359

Db 301 LKPGTYFPVQVRCNPGIYSGKAGIWMESHPTASTPSSRRPGGCGACEPPGSPSS 360

QY 360 GPRREIKQFLGMLKKHAYCSNLSFRLYDQWRAMQKSHKTRNQDEGILPSGRGTARGP 419

Db 361 GPRREIKQFLGMLKKHAYCSNLSFRLYDQWRAMQKSHKTRNQDEGILPSGRGTARGP 420

QY 420 AR 421
Db 421 AR 422

RESULT 14
ABUS7241
ID ABUS7241 standard; protein; 422 AA.

XX ABUS7241;

XX 04-APR-2003 (first entry)

XX Human PRO327 protein.

XX Human; antiinflammatory; antiarteriosclerotic; cardiac;
KM anti-infertility; anti-HIV; cytostatic; antidiabetic; transmembrane;

KW antiinflammatory; anti-HIV; antiarteriosclerotic; cardiant; infertility;
KW anti-infertility; cytosratic; antidiabetic; gene therapy; birth defect;
KW inflammatory disease; organ failure; atherosclerosis; cardiac injury;
KW premature aging; AIDS; cancer; diabetic complication.
XX
XX Homo sapiens.
XX OS
XX PN US2002142958-A1.
XX
XX 03-OCT-2002.
XX PD
XX PF 30-AUG-2001; 2001US-00943762.
XX
XX 16-SEP-1998; 98WO-US019330.
PR 01-DEC-1998; 98WO-US025108.
PR 22-JUN-1999; 99WO-US012252.
PR 15-SEP-1999; 99WO-US021090.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 16-DEC-1999; 99WO-US030095.
PR 11-FEB-2000; 2000WO-US003565.
PR 22-FEB-2000; 2000WO-US004414.
PR 02-MAR-2000; 2000WO-US005841.
PR 30-MAR-2000; 2000WO-US008439.
PR 22-MAY-2000; 2000WO-US014042.
PR 28-JUL-2000; 2000WO-US020710.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 25-MAY-2001; 2001US-00866028.
XX
XX (GENTH) GENENTECH INC.
XX PA
XX Baker KP, Botstein D, Baton DL, Ferrara N, Filvaroff E;
PI Gerltsen ME, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL;
PI Hillan KJ, Kljavin IJ, Napier MA, Roy MA, Tumas D, Wood WI;
XX
XX WPI; 2003-174140/17.
DR N-PSDB; ABX71077.
XX
XX New secreted and transmembrane nucleic acids and polypeptides, designated
PT as PRO, useful for treating inflammation, organ failure, atherosclerosis,
PT cardiac injury, infertility, birth defects, premature aging, AIDS, or
PT cancer.
XX
XX Claim 1; Fig 14; 173pp; English.
XX PS
XX This invention relates to a nucleotide sequence encoding an isolated
CC secreted and/or transmembrane protein. The nucleotide sequences of the
CC invention may have antiinflammatory, antiarteriosclerotic, cardiant, anti
CC -infertility, anti-HIV, cytosratic and antidiabetic activities and may be
CC used in gene therapy. The nucleic acids and polypeptides are useful for
CC treating inflammatory diseases, organ failure, atherosclerosis, cardiac
CC injury, infertility, birth defects, premature aging, AIDS, cancer, or
CC diabetic complications. The nucleic acids are useful as hybridisation
CC probes, in chromosome and gene mapping, and in generating antisense RNA
CC or DNA. The polypeptides are useful as pharmaceuticals, diagnostics,
CC biosensors or bioreactors. Both are useful in tissue typing. The present
CC sequence represents a protein encoded by the nucleic acids of the
XX invention
XX
SQ Sequence 422 AA;
Query Match 99.5%; Score 2279.5; DB 6; Length 422;
Best Local Similarity 99.8%; Pred. No. 3.4e-184;
Matches 421; Conservative 0; Mismatches 0; Indels 1; Gaps 1;
QY 1 MPAGRRGPAAGSARPPPLP-ILLCTVLAGAPRAGSGAHTAVISPDPTLLIGSSILATC 59
DB 1 MPAGRRGPAAGSARPPPLP-ILLCTVLAGAPRAGSGAHTAVISPDPTLLIGSSILATC 60
QY 60 SVHGDPPGATAGELVYTLNGRRLPELSRVINASTLALANLNGSRQSGDNLVGHARD 119
|||||

DB 61 SVHGDPPGATAGELVYTLNGRRLPELSRVINASTLALANLNGSRQSGDNLVGHARD 120
QY 120 GSIIAGSCLYVGLPPEEPVNI SCWSKMKDLTCRTPGAGCEPIHTNYSLKXKLRMYGQ 179
DB 121 GSIIAGSCLYVGLPPEEPVNI SCWSKMKDLTCRTPGAGCEPIHTNYSLKXKLRMYGQ 180
QY 180 DNTCEEYHWGPHSCHPKDLALFTPYEIWEATNRLGSARSVDLTLDIDVYTTDPPD 239
DB 181 DNTCEEYHWGPHSCHPKDLALFTPYEIWEATNRLGSARSVDLTLDIDVYTTDPPD 240
QY 240 VHSRVGGLBEDQLSVRWSPALKDPLFOAKYQIRYVEBSVDMKVVDVSNQTSCLAG 299
DB 241 VHSRVGGLBEDQLSVRWSPALKDPLFOAKYQIRYVEBSVDMKVVDVSNQTSCLAG 300
QY 300 LKPGTVYFVQRCNPFYIGSKKAGISEMSHPPTASTPSEPRPGGACCEPRGEPSS 359
DB 301 LKPGTVYFVQRCNPFYIGSKKAGISEMSHPPTASTPSEPRPGGACCEPRGEPSS 360
QY 360 GPRRELKQFLGWLKKAHAYCSNLSFRLYDQWRAMWQSKHTRNDEGILDPGRRGTARGP 419
DB 361 GPRRELKQFLGWLKKAHAYCSNLSFRLYDQWRAMWQSKHTRNDEGILDPGRRGTARGP 420
QY 420 AR 421
DB 421 AR 422
RESULT 15
ID ABUS6306 standard; protein, 422 AA.
XX
XX ABUS6306;
AC
XX
DT 31-MAR-2003 (first entry)
XX
XX Human secreted/transmembrane protein, PRO327.
XX
XX Human; PRO; antiinflammatory; antiarteriosclerotic; cardiant;
KW gynecological; anti-HIV; cytosratic; antidiabetic; inflammatory disease;
KW organ failure; atherosclerosis; cardiac injury; infertility;
KW birth defect; premature aging; AIDS; acquired immunodeficiency syndrome;
KW cancer; diabetic complication.
XX
XX Homo sapiens.
XX OS
XX PN US2002132981-A1.
XX
XX 19-SEP-2002.
XX PD
XX PF 30-AUG-2001; 2001US-00944396.
XX
XX 03-DEC-1997; 97US-0067411P.
PR 11-DEC-1997; 97US-0069278P.
PR 11-DEC-1997; 97US-0069334P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 16-DEC-1997; 97US-0069694P.
PR 16-DEC-1997; 97US-0069696P.
PR 16-DEC-1997; 97US-0069702P.
PR 17-DEC-1997; 97US-0069870P.
PR 17-DEC-1997; 97US-0069873P.
PR 18-DEC-1997; 97US-0068017P.
PR 05-JAN-1998; 98US-0070440P.
PR 09-FEB-1998; 98US-0074086P.
PR 09-FEB-1998; 98US-0074092P.
PR 25-FEB-1998; 98US-0075945P.
PR 16-SEP-1998; 98WO-US019330.
PR 01-DEC-1998; 98WO-US025108.
PR 16-DEC-1998; 98US-0112850P.
PR 22-DEC-1998; 98US-0113296P.
PR 02-JUN-1999; 99WO-US012252.
PR 28-JUN-1999; 99US-0146222P.
PR 15-SEP-1999; 99WO-US021090.

PR 30-NOV-1999; 99MO-US028313.
 PR 30-NOV-1999; 99MO-US028409.
 PR 01-DEC-1999; 99MO-US028301.
 PR 16-DEC-1999; 99MO-US030095.
 PR 11-FEB-2000; 2000MO-US003565.
 PR 22-FEB-2000; 2000MO-US004414.
 PR 02-MAR-2000; 2000MO-US005841.
 PR 30-MAR-2000; 2000MO-US008439.
 PR 22-MAY-2000; 2000MO-US014042.
 PR 28-JUL-2000; 2000MO-US020710.
 PR 01-DEC-2000; 2000MO-US032678.
 PR 28-FEB-2001; 2001MO-US006520.
 PR 25-MAY-2001; 2001US-00866028.

XX (GETH) GENENTECH INC.

PI Baker KP, Botstein D, Eaton DL, Ferrara N, Filvaroff E;
 PI Geritsen ME, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL;
 PI Hillan KJ, Kijavini ID, Napier MA, Roy MA, Tumas D, Wood WI;
 XX

DR MPI: 2003-147446/14.
 DR N-PSDB; ABX75909.

PT New isolated PRO polypeptide and encoding nucleic acids, useful for the
 PT diagnosis and treatment of disorders such as inflammatory disease,
 PT atherosclerosis, cardiac injury, infertility, AIDS, cancer and diabetic
 PT complications.

PS Claim 12; Fig 14; 171pp; English.

XX
 CC The invention relates to an isolated PRO polypeptide having at least 80%
 CC amino acid sequence identity to and scoring at least 80% positives when
 CC compared to any of 15 fully defined sequences of 235-954 amino acids,
 CC given in the specification. Also included are: (1) an isolated PRO
 CC nucleic acid having at least 80% nucleic acid sequence identity to a
 CC nucleotide sequence that encodes PRO or its extracellular domain, and
 CC comprising any of 15 fully defined nucleotide sequences of 957-3441 bp,
 CC given in the specification and deposited under ATCC accession number
 CC 209526, 209508, 209524, 209528, 209530, 209523, 209492, 209532, 209531,
 CC 209529, 209527, 209570, 209618, 209621 and 209619; (2) a vector
 CC comprising the PRO nucleic acid; (3) a host cell comprising the vector;
 CC (4) producing PRO polypeptides, comprising culturing the cell for
 CC expression of the PRO polypeptide and recovering the PRO polypeptide from
 CC the cell culture; (5) a chimeric molecule comprising PRO fused to a
 CC heterologous amino acid sequence, and (6) an anti-PRO antibody. The
 CC methods and compositions are useful for the diagnosis and treatment of
 CC disorders such as inflammatory disease, organ failure, atherosclerosis,
 CC cardiac injury, infertility, birth defects, premature aging, AIDS
 CC (acquired immunodeficiency syndrome), cancer, diabetic complications and
 CC mutations in general. The present sequence is a PRO polypeptide

XX Sequence 422 AA;

Query Match 99.5%; Score 2279.5; DB 6; Length 422;

Best Local Similarity 99.8%; Pred. No. 3.4e-184; Mismatches 421; Conservative 0; Indels 1; Gaps 1;

QY 1 MPAGRRGPAAGSARPPPLLP-LLLLCVLGAPRAGSGAHTAVISPDPPTLLIGSSLLATC 59
 DB 1 MPAGRRGPAAGSARPPPLLP-LLLLCVLGAPRAGSGAHTAVISPDPPTLLIGSSLLATC 60
 QY 60 SVHGDPPGATAEGLYTLNGRRLLPPELSRYLANSTLALANLNGSRGSGDNLVCHARD 119
 DB 61 SVHGDPPGATAEGLYTLNGRRLLPPELSRYLANSTLALANLNGSRGSGDNLVCHARD 120
 QY 120 GSIIAGSCLYVGLPPEKPVNISCSKMKMDLTCRWTPGAHGETFLHTNYSLKTKLRWYGO 179
 DB 121 GSIIAGSCLYVGLPPEKPVNISCSKMKMDLTCRWTPGAHGETFLHTNYSLKTKLRWYGO 180
 QY 180 DNTCEBYHTVGPHSCHIPKDLALFTPEYIWEATNRLGARSVDVLTLDIVVTTDPPPD 239
 DB 181 DNTCEBYHTVGPHSCHIPKDLALFTPEYIWEATNRLGARSVDVLTLDIVVTTDPPPD 240

QY 240 VHSRVVGLLEDQSLVRWVSPALKDFLFOAKYQIRYRVEDSDVMKVVDVSNQTSCLAG 299
 DB 241 VHSRVVGLLEDQSLVRWVSPALKDFLFOAKYQIRYRVEDSDVMKVVDVSNQTSCLAG 300
 QY 300 LKPGTYFVQVRCNPFGIYGSKKAGIWSWSHPTAASTPRSEPPGCGGACEPRGSPSS 359
 DB 301 LKPGTYFVQVRCNPFGIYGSKKAGIWSWSHPTAASTPRSEPPGCGGACEPRGSPSS 360
 QY 360 GPVRRRLKQFLGWLKKGAVCSNLSFRLYDQWRAMQKSHKTRNQDGGILPSGGRGTARGP 419
 DB 361 GPVRRRLKQFLGWLKKGAVCSNLSFRLYDQWRAMQKSHKTRNQDGGILPSGGRGTARGP 420
 QY 420 AR 421
 DB 421 AR 422

Search completed: February 24, 2005, 03:33:08
 Job time : 79 secs

This Page Blank (uspto)

Db 191 FKILSLHPEQKYLIVYRCKP-----DHGWSAMSAPATFIQIP 227

RESULT 2

A59405

prolactin receptor short form S1a precursor, breast cancer cells T-47D - human

C/Species: Homo sapiens (man)

C/Date: 01-Feb-2002 #sequence_revision 01-Feb-2002 #text_change 09-Jul-2004

C/Accession: A59405; A49400

R/Hu, Z.Z.; Meng, J.; Dufau, M.L.

J. Biol. Chem. 276, 41086-41094, 2001

A/Title: Isolation and characterization of two novel forms of the human prolactin receptor

A/Reference number: A59405; MUID:21538812; PMID:11518703

A/Accession: A59405

A/Status: preliminary

A/Molecule type: DNA

A/Residues: 1-376 <HU1>

A/Cross-references: UNIPROT:Q96P35; GB:AF214012; PIDN:AF214012.1

R/Hu, Z.Z.

submitted to GenBank, December, 1999

A/Reference number: A49400

A/Accession: A49400

A/Status: preliminary

A/Molecule type: DNA

A/Residues: 1-376 <HU2>

A/Cross-references: GB:AF214012; PIDN:AF214012.1

C/Comment: This is one of the short forms (S1a and S1b) of the human prolactin receptor eta-casein gene promoter activation, with S1a less effective than S1b. However, their 11 ted COS-1 and HEK293 cells is due to rapid intracellular turnover of the receptor. #expe

C/Genetics:

A/Gene: GDB:PRLR

A/Cross-references: GDB:120315; OMIM:176761

A/Map position: 5p13.3-5p13.1

C/Keywords: glycoprotein; transmembrane protein

F/1-24/Domain: signal sequence #status predicted <SIG>

F/25-376/Product: prolactin receptor, short form S1a #status predicted <MAT>

F/36-221/Domain: cytokine receptor homology <CRS>

F/59,104,233/Binding site: carbohydrate (Asn) (covalent) #status predicted

Query Match 14.5%; Score 332; DB 2; Length 376;

Best Local Similarity 37.1%; Pred. No. 2.9e-18;

Matches 83; Conservative 28; Mismatches 95; Indels 18; Gaps 8;

QY 122 ILAAGCLVYG-LPPEKPVNISCSKMKMDLTCRWTGAGHGETFLHTNYSLKYLKRWYGD 180

Db 15 LFLNTCLANGOLPPGKPELFCRSPNKEFTFCWMPGTDG--LPTNYSILYTHRGETLM 72

QY 181 NTCEBYHTVGPCHSCHIIPKD-LALFTPYEITWEATNRLGSARSVDLTLDILDVTTDPPD 239

Db 73 HECPPDYITGPNNSCHFGKQYTSWWRITIMVNATNMGSSFSDELVDVTVYVQDPPLE 132

QY 240 VHSVRYVGLIEDQLSVRW--SPALKDF---LFQAKYQIRRYVEDSVDMKVVDVSNQTS 294

Db 133 LAV-EVKQPEDRKPRFLYIMKSPPTLLIDLTGWFLLYIRLKEKAEME-IHFAQQTE 190

QY 295 CRLAGLKPGTVYFVQVRCNPFGIYGSKKAGIWESSHPTASTP 338

Db 191 FKILSLHPEQKYLIVYRCKP-----DHGWSAMSAPATFIQIP 227

RESULT 3

A40144

prolactin receptor long form precursor, hepatoma and breast cancer cells - human

C/Species: Homo sapiens (man)

C/Date: 17-Jul-1992 #sequence_revision 17-Jul-1992 #text_change 09-Jul-2004

C/Accession: A40144; A57018

R/Boutin, J.M.; Edey, M.; Shirota, M.; Jolicœur, C.; Lesueur, L.; Ali, S.; Gould, D.; Mo, Endocrinol. 3, 1455-1461, 1989

A/Title: Identification of a cDNA encoding a long form of prolactin receptor in human he

A/Reference number: A40144; MUID:90114212; PMID:2558309

A/Accession: A40144

A/Molecule type: mRNA

A/Residues: 1-622 <BOU>

A/Cross-references: UNIPROT:P16471; GB:M31661; NID:9190361; PIDN:AAA60174.1; PID:9190362

R/Fuh, G.; Wells, J.A.

J. Biol. Chem. 270, 13133-13137, 1995

A/Title: Prolactin receptor antagonists that inhibit the growth of breast cancer cell li

A/Reference number: A57018; MUID:95286597; PMID:7768908

A/Accession: A57018

A/Status: preliminary; translated from GB/EMBL/DBJ

A/Molecule type: mRNA

A/Residues: 25-228, 'AW' <RES>

A/Cross-references: GB:S78505; NID:9999114; PIDN:AA834470.1; PID:9999115

C/Genetics:

A/Gene: GDB:PRLR

A/Cross-references: GDB:120315; OMIM:176761

A/Map position: 5p13.3-5p13.1

C/Keywords: glycoprotein; transmembrane protein

F/1-24/Domain: signal sequence #status predicted <SIG>

F/25-622/Product: prolactin receptor, long form #status predicted <MAT>

F/36-221/Domain: cytokine receptor homology <CRS>

F/59,104,233/Binding site: carbohydrate (Asn) (covalent) #status predicted

Query Match 14.5%; Score 332; DB 2; Length 622;

Best Local Similarity 37.1%; Pred. No. 5.5e-18;

Matches 83; Conservative 28; Mismatches 95; Indels 18; Gaps 8;

QY 122 ILAAGCLVYG-LPPEKPVNISCSKMKMDLTCRWTGAGHGETFLHTNYSLKYLKRWYGD 180

Db 15 LFLNTCLANGOLPPGKPELFCRSPNKEFTFCWMPGTDG--LPTNYSILYTHRGETLM 72

QY 181 NTCEBYHTVGPCHSCHIIPKD-LALFTPYEITWEATNRLGSARSVDLTLDILDVTTDPPD 239

Db 73 HECPPDYITGPNNSCHFGKQYTSWWRITIMVNATNMGSSFSDELVDVTVYVQDPPLE 132

QY 240 VHSVRYVGLIEDQLSVRW--SPALKDF---LFQAKYQIRRYVEDSVDMKVVDVSNQTS 294

Db 133 LAV-EVKQPEDRKPRFLYIMKSPPTLLIDLTGWFLLYIRLKEKAEME-IHFAQQTE 190

QY 295 CRLAGLKPGTVYFVQVRCNPFGIYGSKKAGIWESSHPTASTP 338

Db 191 FKILSLHPEQKYLIVYRCKP-----DHGWSAMSAPATFIQIP 227

RESULT 4

A36337

membrane glycoprotein gp130 precursor - human

C/Species: Homo sapiens (man)

C/Date: 12-Apr-1991 #sequence_revision 12-Apr-1991 #text_change 09-Jul-2004

C/Accession: A36337

R/Hibi, M.; Murakami, M.; Saito, M.; Hirano, T.; Taga, T.; Kishimoto, T.

Cell 63, 1149-1157, 1990

A/Title: Molecular cloning and expression of an IL-6 signal transducer, gp130.

A/Reference number: A36337; MUID:91084844; PMID:2261637

A/Accession: A36337

A/Status: preliminary

A/Molecule type: mRNA

A/Residues: 1-918 <HIB>

A/Cross-references: UNIPROT:P40189; GB:M57230; NID:9186353; PIDN:AAA59155.1; PID:9186354

C/Genetics:

A/Gene: GDB:IL6ST; GP130

A/Cross-references: GDB:126725; OMIM:600694

A/Map position: 5q11-5q11

C/Keywords: glycoprotein; membrane protein

F/134-316/Domain: cytokine receptor homology <CRS>

Query Match 14.1%; Score 323; DB 2; Length 918;

Best Local Similarity 28.2%; Pred. No. 4.5e-17;

Matches 87; Conservative 52; Mismatches 151; Indels 18; Gaps 8;

QY 42 ISPDPPTLLIGSSLATGCVHG---DPRATAGLWTLNGRRRLPPELSRVINASTLA 98

Db 31 IIPESVVOJLHNFPAVVCYLKCKMDYFVNANVYVWKTHFTIPEQYTIINRTASSVT 90

QY 99 LANLNGRSGSDNIVCHARDSILAGCLVYGLPPEKPVNISCSKMKMDLTCRWTPGA 158

```

Db      91 FTDLASLNLQITCNILIFGQLEQNVYGIITISGLPPEKPKNLISGVNKGKMRCEMDGCR 150
      159 HGETFLHTNYSLKTKLRWYGQDNTCEHYHTVGPISHCIPKDLALFTPEYIWEATNRLG 218
      151 --ETHELTNTLTKSEMAHFKADCKARDT--PTSCIVDSYTVFVNIIEVVEAENALGK 206
      219 ARBQVLTLDLIDVYTTTPPPVNHVSRRGLEDQLSVWMSPPALKDLPQAKYQIRRV 278
      207 VTSDHNIHFDVYKRPKPPHNLVSYNSEELSLIKLTWTN-PSIKSVIT-LKXNIQYRTK 264
      279 DSVDMKVY---DVSNOTSCRLAGLKPGTVYFVOVRCNPFQISGSKAGIEMSEHPTAA 335
      265 DASWMSQIPPEDTASTSSFTVQDLKPFTEYFRIKRC-----MEDDKGYSMDSEASG 319
      336 STPSERP 343
      320 IT-YEDRP 326

```

RESULT 5

```

glycoprotein 130 - mouse
C/Species: Mus musculus (house mouse)
C/Date: 02-Aug-1996 #sequence_revision 02-Aug-1996 #text_change 09-Jul-2004
C/Accession: I49499, I48370
R/Saito, M.; Yoshida, K.; Hibi, M.; Taga, T.; Kishimoto, T.
J. Immunol. 148, 4066-4071, 1992
A/Title: Molecular cloning of a murine IL-6 receptor-associated signal transducer, gp130
A/Reference number: I48370, MUID:92291532, PMID:1602143
A/Accession: I49699
A/Status: translated from GB/EMBL/DBJ
A/Molecule type: mRNA
A/Residues: 1-917 <RES>
A/Cross-references: UNIPROT:Q00560; GB:M83336; NID:9193591; PID:AAA37723.1; PID:9193592
A/Accession: I48370
A/Status: translated from GB/EMBL/DBJ
A/Molecule type: mRNA
A/Residues: 1-917 <RES>
A/Cross-references: EMBL:X62646; NID:9840816; PID:CAA44515.1; PID:9840817
C/Genetics:
A/Gene: gp130
C/Keywords: glycoprotein
F/134-314/Domain: cytokine receptor homology <CRS>

```

```

Query Match      13.9%; Score 317.5; DB 2; Length 917;
Best Local Similarity 29.6%; Pred. No. 1.2e-16;
Matches 92; Conservative 50; Mismatches 146; Indels 23; Gaps 10;

```

```

      42 ISPDPTLLIGSSILATCSVHG--DPPGATAGLWYTLNGRLRPPELSRVLAASLALA 98
      31 IYEPFPVVGSGNSFTATCVLKEACLOHYVNASYIWKTNAAAPREQVTVINNTSSVT 90
      99 LANINGSRQSGDNLVCHARDGSLIAGSCLVVGAPPEKPVNISGMSKMDLTCRWTPGA 158
      91 FTDLVLPVQVLTCTNLSFGQLEQNVYGIITISGLPPEKPKNLISGVNKGKMRCEMDGCR 150
      159 HGETFLHTNYSLKTKLRWYGQD--NTCEHYHTVGPISHCIPKDLALFTPEYIWEATNRLG 217
      151 --ETHELTNTLTKSE--WATEKFPDQCSKIGT---SCNVSMFPIYVNIIEVVEAENALG 203
      218 SANSQVLTLDLIDVYTTTPPPVNHVSRRGLEDQLSVWMSPPALKDLPQAKYQIRRV 277
      204 KVSSESINFPVDKPKPTPNLVSITNSEELSLIKLTWSSSGV--GGLDLKSDIDYRT 261
      278 EDSVDMKVY---DVSNOTSCRLAGLKPGTVYFVOVRCNPFQISGSKAGIEMSEHPTAA 334
      262 KDASTWQVLPEDTMSPTSTFTVQDLKPFTEYFRIKRC-----SIDSGK-GTWSMDSEASG 316
      335 ASL--PSERP 343
      317 GTTYEDRPSRP 327

```

RESULT 6

```

prolactin receptor - pigeon
C/Species: Columba livia (domestic pigeon)
C/Date: 13-Sep-1996 #sequence_revision 13-Sep-1996 #text_change 09-Jul-2004
C/Accession: I50455
R/Chen, X.; Horeman, N.D.
Endocrinology 135, 269-276, 1994
A/Title: Cloning, expression, and mutational analysis of the pigeon prolactin receptor.
A/Reference number: I50455, MUID:94283267, PMID:7516866
A/Accession: I50455
A/Status: preliminary; translated from GB/EMBL/DBJ
A/Molecule type: mRNA
A/Residues: 1-830 <CHB>
A/Cross-references: UNIPROT:Q90374; EMBL:U07694; NID:9466381; PID:AAA20646.1; PID:9466
F/36-220/Domain: cytokine receptor homology <CRS1>
F/240-426/Domain: cytokine receptor homology <CRS2>

```

```

Query Match      13.8%; Score 316; DB 2; Length 830;
Best Local Similarity 36.6%; Pred. No. 1.4e-16;
Matches 75; Conservative 30; Mismatches 82; Indels 18; Gaps 8;

```

```

      133 PPEKPVNISGMSKMDLTCRWTPGAHGETFLH-TNYSLKTKLRWYGQDNTCEHYHTVGP 191
      231 PPEKPTIKRSPBEKETFTCMKFGSDG--HPTVTLTYSKEGSERYVECPDYKTAGP 287
      192 HSCHI-PKDLALFTPEYIWEATNRLGARSQVLTLDLIDVYTTTPPPV--HVSRYGL 248
      288 NSCFPDKHYSFWTIYITVKAINEIGSNVSDPLYVDVYIYQTDPPVNTLEKTKVNR 347
      249 EDQLSVRWSPPLAKD--LPQAKYQIRRVSDSVDMKVVDVSNOTSCRLAGLKPGTV 305
      348 KPYLVLTW--SPPLADVRSGMLTLDYELRLKPEABEWET-FVGGQTHYKMSPLNGKK 405
      306 YFVQVRCNPFQISGSKAGIEMSEMS 330
      406 YIVQIHCKP-----DHGSMSEMS 424

```

RESULT 7

```

interleukin-6 signal transducing molecule gp130 - rat
C/Species: Rattus norvegicus (Norway rat)
C/Date: 30-Apr-1993 #sequence_revision 18-Nov-1994 #text_change 09-Jul-2004
C/Accession: A44257
R/Mang, Y.; Nesbitt, J.B.; Fuentes, N.L.; Fuller, G.M.
Genomics 14, 666-672, 1992
A/Title: Molecular cloning and characterization of the rat liver IL-6 signal transducin.
A/Reference number: A44257, MUID:93052397, PMID:1427893
A/Accession: A44257
A/Status: preliminary; not compared with conceptual translation
A/Molecule type: mRNA
A/Residues: 1-918 <MAN>
A/Cross-references: UNIPROT:P40190
A/Experimental source: liver
A/Note: Sequence extracted from NCBI backbone (NCBI:P118488)
C/Keywords: transmembrane protein
F/134-315/Domain: cytokine receptor homology <CRS>

```

```

Query Match      13.7%; Score 314.5; DB 2; Length 918;
Best Local Similarity 29.7%; Pred. No. 2e-16;
Matches 93; Conservative 51; Mismatches 140; Indels 29; Gaps 11;

```

```

      42 ISPDPTLLIGSSILATC-----SVHGDPGATAGLWYTLNGRLRPPELSRVLAASL 94
      31 IYEPFPVVGSGNSFTATCVLKEACLOVY---SVNATYIWKTNHVAVPEQVTVINRTA 86
      95 LALALANINGSRQSGDNLVCHARDGSLIAGSCLVVGAPPEKPVNISGMSKMDLTCRW 154
      87 SSVTFDVVQVQVLTCTNLSFGQLEQNVYGIITISGLPPEKPKNLISGVNKGKMRCEMDGCR 146
      155 TPQAHGETFLHTNYSLKTKLRWYGQD--NTCEHYHTVGPISHCIPKDLALFTPEYIWEAT 213

```

```

Db      147 DPGR--ETYLENTNTLTKSE--WATEKPPDCKTKH--GTSSCMGPTPIYFNLTVEWWEAE 200
Qy      214 NRIUGASRDVLTLLDLDVVTTPDPDVHVSXVGLIEDQLSVRWVSPPALXDPLFOAKYQI 273
Db      201 NALGNVSESEPINFDPVDKVKPSPPHNLNLTVMSELSLILKLAWNSSL--DSLIRLKSIDI 258
Qy      274 RYRVEDSVDMKVY--DDVSNQTSGLAGLKEPTIVYQVRCNDFGIYSKKAQINSEWS 330
Db      259 QYRTKDASTWYQVPLEBTVSPTSTFTODLKEPTEYVFRIR---SIKENKG-GYMSDWS 313
Qy      331 HPTASTPERSERP 343
Db      314 E-EASGTTIEDRP 325

RESULT 8
A29884
prolactin receptor precursor - rat
C:Species: Rattus norvegicus (Norway rat)
C:Date: 30-Sep-1989 #sequence_revision 30-Sep-1989 #text_change 09-Jul-2004
C:Accession: A29884
R:Boivin, J.M.; Jolicoeur, C.; Okamura, H.; Gagnon, J.; Gdery, M.; Shiota, M.; Barville
Cell 53, 69-77, 1988
A:Title: Cloning and expression of the rat prolactin receptor, a member of the growth ho
A:Reference number: A29884; MUID:86165059; PMID:2832068
A:Accession: A29884
A:Molecule type: mRNA
A:Residues: 1-310 <BOU>
C:Keywords: transmembrane protein
F:1-19/Domain: signal sequence #status predicted <SIG>
F:20-310/Product: prolactin receptor #status predicted <NAT>
F:31-216/Domain: cytokine receptor homology <CRS>

```

	A.Reference number: I55417, MUID:95014432, PMID:7929319
	A.Accession: I55417
	A.Status: translated from GB/EMBL/DBJ
	A.Molecule type: mRNA
	A.Residues: 1-412 <RES>
	A.Cross-references: EMBL:U07567; NID:9641963; PIDN:AA61784.1; PID:9641964
	A.Experimental source: NB2-11C cell line
	C.Keywords: transmembrane protein
	F.31-216/Domain: cytokine receptor homology <CRS>
Query Match	13.7%; Score 313; DB 2; Length 412;
Best Local Similarity	35.0%; Pred. No. 9.9e-17;
Matches	79; Conservative 36; Mismatches 85; Indels 26; Gaps 10;
QY	121 SIIAGSCLVGLPPEKRVNISCSKMKDITCRTPGAHBEFLHINYSLKTKLRWYGOD 180
DB	15 SIIKGOS-----PRGKEIKHCRSPDKREFTCWNNPPTDGG--LPTNYSLTYSKE--GEK 65
QY	181 NT---CEEHTHTVGPSCII PKD-LALPFRYEIWEATRLGASADVLTLLIDVVTDDPP 237
DB	66 TTVECPDYKISGEPNSCFPSKQYTSIMKIYITIVNATQWSSSDPLVDDVTYIVBEPP 125
QY	238 PDVEHSEVSGIEDLDLSYRWV--SEPALKDF---LFOAKYQIRYVEDSVMKRVVDVSNQ 292
DB	126 RNLRL- EYKQIKDKKTYLWVXMSPTLTIDVKTGFTMEYEIRLKPDEAAEME--IHPTGHQ 183
QY	293 TSCSLAGLRGTYVYVQVRCNPRFQIYSKKAQIGISEMSHPTLAATP 338
DB	184 TQFVFDLPYEQKYLVTQCKP-----DHGWSRMSQSSSVEMP 222

	Query Match	13.7%	Score 313;	DB 2;	Length 310;
	Best Local Similarity	35.0%;	Pred. No. 7e-17;		
	Matches	Conservative 36;	Mismatches 85;	Indels 26;	Gaps 10;
Oy	121 SLIAGSLCYGLPREKPVNISCMKNMKDLTCRTPGAHGTFPHNTYSLTKYLRMGOD	160			
Dd	15 SLLKGQS-----PQGRKEIHKCRSPDKETFCVMNPGITDGG--LPITYSLTYSKE--GEK	65			
Oy	181 NT---CEEHYTHVGPCHSICHPKD-LALFTPEYEIVWEATRLGSARSADVTLTILIDVVTTDP	237			
Dd	66 TTTECPDYKISGPRSCFESKOYTSMKIYITTVATNQMSSSSDPLVAVTYIIIVEEPP	125			
Oy	238 PDVAHSRVLGEDQLSVRWV--SPPALKDFF--LFQAQYQIRRVEDSDMKTVDVSNQ	292			

C|Species: Rattus norvegicus (Norway rat)
C|Date: 13-Jul-1990 #sequence_revision 09-Oct-1992 #text_change 09-Jul-2004
C|Accession: A34631
R|Zhang, R.; Buczek, E.; Tsai-Morris, C.H.; Hu, Z.Z.; Dufnu, M.L.
Biochem. Biophys. Res. Commun. 168, 415-422, 1990
A|Title: Isolation and characterization of two novel rat ovarian lactogen receptor cDNA
A|Reference number: A34631; MUID:90241201; PMID:2159291
A|Accession: A34631
A|Status: preliminary
A|Molecule type: mRNA
A|Residues: 1-610 <ZHA>
A|Cross-references: UNIPROT:P05710; GB:M34083; NID:G205122; PIND:AAA79273.1; PID:G205122222
A|Note: The authors translated the codon GAG for residue 533 as Gly
F|31-216|Domain: cytokine receptor homology <CR>

```

Oy      293  TSCSLAGKPGTYEYFVQRCNPFGIYSKKAGIMSESHPTASTP 338
      ::  ::  ::  ::  ::  ::  ::  ::  ::  ::  ::  ::  ::  ::  ::  ::
Db      184  TQFVFDLYPGQKYLVTQRCP-----DHGIWSRWSQSSVEVMP 222

RESULT 9
A41070
P:prolactin receptor NB2 precursor - rat
C:Species: Rattus norvegicus (Norway rat)
C:Date: 12-Jun-1992 #sequence_revision 12-Jun-1992 #text_change 09-Jul-2004
C:Accession: A41070; I55417
R:Ali, S.; Pellegrini, I.; Kelly, P.A.
J. Biol. Chem. 266, 20110-20117, 1991
A:Title: A prolactin-dependent immune cell line (NB2) expresses a mutant form of prolactin
A:Reference numbers: A41070; MUID:92041834; PMID:11718958
A:Accession: A41070
A:Molecule type: mRNA
A:Residues: 1-412 <Ali>
A:Cross-references: UNIPROT:P05710; GB:M74152; NID:g206389; PIDN:AAA41946.1; PID:g206390
R:O'Neal, K.D.; Yu-Lee, L.Y
J. Biol. Chem. 269, 26076-26082, 1994
A:Title: Differential signal transduction of the short, NB2, and long prolactin receptor

```

[illegible]

C/Species: Rattus norvegicus (Norway rat)
 C/Date: 28-Mar-1991 #sequence_revision 28-Mar-1991 #text_change 09-Jul-2004
 C/Accession: A36116
 R/Shiota, M.; Banville, D.; Ali, S.; Jolicoeur, C.; Boutin, J.M.; Edey, M.; Djiane, J.
 Mol. Endocrinol. 4, 1136-1143, 1990
 A/Title: Expression of two forms of prolactin receptor in rat ovary and liver.
 A/Reference number: A36116; MUID:91155946; PMID:2293022
 A/Accession: A36116
 A/Status: preliminary
 A/Molecule type: mRNA
 A/Residues: 1-610 <SHI>
 A/Cross-references: UNIPROT:P05710; GB:M57668; NID:g206366; PIDN:AAA1938.1; PID:g206367
 F/31-216/Domain: cytokine receptor homology <CRS>

Query Match 13.7%; Score 313; DB 2; Length 610;
 Best Local Similarity 35.0%; Pred. No. 1.6e-16;
 Matches 79; Conservative 36; Mismatches 85; Indels 26; Gaps 10;

121 SLAGSCLVYGLPEPEKVNISCKMKNKDLTCRWTGAGHGFPLHTNYSKYKLRWYGD 180
 15 SLKKGQ-----PGKREIHKCRSPDKETFCMNPGLDGG--LPTNYSLYTSKE--GEK 65
 181 NT--CEHYHTVGPISCHIPKD-LALFTPEIWEATNRLGARSQDVLTLIDLVTTDP 237
 66 TTECPDYKTSKSPNSCFKSKOYTSIMKIYIITVNATQMGSSSDPLVYDVYIYEPEPP 125
 238 PDHVSRRVGLLEDLSRWV--SPALKDF--LFOAKYQIRRVEDSVMKVVDVDSNQ 292
 126 RNELT-EVKQKDKKTYLWKMSPPTITDVKTGMFTWEYERLKEEAEWE-IFHTGHQ 183
 293 TSGRLAKPEQTVFYVQRCNPFQYSGSKAGIWESESHPTAATP 338
 184 TQKVPFLYPGOKLYVQTRCKP-----DHGYWRRSQESVEMP 222

RESULT 12
 177525
 prolactin receptor precursor - mouse
 C/Species: Mus musculus (house mouse)
 C/Date: 02-Aug-1996 #sequence_revision 02-Aug-1996 #text_change 09-Jul-2004
 C/Accession: I77925
 R/Davis, J.A.; Linzer, D.I.H.
 Mol. Endocrinol. 3, 674-680, 1989
 A/Title: Expression of multiple forms of the prolactin receptor in mouse liver.
 A/Reference number: I57699; MUID:89261824; PMID:2725531
 A/Accession: I77925
 A/Status: preliminary; translated from GB/EMBL/DBJ
 A/Molecule type: mRNA
 A/Residues: 1-292 <RES>
 A/Cross-references: UNIPROT:Q08501; GB:M22959; NID:g200481; PIDN:AAA39977.1; PID:g200482
 F/31-216/Domain: cytokine receptor homology <CRS>

Query Match 13.5%; Score 309.5; DB 2; Length 292;
 Best Local Similarity 31.4%; Pred. No. 1.2e-16;
 Matches 82; Conservative 38; Mismatches 94; Indels 47; Gaps 10;

86 LSRVLAATLALANLNGSRGSDNLVCHARDGSLAASCLYGLPEKPVNISGWSK 145
 1 MSSALAYMLLVLSLNGQS-----PGKPEIHKCRSP 34
 146 NMKDLTCRWTGAGHGFPLHTNYSKYKLRWYGDNT--CEHYHTVGPISCHIPKD-LAL 202
 35 DKETFTCMNPGSDGG--LPTNYSLYTSKE--GEKNTYECPDYKTSKPNCFKSKOYTSI 90
 203 FTPEIWEATNRLGARSQDVLTLIDLVTTDPDPHVSRRVGLLEDLSVRWVS--PP 260
 91 WKIYIITVNATNMGSTSDPLVYDVYIYEPEPPRLTL-EVKQKDKKTYLWKMVLP 149
 261 ALKDF--LFOAKYQIRRVEDSVMKVVDVDSNQTSCLAGLKPQTVFYVQRCNPFQI 317
 150 TITDVKTGMFTWEYERLKEEAEWE-IFHTGHQTFKVFYDLPGOKLYVQTRCKP--- 205
 318 YGSKKAGIWESESHPTAATP 338

Db 206 ----DHGYWRRSQEKSEIIP 222

RESULT 13
 177524
 prolactin receptor precursor - mouse
 C/Species: Mus musculus (house mouse)
 C/Date: 02-Aug-1996 #sequence_revision 02-Aug-1996 #text_change 09-Jul-2004
 C/Accession: I77524
 R/Davis, J.A.; Linzer, D.I.H.
 Mol. Endocrinol. 3, 674-680, 1989
 A/Title: Expression of multiple forms of the prolactin receptor in mouse liver.
 A/Reference number: I57699; MUID:89261824; PMID:2725531
 A/Accession: I77524
 A/Status: preliminary; translated from GB/EMBL/DBJ
 A/Molecule type: mRNA
 A/Residues: 1-303 <RES>
 A/Cross-references: UNIPROT:Q08501; GB:M22958; NID:g200479; PIDN:AAA39976.1; PID:g20048
 F/31-216/Domain: cytokine receptor homology <CRS>

Query Match 13.5%; Score 309.5; DB 2; Length 303;
 Best Local Similarity 31.4%; Pred. No. 1.3e-16;
 Matches 82; Conservative 38; Mismatches 94; Indels 47; Gaps 10;

86 LSRVLAATLALANLNGSRGSDNLVCHARDGSLAASCLYGLPEKPVNISGWSK 145
 1 MSSALAYMLLVLSLNGQS-----PGKPEIHKCRSP 34
 146 NMKDLTCRWTGAGHGFPLHTNYSKYKLRWYGDNT--CEHYHTVGPISCHIPKD-LAL 202
 35 DKETFTCMNPGSDGG--LPTNYSLYTSKE--GEKNTYECPDYKTSKPNCFKSKOYTSI 90
 203 FTPEIWEATNRLGARSQDVLTLIDLVTTDPDPHVSRRVGLLEDLSVRWVS--PP 260
 91 WKIYIITVNATNMGSTSDPLVYDVYIYEPEPPRLTL-EVKQKDKKTYLWKMVLP 149
 261 ALKDF--LFOAKYQIRRVEDSVMKVVDVDSNQTSCLAGLKPQTVFYVQRCNPFQI 317
 150 TITDVKTGMFTWEYERLKEEAEWE-IFHTGHQTFKVFYDLPGOKLYVQTRCKP--- 205
 318 YGSKKAGIWESESHPTAATP 338
 206 ----DHGYWRRSQEKSEIIP 222

RESULT 14
 153269
 prolactin receptor, long form - mouse
 C/Species: Mus musculus (house mouse)
 C/Date: 02-Aug-1996 #sequence_revision 02-Aug-1996 #text_change 09-Jul-2004
 C/Accession: I53269; J0671; S34356
 R/Claire, D.L.; Linzer, D.I.H.
 Endocrinology 133, 224-232, 1993
 A/Title: Changes in prolactin receptor expression during pregnancy in the mouse ovary.
 A/Reference number: I53269; MUID:93307149; PMID:8319571
 A/Accession: I53269
 A/Status: preliminary; translated from GB/EMBL/DBJ
 A/Molecule type: mRNA
 A/Residues: 1-608 <RES>
 A/Cross-references: UNIPROT:Q08501; GB:L14811; NID:g293769; PIDN:AAA02686.1; PID:g29377
 R/Moore, R.C.; Oka, T.
 Gene 134, 263-265, 1993
 A/Title: Cloning and sequencing of the cDNA encoding the murine mammary gland long-form
 A/Accession: J0671; MUID:94085788; PMID:8262385
 A/Molecule type: mRNA
 A/Residues: 1-608 <MOO>
 A/Cross-references: GB:L13593; NID:g347398; PIDN:AA037641.1; PID:g347842
 R/Edey, M.; Pezet, A.; Nandi, S.; Kelly, P.A.
 submitted to the EMBL Data Library, June 1993
 A/Description: Isolation and nucleotide sequence of a mouse cDNA prolactin receptor.
 A/Reference number: S34356

A:Accession: S34356
A:Molecule type: mRNA
A:Residues: 1-557, 'F', 559-608 <EDB>
A:Cross-references: EMBL:X7372; NID:g312696; PIDN:CAA51789.1; PID:g312697
C:Comment: Prolactin receptor have long form and short form which are resulted from alternative splicing.
C:Keywords: receptor; transmembrane protein
F:31-216/Domain: cytokine receptor homology <CRS>
F:230-253/Domain: transmembrane #status predicted <TM>

Query Match 13.5%; Score 309.5; DB 2; Length 608;
Best Local Similarity 31.4%; Pred. No. 3e-16;
Matches 82; Conservative 38; Mismatches 94; Indels 47; Gaps 10;

QY 86 LSRVLAASLTALALANLNGSRQSGDNLVCHARDGSLIAGSCLYGLPPEKPNVISCWSK 145
DB 1 MSSALVMLVLSISLNGQS-----PPEKPEIHKCRSP 34
QY 146 NMKDLTCRWTPGAHGEFTLHNYSLKYKLRWYGODNT--CEBYHTVGPSCHI PKD-LAL 202
DB 35 DKHPTCWMNPGSDG--LPTNYSLTYSKE--GEKNYECPPDYKTSGPSNCFPSKQYTSI 90
QY 203 FTRPEIWEATNRLSGASDVLTLIDLVTTPDPDVHVSRYGVGEDQLSVRWVS--PP 260
DB 91 WKIYIITVNAIVNMGSGSTSDPLYVDYIYEPEPRNLTL-EVKQLKDKKTYLWVKMLPP 149
QY 261 ALKDF---LFOAKYQIRYVEDSVDMKVVDVSNQTSCLAGLKPGTVYFVQYRCNPFGI 317
DB 150 TITDVKTGMFTWEYELRLSEADEWE-IHFTGHQTFKVFYDLPGQKYLVTQTRCP--- 205
QY 318 YGSKKAGIWEWSHPTRAATP 338
DB 206 ----DHGYWSRMGQEKSEIEP 222

RESULT 15

JQ1655

prolactin receptor precursor - chicken

C:Species: Gallus gallus (chicken)

C>Date: 30-Sep-1993 #sequence_revision 30-Sep-1993 #text_change 09-Jul-2004

C:Accession: JQ1655

R:Tanaka, M.; Maeda, K.; Okubo, T.; Nakashima, K.

Biochem. Biophys. Res. Commun. 188, 490-496, 1992

A:Title: Double antenna structure of chicken prolactin receptor deduced from the cDNA se

A:Reference number: JQ1655; MID:93075121; PMID:1445292

A:Accession: JQ1655

A:Molecule type: mRNA

A:Residues: 1-831 <TAN>

A:Cross-references: UNIPROT:Q04594; DDBJ:D13154; NID:g222848; PIDN:BA02439.1; PID:g2228

A:Experimental source: kidney

C:Keywords: glycoprotein; transmembrane protein

F:1-23/Domain: signal sequence #status predicted <SIG>

F:24-831/Product: prolactin receptor #status predicted <MAT>

F:36-219/Domain: cytokine receptor homology <CRS1>

F:239-425/Domain: cytokine receptor homology <CRS2>

F:439-462/Domain: transmembrane #status predicted <TM>

F:59,91,100,112,132,262,303,315,335,647,701,800/Binding site: carbohydrate (Asn) (coval

Query Match 13.4%; Score 308; DB 2; Length 831;
Best Local Similarity 34.6%; Pred. No. 5.8e-16;
Matches 75; Conservative 28; Mismatches 96; Indels 18; Gaps 8;

QY 133 PPEKPNVISCWSKMKDLTCRWTPGAHGEFTLH-TNYSILKYKLRWYGODNTCEYHTVGP 191
DB 230 PPEKPTIICRSPKEFTTCWMPKGLDG--HPTNYTLISKEGEBQYECPPDYTAGP 286
QY 192 HSCHI-PKDLALFTPEIWEATNRLSGASDVLTLIDLVTTPDPDPV--HVSRYGGL 248
DB 287 NSCYFPDKHHSFTIINITRAINEMGSNSDPHYVDVYIYQDPFPVAVTLELKKPINR 346
QY 249 EDQLSVRWVSPPALKDF---LFOAKYQIRYVEDSVDMKVVDVSNQTSCLAGLKPGTV 305
DB 347 KPYLVLTW--SPPLADVRSGLTLIEYELRLKPEEGEWEI-FVGOOTQYKMFSLNPGKK 404

QY 306 YFVQYRCNPFGIYGSKKAGIWEWSHPTRAATP PRSR 342
DB 405 YIIQIHCRP-----DHGWSWSESENYYQLPNDPR 435

Search completed: February 24, 2005, 03:36:50
Job time : 42 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: February 24, 2005, 03:25:17 ; Search time 172 Seconds
(without alignments)
1253.403 Million cell updates/sec

Title: us-09-037-657-44

Perfect score: 2290

Sequence: 1 MPAGRGPAQASARPPPL.....NODEGILSGRGRTAGPAR 421

Scoring table: BLOSUM62

dapop 10.0, Gapext 0.5

Searched: 1612378 seqs, 512079187 residues

Total number of hits satisfying chosen parameters: 1612378

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database: 1: uniprot_sprot.*

2: uniprot_trembl.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	2279.5	99.5	422	1	CRL1_HUMAN
2	2178	95.1	425	1	CRL1_MOUSE
3	1418.5	61.9	389	2	O6DG28
4	1384.5	60.5	394	2	O6UN05
5	1365.5	16.0	918	2	O9W6U9
6	1354	15.5	881	2	O57519
7	1333	14.5	288	2	O8TD78
8	1332	14.5	288	2	O96P36
9	1332	14.5	349	2	O9UN45
10	1332	14.5	376	2	O96P35
11	1332	14.5	622	1	PRLR_HUMAN
12	1327.5	14.3	1010	2	O7TQ89
13	1325.5	14.2	206	2	O16354
14	1323	14.1	918	1	IL6B_HUMAN
15	1317.5	13.9	917	2	IL6B_MOUSE
16	1317.5	13.9	917	2	O6PD19
17	1317	13.8	622	2	O9N0J7
18	1316	13.8	830	1	PRLR_COLL1
19	1315	13.8	622	2	O865V4
20	1314.5	13.7	918	1	IL6B_PAT
21	1313	13.7	610	1	PRLR_PAT
22	1309.5	13.5	282	2	O8CTG1
23	1309.5	13.5	581	1	PRLR_SHEEP
24	1309.5	13.5	608	1	PRLR_MOUSE
25	1309.5	13.5	608	2	O99JZ1
26	1308	13.4	460	2	O7TQZ0
27	1308	13.4	625	1	PRLR_PIG
28	1308	13.4	831	1	PRLR_CHICK
29	1308	13.4	831	2	O6QDA0
30	1307	13.4	831	1	PRLR_MEIGA
31	1306.5	13.4	581	1	PRLR_BOVIN

32	304	13.3	581	1	PRLR_CEREL	O28235 cervus elap
33	300.5	13.1	616	1	PRLR_RABIT	P14787 oryctolagus
34	294	12.8	611	2	O9PTI9	O9PTI9 xenopus lae
35	292.5	12.8	611	2	O9IBP6	O9IBP6 xenopus lae
36	292.5	12.8	611	2	O9PTI0	O9PTI0 xenopus lae
37	291.5	12.7	604	2	O6UNP8	O6UNP8 tetraodon n
38	291	12.7	870	2	O6UNAO	O6UNAO tetraodon n
39	290	12.7	626	2	O9OWG7	O9OWG7 cynops pyr
40	290	12.7	819	2	O6IEF7	O6IEF7 eublepharis
41	281.5	12.3	617	2	O75821	O75821 rana catesb
42	279.5	12.2	402	2	O7T121	O7T121 brachydanio
43	270.5	11.8	227	2	O9GLW3	O9GLW3 ursus marit
44	270.5	11.8	346	2	O93404	O93404 oreochromis
45	270.5	11.8	625	2	O9X892	O9X892 trichosurus

ALIGNMENTS

RESULT 1	ID	CR1_HUMAN	STANDARD	PRT	422 AA.
AC	O75462; O9UHS5				
DT	29-MAR-2004 (Rel. 43, Created)				
DT	29-MAR-2004 (Rel. 43, Last sequence update)				
DT	25-JAN-2005 (Rel. 46, Last annotation update)				
DE	Cytokine receptor-like factor-1 precursor (Cytokine-like factor-1)				
DE	(CLF-1) (CYTOK5) (UNQ288/PRO327).				
GN	Name=CR1; Synonyms=CYTOK5;				
OS	Homo sapiens (Human).				
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;				
OC	Mammalia; Butiridae; Primates; Catarrhini; Homnidae; Homo.				
OX	NCBI_Taxid=9606;				
RP	SEQUENCE FROM N.A., SUBUNIT, SUBCELLULAR LOCATION, TISSUE SPECIFICITY,				
RP	AND INDUCTION.				
RC	TISSUE=Petal lung;				
RX	PubMed=9686600;				
RA	Elson G.C.A., Graber P., Loebinger C., Herren S., Grotzner D.,				
RA	Menoud L.N., Wells T.N.C., Kosco-Vilbois M.H., Gauchat J.-F.,				
RT	"Cytokine-like factor-1, a novel soluble protein, shares homology with				
RL	members of the cytokine type I receptor family.";				
RL	J. Immunol. 161:1371-1379(1998).				
RN	[2]				
RP	SEQUENCE FROM N.A.				
RA	Magrangeas F., Jacques Y., Minvielle S.,				
RA	"Cloning and expression of a novel soluble protein containing				
RT	hematopoietic cytokine receptor domains.";				
RL	Submitted (JUN-1998) to the EMBL/GenBank/DBJ databases.				
RN	[3]				
RP	SEQUENCE FROM N.A.				
RA	Lok S., Preenell S.R., Jellnberg A.C., Gilbert T., Whitmore T.E.,				
RA	Foster D.C., Adams R.L., Lehner J.M., O'Hara P.J.,				
RL	Submitted (AUG-1999) to the EMBL/GenBank/DBJ databases.				
RN	[4]				
RP	SEQUENCE FROM N.A.				
RX	MEDLINE=22867286; PubMed=12975309; DOI=10.1101/gr.1293003;				
RA	Clark H.F., Gurney A.L., Abaya E., Baker K., Baldwin D., Brush J.,				
RA	Chen J., Chow B., Chui C., Crowley C., Currell B., Dowd P.,				
RA	Easton D., Foster J., Grimaldi C., Gu O., Hase P.E., Heidens S.,				
RA	Huang A., Kim H.S., Klimowski L., Jin Y., Johnson S., Lee J.,				
RA	Lewis L., Liao D., Mark M., Robbie E., Sanchez C., Schoenfeld J.,				
RA	Seehagiri S., Simmons L., Singh J., Smith V., Stinson J., Vagts A.,				
RA	Vandlen R., Watanabe C., Wleand D., Woods K., Xie M.-H., Yansura D.,				
RA	Yi S., Yu G., Yuan J., Zhang M., Zhang Z., Goddard A., Wood W.I.,				
RT	"The secreted protein discovery initiative (SPDI), a large-scale				
RT	effort to identify novel human secreted and transmembrane proteins: a				
RT	bioinformatics assessment.";				
RL	Genome Res. 13:2265-2270(2003).				
RN	[5]				
RP	SEQUENCE FROM N.A.				
RP	TISSUE=Lymph;				

RA MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
 RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
 RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
 RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
 RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Heish F.,
 RA Datchenko L., Mausina K., Farmer A.A., Rubin G.M., Hong L.,
 RA Stapleton M., Soares M.B., Donald M.P., Casavant T.L., Scheetz T.E.,
 RA Brownstein M.U., Ueda T.B., Toshlyuk S., Carninci P., Prange C.,
 RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaly S.J.,
 RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
 RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
 RA Villalon D.K., Murty D.M., Sodergren E.J., Lu X., Gibbs R.A.,
 RA Fahy J., Helton E., Kettelman M., Madan A., Rodriguez S., Sanchez A.,
 RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
 RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
 RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
 RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smalins D.E.,
 RA Scherch A., Schein J.E., Jones S.J.M., Marra M.A.,
 RT "Generation and initial analysis of more than 15,000 full-length human
 RT and mouse cDNA sequences.";
 RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
 [6]
 RP SEQUENCE OF 38-52.
 RX PubMed=15340161; DOI=10.1110/ps.04682504;
 RA Zhang Z., Henzel W.J.,
 RT "Signal peptide prediction based on analysis of experimentally
 RT verified cleavage sites.";
 RL Protein Sci. 13:2819-2824(2004).
 [7]
 RP INTERACTIONS WITH CLC AND CNTFR.
 RX PubMed=10966616; DOI=10.1038/78765;
 RA Elson G.C.A., Lelievre E., Guillet C., Chevalier S., Plun-Favreau H.,
 RA Froger J., Suard I., de Coignac A.B., Delneste Y., Bonnetoy J.Y.,
 RA Gauchat J.-F., Gascan H.,
 RT "CLF associates with CLC to form a functional heteromeric ligand for
 RT the CNTF receptor complex.";
 RL Nat. Neurosci. 3:867-872(2000).
 [8]
 RP VARIANTS C1SS HIS-81 AND ARG-374.
 RX PubMed=12509788;
 RA Knapyskog P.M., Majewski J., Llynech A., Nilsen P.T.R., Bringsall J.S.,
 RA Ott J., Boman H.,
 RT "Cold-induced sweating syndrome is caused by mutations in the CRPL
 RT gene.";
 RL Am. J. Hum. Genet. 72:375-383(2003).
 CC -1- FUNCTION: Cytokine receptor subunit, possibly playing a regulatory
 CC role in the immune system and during fetal development. May be
 CC involved in nervous system development.
 CC -1- SUBUNIT: Forms covalently linked di- and tetramers. Forms a
 CC heteromeric complex with cardiotrophin-like cytokine (CLC); the
 CC CRPL/CLC complex is a ligand for the ciliary neurotrophic factor
 CC receptor (CNTFR).
 CC -1- SUBCELLULAR LOCATION: Secreted.
 CC -1- TISSUE SPECIFICITY: Highest levels of expression observed in
 CC spleen, thymus, lymph node, appendix, bone marrow, stomach,
 CC placenta, heart, thyroid and ovary. Strongly expressed also in
 CC fetal lung.
 CC -1- INDUCTION: Up-regulated in fibroblast primary cell cultures under
 CC stimulation by IFN-gamma, TNF-alpha and IL-6.
 CC -1- DOMAIN: The WSXWS motif appears to be necessary for proper protein
 CC folding and thereby efficient intracellular transport and cell-
 CC surface receptor binding.
 CC -1- DISEASE: Defects in CRPL are the cause of cold-induced sweating
 CC syndrome (C1SS) [MIM:272430]. C1SS is an autosomal recessive
 CC disorder characterized by profuse sweating induced by cool
 CC surroundings (temperatures of 7 to 18 degrees Celsius). Additional
 CC abnormalities include a high-arched palate, nasal voice, depressed
 CC nasal bridge, inability to fully extend the elbows and
 CC hypohidrosis.
 CC -1- SIMILARITY: Belongs to the type I cytokine family of receptors.
 CC Subfamily 3.
 CC -1- SIMILARITY: Contains 2 fibronectin type III domains.
 CC -1- SIMILARITY: Contains 1 immunoglobulin-like C2-type domain.

CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (see <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).

 DR EMBL; AF075293; AAC28335.1; -
 DR EMBL; AF073515; AAD39681.1; -
 DR EMBL; AF178684; AAD54385.1; -
 DR EMBL; AY158291; AAO88658.1; -
 DR EMBL; BC044634; AAH44634.1; -
 DR HSSP; P40223; ICD9.
 DR Genew; HGNC:2364; CRPL.
 DR MIM; 604237; -
 DR GO; GO:0005615; C:extracellular space; TAS.
 DR GO; GO:0004872; F:receptor activity; TAS.
 DR GO; GO:0019735; P:antimicrobial humoral response (sensu Verte. . .; TAS.
 DR InterPro; IPR002996; Cytok. Recept. B/G.
 DR InterPro; IPR003961; FN_III.
 DR InterPro; IPR008957; FN_III-like.
 DR Pfam; PF00041; fn3; 2.
 DR PROSITE; PS50853; FN3; 2.
 DR PROSITE; PS50835; IG_LIKE; FALSE_NEG.
 DR Direct protein sequencing; Disease mutation; Glycoprotein.
 KW Immunoglobulin domain; Phosphorylation; Receptor; Repeat; Signal.
 FT SIGNAL 1 37
 FT CHAIN 38 422 Cytokine receptor-like factor 1.
 FT DOMAIN 38 131 IG-like C2-type.
 FT DOMAIN 134 229 Fibronectin type-III 1.
 FT DOMAIN 234 334 Fibronectin type-III 2.
 FT SITE 327 331 WSXWS motif.
 FT DISULFID 143 153 By similarity.
 FT DISULFID 184 195 Phosphoserine (By similarity).
 FT MOD RES 219 219 N-linked (GlcNAc . .) (potential).
 FT CARBOHYD 92 92 N-linked (GlcNAc . .) (potential).
 FT CARBOHYD 104 104 N-linked (GlcNAc . .) (potential).
 FT CARBOHYD 140 140 N-linked (GlcNAc . .) (potential).
 FT CARBOHYD 168 168 N-linked (GlcNAc . .) (potential).
 FT CARBOHYD 292 292 N-linked (GlcNAc . .) (potential).
 FT CARBOHYD 382 382 N-linked (GlcNAc . .) (potential).
 FT VARIANT 81 81 R -> H (in C1SS).
 FT VARIANT 374 374 P/Tid=VAR_017865.
 FT VARIANT 374 374 L -> R (in C1SS).
 FT CONFLICT 240 240 /FTid=VAR_017866.
 FT CONFLICT 422 422 D -> E (in Ref. 3).
 SQ SEQUENCE 422 AA; 46301 MW; AD9DEFGB01B84228 CRC64;
 Query Match 99.5%; Score 2279.5; DB 1; Length 422;
 Best Local Similarity 99.8%; Pred. No. 7.1e-165;
 Matches 421; Conservative 0; Mismatches 0; Indels 1; Gaps 1;
 QY 1 MPAGRGPAAGSARRPPLLP-LLLLCVAGPAGSGATTAVISPDPPTLLIGSSILATC 59
 DB 1 MPAGRGPAAGSARRPPLLP-LLLLCVAGPAGSGATTAVISPDPPTLLIGSSILATC 60
 QY 60 SVHGDPGATAGLWYTLNGRRLPELSRVNASTLATLANLNGSRGSGNLYCHAD 119
 DB 61 SVHGDPGATAGLWYTLNGRRLPELSRVNASTLATLANLNGSRGSGNLYCHAD 120
 QY 120 GSTLASCLYGLPPEKPNVISCWSNMKDLTCRWTPGAGHGTPLHTNYSLKLRWYQ 179
 DB 121 GSTLASCLYGLPPEKPNVISCWSNMKDLTCRWTPGAGHGTPLHTNYSLKLRWYQ 180
 QY 180 DNTCEHYHTVGPSCCHPKDIALFTPEYIWEATNRLSGARSQDVLTLDDVTTDPPD 239
 DB 181 DNTCEHYHTVGPSCCHPKDIALFTPEYIWEATNRLSGARSQDVLTLDDVTTDPPD 240
 QY 240 VHSRVGLEDOLSVRWSPALKDFLFQAKQIRYVEDSVDMKVVDVSNQTSCLTAG 299

```

DB 241 VHSRVSGLJEDQSVWVSPALKDFLQAKYQIRRVEDSVWVKVVDVSNQTSCLAG 300
QY 300 LKSGTYFVQVVRNPNPGIYSSKAGIMSEWSHPTASTPSSRPGGACGCEPGRGSS 359
DB 301 LKSGTYFVQVVRNPNPGIYSSKAGIMSEWSHPTASTPSSRPGGACGCEPGRGSS 360
QY 360 GPVRRRLKQFLGWLKKGAYCSNLSFRLYDQWRAMQSKHTRNODGILPSGRGRTARGP 419
DB 361 GPVRRRLKQFLGWLKKGAYCSNLSFRLYDQWRAMQSKHTRNODGILPSGRGRTARGP 420
QY 420 AR 421
DB 421 AR 422
DB 421 AR 422

RESULT 2
CRL1_MOUSE STANDARD; PRT; 425 AA.
ID CRL1_MOUSE
AC 09JUN8;
DT 29-MAR-2004 (Rel. 43, Created)
DT 29-MAR-2004 (Rel. 43, Last sequence update)
DT 25-JUN-2005 (Rel. 46, Last annotation update)
DE Cytokine receptor-like factor 1 precursor (Cytokine-like factor-1)
DE (CLF-1) (Cytokine receptor-like molecule 3) (CRLM-3) (NR6).
GN Name=Crlf1; Synonyms=Crlm3;
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OC NCBI_Taxid=10090;
[1] _SEQUENCE FROM N.A.
RP Hitroyama T., Iwama A., Nakamura Y., Nakauchi H.;
RL Submitted (MAR-2000) to the EMBL/GenBank/DBJ databases.
RN [2]
RN FUNCTION, AND TISSUE SPECIFICITY.
RX PubMed=10359701; DOI=10.1016/S0960-9822(99)80266-8;
RA Alexander W.S., Rakar S., Robb L., Farley A., Willson T.A.,
RA Zhang J.-G., Hartley L., Kikuchi Y., Kojima T., Nomura H.,
RA Hasegawa M., Meda M., Fabri L., Jachno K., Nash A., Metcalfe D.,
RA Nicola N.A., Hilton D.J.;
RA "Suckling defect in mice lacking the soluble haemopoietin receptor
NR6."
RL Curr. Biol. 9:605-608(1999).
RN [3]
RN PHOSPHORYLATION SITE SER-222.
RX PubMed=15378723; DOI=10.1002/jcm.1604;
RA Jin W.H., Dai J., Zhou H., Xia O.C., Zou H.F., Zeng R.;
RT "Phosphoproteome analysis of mouse liver using immobilized metal
RT affinity purification and linear ion trap mass spectrometry."
RL Rapid Commun. Mass Spectrom. 18:2169-2176(2004).
CC -1- FUNCTION: Cytokine receptor subunit, possibly playing a regulatory
CC role in the immune system and during fetal development. May be an
CC essential role in the initiation and/or maintenance of suckling in
CC neonatal mice.
CC -1- SUBUNIT: Forms covalently linked di- and tetramers. Forms a
CC heteromeric complex with cardiotrophin-like cytokine (CLC); the
CC CRL1/CLC complex is a ligand for the ciliary neurotrophic factor
CC receptor (CNTFR) (By similarity).
CC -1- SUBCELLULAR LOCATION: Secreted (By similarity).
CC -1- TISSUE SPECIFICITY: Widely expressed in the embryo. Not detected
CC in the brain of adult mice.
CC -1- DOMAIN: The WSXWS motif appears to be necessary for proper protein
CC folding and thereby efficient intracellular transport and cell-
CC surface receptor binding.
CC -1- SIMILARITY: Belongs to the type I cytokine family of receptors.
CC Subfamily 3.
CC -1- SIMILARITY: Contains 2 fibronectin type III domains.
CC -1- SIMILARITY: Contains 1 immunoglobulin-like C2-type domain.
CC This Swiss-Prot entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -

```

CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.1sb-sib.ch/announce/>
 CC or send an email to license@1sb-sib.ch).

```

CC EMBL; AB040038; BAA92777.1; -.
DR HSSP; P40223; 1CD9.
DR MGD; MGI:1340030; Crlf1.
DR InterPro; IPR002996; Cyt_kn_recept_B/G.
DR InterPro; IPR003961; FN_III.
DR InterPro; IPR008957; FN_III-like.
DR InterPro; IPR007110; Ig-III-like.
DR Pfam; PF00041; fn3; 2.
DR SMART; SM00060; FN3; 2.
DR PROSITE; PS00853; FN3; 2.
DR PROSITE; PS00835; IG_LIKE; FALSE_NEG.
KW Glycoprotein; Immunoglobulin domain; Phosphorylation; Receptor;
KW Repeat; Signal.
FT SIGNAL 1 33
FT CHAIN 34 425
FT DOMAIN 35 134
FT DOMAIN 137 232
FT DOMAIN 237 337
FT SITE 330 334
FT SITE 330 334
FT DISUPID 146 156
FT MOD_RES 187 198
FT MOD_RES 222 222
FT CARBOHYD 95 95
FT CARBOHYD 107 107
FT CARBOHYD 143 143
FT CARBOHYD 171 171
FT CARBOHYD 295 295
FT CARBOHYD 385 385
SQ SEQUENCE 425 AA; 46662 MW; 910535629CA7056 CRC64;

Query Match 95.1%; Score 2178; DB 1; Length 425;
Best Local Similarity 94.8%; Pred. No. 3 7e-157;
Matches 402; Conservative 5; Mismatches 13; Indels 4; Gaps 2;

QY 1 MPAGRRGPAQAASARRP-PLPLP---LLLCVIGAPRAGGAAHTAVISPDPFTLLIGSSLL 56
DB 1 MPAGRRGPAQAASARRPRLSSLSMPLLCVIGAPRAGGAAHTAVISPDPFTLLIGSSLLQ 60
QY 57 ATCSVHGDPGPGATAGLYTTNGRRLLPELSRYLANSTALALANLNGSRQSGDNLVCH 116
DB 61 ATCSVHGDPGPGATAGLYTTNGRRLLPELSRYLANSTALALANLNGSRQSGDNLVCH 120
QY 117 ARDGSILASCLVYGLPPKPKPVNISQWSKMDLTCRWTPGAHGETFLHTNYSLKTKLNR 176
DB 121 ARDGSILASCLVYGLPPKPKPVNISQWSKMDLTCRWTPGAHGETFLHTNYSLKTKLNR 180
QY 177 YGQDNTCEHYHTVGPSPHSCHI PKDLALFTPEYIWEATNLSARSVDLTLDLVVTTDP 236
DB 181 YGQDNTCEHYHTVGPSPHSCHI PKDLALFTPEYIWEATNLSARSVDLTLDLVVTTDP 240
QY 237 PPDVHSRVVGLJEDQSVWVSPALKDFLQAKYQIRRVEDSVWVKVVDVSNQTSCLR 296
DB 241 PPDVHSRVVGLJEDQSVWVSPALKDFLQAKYQIRRVEDSVWVKVVDVSNQTSCLR 300
QY 297 LAGLKGTYFVQVVRNPNPGIYSSKAGIMSEWSHPTASTPSSRPGGACGCEPGRG 356
DB 301 LAGLKGTYFVQVVRNPNPGIYSSKAGIMSEWSHPTASTPSSRPGGACGCEPGRG 360
QY 357 PPSGPRRLKQFLGWLKKGAYCSNLSFRLYDQWRAMQSKHTRNODGILPSGRGRTA 416
DB 361 PPSGPRRLKQFLGWLKKGAYCSNLSFRLYDQWRAMQSKHTRNODGILPSGRGRTA 420
QY 417 RGPA 420
DB 421 RGPA 424

```

```
RESULT 3
Q6DG28 PRELIMINARY; PRT; 389 AA.
ID Q6DG28;
AC Q6DG28;
DT 25-OCT-2004 (TrEMBLrel. 28, Created)
DT 25-OCT-2004 (TrEMBLrel. 28, Last sequence update)
DT 25-OCT-2004 (TrEMBLrel. 28, Last annotation update)
DE Zgc:91992.
GN Name=zgc:91992.
OS Brachydanio rerio (Zebrafish) (Danio rerio).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Actinopterygii; Neopterygii; Teleostei; Ostariophysi; Cypriniformes;
OC Cyprinidae; Danio.
OK NCBI_TaxID=7955;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Whole;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scherz T.E.,
RA Brownstein M.J., Ustin T.B., Tschjunkt S., Carninci P., Prange C.,
RA Raha S.S., Loughellano N.A., Peters G.J., Abramson R.D., Mullany S.J.,
RA Bosak S.A., McSwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Morley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahy J., Helton E., Kettman M., Madan A., Rodriguez S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
RA Krzywinski M.I., Skalski U., Smalios D.E., Schmech A., Schein J.E.,
RA Jones S.J., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP SEQUENCE FROM N.A.
RC TISSUE=Whole;
RA Strausberg R.;
RX Submitted (JUL-2004) to the EMBL/GenBank/DBJ databases.
RA EMBL: BC076526; AAH76526.1; -
DR InterPro: IPR002996; CytKn_recept_B/G.
DR InterPro: IPR003961; FN_III.
DR InterPro: IPR008957; FN_III-like.
DR Pfam: PF00041; fn3; 1.
DR SMART: SM00060; FN3; 2.
DR PROSITE: PS50853; FN3; 2.
SQ SEQUENCE 389 AA; 43314 MW; E30903B99639864A CRC64;

Query Match 61.9%; Score 1418.5; DB 2; Length 389;
Best Local Similarity 67.6%; Pred. No. 1.7e-99;
Matches 261; Conservative 50; Mismatches 70; Indels 5; Gaps 4;
```

```
DB 240 PPALDPLFQAKYQIRYRVEDSDVMKVVDVSNQTSCLGLKPGTVYFVQVRCNPGIY 318
QY 319 GSKKAGIWSHNPAASTPNSERPFGGACERPGEBSGPVRELKQIFGIMKTAY 378
DB 300 GSRKAGISDWSHPAASTPNSERFLT--GSCDSKAGQONS-TLRDIDKQFGWVRKAY 356
QY 379 -CSNLSFRLYDQWRAMQKSHKTRNQ 403
DB 357 GSGWSIKLYDQWRVWLQKSHKTRNQ 382

RESULT 4
Q6UA05 PRELIMINARY; PRT; 394 AA.
ID Q6UA05;
AC Q6UA05;
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE Class I helical cytokine receptor number 1.
GN Name=CRFAL1.
OS Tetraodon nigroviridis (Green puffer).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Actinopterygii; Neopterygii; Teleostei; Euteleostei; Neoteleostei;
OC Acanthomorpha; Acanthopterygii; Percomorpha; Tetraodontiformes;
OC Tetraodontidae; Tetraodonti; Tetraodon.
OK NCBI_TaxID=99883;
RN [1]
RP SEQUENCE FROM N.A.
RA Jallón O., Aury J.-M., Brunet F., Petit J.-L., Strange-Thomann N.,
RA Mauceli E., Bouneau L., Fischer C., Ozou-Costas C., Bernot A.,
RA Nicoud S., Jaffe D., Fisher S., Lutfalla G., Dossat C., Seguens B.,
RA Dasilva C., Salanoubat M., Levy M., Boudet N., Castellano S.,
RA Antouard V., Jubin C., Castelli V., Katinka M., Vacherie B.,
RA Blumont C., Skalli Z., Cattelico L., Poulain V., Berardins Vd.,
RA Crnaud C., Duprat S., Broctier P., Coutanceau J.-P., Gouzy U.,
RA Parra G., Lardier G., Chapelle C., McKernan K.J., McSwan P., Bosak S.,
RA Kellis M., Volff J.-N., Guigs R., Zody M.C., Meisrov J.,
RA Lindblad-Toh K., Birren B., Nusbaum C., Kahn D., Robinson-Rechavi M.,
RA Laudet V., Schachter V., Quittier F., Saurin W., Scarpelli C.,
RA Wincker P., Lander E.S., Weissbach U., Collins H.R.;
RT "Analysis of the Tetraodon nigroviridis genome reveals the
RT prokaryocyte of bony vertebrates and its duplication in teleost
RT fish.";
RL Nature 0:0-0(2004).
DR EMBL: AY374473; AAR25664.1; -
DR GO: GO:004872; F:receptor activity, IEA.
DR InterPro: IPR002996; CytKn_recept_B/G.
DR InterPro: IPR003961; FN_III.
DR InterPro: IPR008957; FN_III-like.
DR InterPro: IPR007110; Ig-like.
DR Pfam: PF00041; fn3; 2.
DR SMART: SM00060; FN3; 2.
DR PROSITE: PS50853; FN3; 2.
DR PROSITE: PS50835; IG_LIKE; 1.
DR Receptor.
SQ SEQUENCE 394 AA; 44022 MW; EE60B16FA2C2896C CRC64;

Query Match 60.5%; Score 1384.5; DB 2; Length 394;
Best Local Similarity 67.6%; Pred. No. 6.6e-97;
Matches 259; Conservative 41; Mismatches 78; Indels 5; Gaps 4;
```


RESULT 8	
Q96P36	
ID	Q96P36
AC	Q96P36;
DT	01-DEC-2001 (TrEMBLrel. 19, Created)
DT	01-DEC-2001 (TrEMBLrel. 19, last sequence update)
DT	01-OCT-2003 (TrEMBLrel. 25, last annotation update)
DE	Prolactin receptor short isoform 1b.
GN	Name=PRLR;
OS	Homo sapiens (Human).
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi
OC	Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX	NCBI_TaxID=9606;
RN	[1]
RP	SEQUENCE FROM N.A.
RC	TISSUE=Placenta.
RA	Trott J.F., Hovey R.C., Vonderhaar B.K.;
RL	Submitted (SEP-2001) to the EMBL/GenBank/DBJ databases.
EMBL	AF416618; AAL23914.1; -

```

RESULT 9
ID Q9UHU5 PRELIMINARY; PRT; 349 AA.
AC Q9UHU5;
DT 01-MAY-2000 (TREMBLrel. 13, Created)
DT 01-MAY-2000 (TREMBLrel. 13, Last sequence update)
DT 01-OCT-2003 (TREMBLrel. 25, Last annotation update)
DE Intermediate prolactin receptor isoform.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.
OX NCBI_TaxId=9606;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=20054419; PubMed=10585417; DOI=10.1074/jbc.274.50.35461;
RA Kline J.B., Roehrs H., Clevenger C.V.;
RT "Functional characterization of the intermediate isoform of the human
RL prolactin receptor.";
RL J. Biol. Chem. 274:35461-35468 (1999).
DR EMBL; AF16329; A049855.1; -.
DR HSSP; P16471; 1BP3.
DR GO; GO:0009986; C:cell surface; IDA.
DR GO; GO:0042978; F:ornithine decarboxylase activator activity; NAS.
DR GO; GO:0004925; F:prolactin receptor activity; NAS.
DR GO; GO:0024803; F:protein homodimerization activity; NAS.
DR GO; GO:0006916; P:anti-apoptosis; NAS.
DR GO; GO:0007186; P:cell surface receptor linked signal transdu. .; NAS
DR GO; GO:0007595; P:lactation; NAS.
DR GO; GO:0006694; P:steroid biosynthesis; NAS.
DR GO; GO:0042110; P:T-cell activation; NAS.
DR GO; GO:0007117; P:transmembrane receptor protein tyrosine kin. .; IDA
DR GO; GO:0042977; P:tyrosine phosphorylation of JAK2 protein; NAS.
DR InterPro; IPR003961; Cytna_recept_B/G.
DR InterPro; IPR003961; FN_III.
DR InterPro; IPR008957; FN_III-1like.
DR InterPro; IPR003528; Hemtprecapt_F1.

```

DR Pfam; PF00041; fn3; 2.
DR SMART; SM00060; FN3; 2.
DR PROSITE; PSS0853; FN3; 2.
DR PROSITE; PS01352; HEMATOPO_REC_L_F1; 1.
DR Receptor.
SQ SEQUENCE 349 AA; 39806 MW; 932F200E850CD27 CRC64;

Query Match 14.5%; Score 332; DB 2; Length 349;
Best Local Similarity 37.1%; Pred. No. 5.4e-17;
Matches 83; Conservative 28; Mismatches 95; Indels 18; Gaps 8;

QY 122 ILAGSCLVYG-LPPEKPVNISCSKMKDLCRTWPGAHGETFLHTNYSLSKYKLRWGOD 180
DB 15 LFLNTCLNLQPLPGKGEIFKCRSPNKETFTCMWRPCTDGG--LPTNYSLSLYHREGFTLM 72
QY 181 NTCEHYHTVPHSGHAIKPD-LALFTPEIWEATNRLGARSADVLTLTIDVTTDPPD 239
DB 73 HECPDYITGSPNCHGKQYTSWMRYIMVNVNATNGGSSFSDELVYDVYIYQPDPLE 132
QY 240 VHSRVGGLDQSVRVV--SPPALKDF--LFQAKYQIRYVDSVDMKVVDVNSQTS 294
DB 133 LAV-EVQPEDRKPYLMIKWSPPTLIDLTGWFLLYEIRLKPEKAAEWI-IHPAGQOTE 190
QY 295 CRLAGLKPGTVYFVQVRCNPFGIYSGKKAGIWESESHPTAATP 338
DB 191 FKILSLHPGQKYLVOVRCKP-----DHGYWSMSPATFIQIP 227

RESULT 10
Q96P35 PRELIMINARY; PRT; 376 AA.
AC Q96P35;
DT 01-DEC-2001 (TrEMBLrel. 19, Created)
DT 01-DEC-2001 (TrEMBLrel. 19, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Prolactin receptor short isoform 1a.
GN Name=PRLR;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Cranialta; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
RN NCBI_TaxID=9606;
RX [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Placenta;
RA Trott J.F., Hovey R.C., Vonderhaar B.K.;
RL Submitted (SEP-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; AF16619; AL23915.1; -
DR PIR; A59405; A59405.
DR HSSP; P16471; 1BP3.
DR GO; GO:0009866; C:cell surface; ISS.
DR GO; GO:0042378; F:ornithine decarboxylase activator activity; ISS.
DR GO; GO:0004925; F:prolactin receptor activity; ISS.
DR GO; GO:0042803; F:protein homodimerization activity; ISS.
DR GO; GO:0006916; P:anti-apoptosis; ISS.
DR GO; GO:0007166; P:cell surface receptor linked signal transdu. . .; ISS.
DR GO; GO:0007895; P:lactation; ISS.
DR GO; GO:0006994; P:steroid biosynthesis; ISS.
DR GO; GO:0042110; P:T-cell activation; ISS.
DR GO; GO:0007171; P:transmembrane receptor protein tyrosine kin. . .; ISS.
DR InterPro; IPR002996; Cytn recept_B/G.
DR InterPro; IPR003961; FN_III.
DR InterPro; IPR008957; FN_III-like.
DR InterPro; IPR003528; Hemtrecept_FL.
DR Pfam; SM00041; fn3; 2.
DR SMART; SM00060; FN3; 2.
DR PROSITE; PSS0853; FN3; 2.
DR PROSITE; PS01352; HEMATOPO_REC_L_F1; 1.
DR Receptor.
SQ SEQUENCE 376 AA; 42639 MW; 112DC2555FBC4601 CRC64;

Query Match 14.5%; Score 332; DB 2; Length 376;
Best Local Similarity 37.1%; Pred. No. 5.9e-17;

Matches 83; Conservative 28; Mismatches 95; Indels 18; Gaps 8;

QY 122 ILAGSCLVYG-LPPEKPVNISCSKMKDLCRTWPGAHGETFLHTNYSLSKYKLRWGOD 180
DB 15 LFLNTCLNLQPLPGKGEIFKCRSPNKETFTCMWRPCTDGG--LPTNYSLSLYHREGFTLM 72
QY 181 NTCEHYHTVPHSGHAIKPD-LALFTPEIWEATNRLGARSADVLTLTIDVTTDPPD 239
DB 73 HECPDYITGSPNCHGKQYTSWMRYIMVNVNATNGGSSFSDELVYDVYIYQPDPLE 132
QY 240 VHSRVGGLDQSVRVV--SPPALKDF--LFQAKYQIRYVDSVDMKVVDVNSQTS 294
DB 133 LAV-EVQPEDRKPYLMIKWSPPTLIDLTGWFLLYEIRLKPEKAAEWI-IHPAGQOTE 190
QY 295 CRLAGLKPGTVYFVQVRCNPFGIYSGKKAGIWESESHPTAATP 338
DB 191 FKILSLHPGQKYLVOVRCKP-----DHGYWSMSPATFIQIP 227

RESULT 11
PRLR_HUMAN STANDARD; PRT; 622 AA.
AC P16471; Q9BX87;
DT 01-AUG-1990 (Rel. 15, Created)
DT 01-AUG-1990 (Rel. 15, Last sequence update)
DT 25-OCT-2004 (Rel. 45, Last annotation update)
DE Prolactin receptor precursor (PRL-R).
GN Name=PRLR;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Cranialta; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
RN NCBI_TaxID=9606;
RX [1]
RP SEQUENCE FROM N.A. (ISOFORM 1).
RX MEDLINE=90114212; PubMed=2558309;
RA Boutin J.-M., Edey M., Shirota M., Jolicoeur C., Lesueur L., Ali S.,
RA Gould D., Djiane J., Kelly P.A.;
RT "Identification of a cDNA encoding a long form of prolactin receptor
RT in human hepatoma and breast cancer cells.";
RL Mol. Endocrinol. 3:1455-1461(1989).
RN [2]
RP SEQUENCE FROM N.A. (ISOFORM 1).
RX MEDLINE=99182102; PubMed=10084611; DOI=10.1210/jc.84.3.1153;
RA Ha Z.-Z., Zhuang L., Meng J., Leonidree M., Dufat M.L.;
RT "The human prolactin receptor gene structure and alternative promoter
RT utilization: the generic promoter hplii and a novel human promoter
RT hpl(N).";
RL J. Clin. Endocrinol. Metab. 84:1153-1156(1999).
RN [3]
RP SEQUENCE FROM N.A. (ISOFORM 2).
RC TISSUE=Breast carcinoma;
RA Kline J.B., Clevenger C.V.;
RT "Characterization of a novel and functional human prolactin receptor
RT isoform (delta-S1 PRLr) containing only one extracellular fibronectin-
RT like domain.";
RL Submitted (FEB-2001) to the EMBL/GenBank/DBJ databases.
RN [4]
RP SEQUENCE FROM N.A. (ISOFORM 1).
RC TISSUE=Placenta;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buettow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Schaefer T.E.,
RA Brownstein M.J., Ustin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loggellano N.A., Peters G.D., Abramson R.D., Mulany S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Huiyk S.W.,
RA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs J., Huiyk S.W.,
RA Pahey J., Helton E., Ketterman M., Madan A.C., Rodriguez S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,

DT 01-MAR-2004; (TReMBLrel. 26, last annotation update)
 DE Aci055.
 OS Rattus norvegicus (Rat).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.
 ON NBI_TaxID=10116;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=Sprague-Dawley;
 RA Xu C.S., Li W.O., Li Y.C., Han H.P., Wang G.P., Chai L.O., Yuan J.Y.,
 Yang K.J., Yan H.M., Chang C.F., Zhao L.F., Ma H., Wang L., Wang S.F.,
 Shi J.B., Raiman S., Wang Q.N., Zhang J.B.,
 RL Submitted (MAY-2003) to the EMBL/GenBank/DBJ databases.
 DR EMBL; AY310138; AAP78746.1; -
 DR HSSP; P40189; 1BJ8.
 DR InterPro: IPR002996; Cytn_recept_B/G.
 DR InterPro: IPR003961; FN_III.
 DR InterPro: IPR008957; FN_III-1like.
 DR Pfam; PF00041; fn3; 4.
 DR SMART; SM00060; FN3; 4.
 DR PROSITE; PSS0853; FN3; 4.
 SO SEQUENCE 1010 AA; 112942 MW; 78F3CE56C952DBD7 CRC64;

Query Match 14.3%; Score 327.5; DB 2; Length 1010;
 Best Local Similarity 30.0%; Pred. No. 4.5e-16;
 Matches 94; Conservative 51; Mismatches 139; Indels 29; Gaps 11;

QY 42 ISQDPLILIGSSILATC-----SYHGDPGATAGLTYTLNGRLPPELSVYLAAT 94
 DB 21 IYEPFVVGSGNSMTATCVLKEKCLQY---SVNATYIWKTHVAVPKEQVIVNRTA 76
 QY 95 LALALANLNGSRSGNGLVCHARDGSLIAGSLYGLPPEKPNISGSKMMDLCLRW 154
 DB 77 SSYTFDVGQNNQLTNIIISFGQIEQNVGITTLSGVPDIPNLSCLYNIEGKMLCOW 136
 QY 155 TPQAGETPLHTVSLKYLKRWYQD-NTCEBHTVPHSCHIPKDALFTPEIWEAT 213
 DB 137 DPGR--ETVLETNYTLKSE--WATEKPPDRKTH--GTSSGOMGYTFIYFANIEWVEAE 190
 QY 214 NRGASASDVLTLDIDVTTDPPDVHVSRGVLEQLSVRWSPALDPLFOAKYQI 273
 DB 191 NALGNVSSSEIPNDPVKVPSPHNVSYNSELSILKLAWSGL--DSILRLSDI 248
 QY 274 RYRVEDSDVKWV---DDVSNQTSCLAGLKPQVTVVQVRCNFGYSGKKAIGSEMS 330
 DB 249 QITKQDSTWIOVPLEDTVSPTSFTVQDLKPTETVFRIR---SIKENGK-GYWSWDS 303
 QY 331 HPTASTPSESRP 343
 DB 304 E-EASGTTVEDRP 315

RESULT 13
 Q16354 PRELIMINARY; PRT; 206 AA.
 AC 016354;
 DT 01-NOV-1996 (TReMBLrel. 01, Created)
 DT 01-NOV-1996 (TReMBLrel. 01, last sequence update)
 DT 01-MAR-2004 (TReMBLrel. 26, last annotation update)
 DE Prolactin receptor (Fragment).
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
 ON NBI_TaxID=9606;
 RN [1]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=9528597; PubMed=7768908; DOI=10.1074/jbc.270.22.11133;
 RA Puh G., Wells J.A.;
 RT "Prolactin receptor antagonists that inhibit the growth of breast
 cancer cell lines";
 RL J. Biol. Chem. 270:11133-11137(1995).
 DR EMBL; S78505; AAB34470.1; -
 DR HSSP; P16471; 1BP3.

DR GO; GO:0016020; C:membrane; IEA.
 DR GO; GO:0004896; F:hematopoietin/interferon-class (D200-domain. . .; IEA.
 DR GO; GO:0004872; F:receptor activity; IEA.
 DR InterPro: IPR002996; Cytn_recept_B/G.
 DR InterPro: IPR003961; FN_III.
 DR InterPro: IPR008957; FN_III-1like.
 DR InterPro: IPR003528; Hemprecept_F1.
 DR Pfam; PF00041; fn3; 2.
 DR SMART; SM00060; FN3; 2.
 DR PROSITE; PSS0853; FN3; 2.
 DR PROSITE; PS01352; HEMATOPO_REC_L_F1; 1.
 DR Receptor.
 FT NON TER 1
 SO SEQUENCE 206 AA; 23950 MW; CED939781B3C804E CRC64;

Query Match 14.2%; Score 325.5; DB 2; Length 206;
 Best Local Similarity 37.6%; Pred. No. 8.8e-17;
 Matches 80; Conservative 26; Mismatches 90; Indels 17; Gaps 7;

QY 132 LPPEKPNISGSKMMDLRCWTPGAGHGTPLHTVSLKYKLRWYQDNTCEBHTVGP 191
 DB 2 LPPEKPEIFKCRSPNKSTFTCMWRPGTDG--LPTNYSLYHREGFTLMECPDYITGP 59
 QY 192 HSGHIPKD-LALFTPEIWEATNRLGASASDVLTLDIDVTTDPPDVHVSRGVLE 250
 DB 60 NSCHFQGYQYSMRTYIMVNAVNTQKSSFSDELVDVYTVIOPDPLLEAV-EVKQPD 118
 QY 251 QLSRVNV--SPPAIKDF--LFOAKYQIRYRVSDVKWVVDVSNQTSCLAGLKPQV 305
 DB 119 RKVYLWIKMSPPLTLDIKTGMFTLIRLKEPKAEWE-IHFAGQCTEFRLSLHGGK 177
 QY 306 YFQVRCNPGIYSGKKAIGSEMSHPTASTP 338
 DB 178 YLVQVRCKP-----DHGYWSAMSPATFIQIP 203

RESULT 14
 IL6B HUMAN STANDARD; PRT; 918 AA.
 ID IL6B HUMAN
 AC P40189; Q9UQ41;
 DT 01-FEB-1995 (Rel. 31, Created)
 DT 01-FEB-1995 (Rel. 31, last sequence update)
 DT 25-OCT-2004 (Rel. 45, last annotation update)
 DE Interleukin-6 receptor, beta chain precursor (IL-6R-beta) (interleukin
 6 signal transducer) (Membrane glycoprotein 130) (gp130) (Oncofostatin M
 receptor) (CDW130) (CD130 antigen).
 DE Name=IL6ST;
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
 ON NBI_TaxID=9606;
 RN [1]
 RP SEQUENCE FROM N.A. (ISOFORM 1).
 RC TISSUE=Myeloma, and Placenta;
 RX MEDLINE=91084844; PubMed=2261637; DOI=10.1016/0092-8674(90)90411-7;
 RA Hibi M., Murakami M., Saito M., Hirano T., Tega T., Kishimoto T.;
 RT "Molecular cloning and expression of an IL-6 signal transducer,
 gp130.";
 RL Cell 63:1149-1157(1990).
 RN [2]
 RP SEQUENCE FROM N.A. (ISOFORM 2).
 RC TISSUE=Synovium;
 RX MEDLINE=20341529; PubMed=10880057;
 RA Tanaka M., Kishimura M., Ozaki S., Osakada F., Hashimoto H., Okubo M.,
 RA Murakami M., Nakao K.;
 RT "Cloning of novel soluble gp130 and detection of its neutralizing
 RT autoantibodies in rheumatoid arthritis.";
 RL J. Clin. Invest. 106:137-144(2000).
 RN [3]
 RP PARTIAL SEQUENCE, DISULFIDE BONDS, AND CARBOHYDRATE-LINKAGE SITES.
 RX MEDLINE=21269388; PubMed=11098061; DOI=10.1074/jbc.M009979200;
 RA Moritz R.L., Hall N.E., Connolly L.M., Simpson R.J.;
 RT "Determination of the disulfide structure and N-glycosylation sites of

FT	STRAND	283	286
FT	TUN	291	292
FT	STRAND	294	303
FT	TUN	304	305
FT	STRAND	317	320
SO	SEQUENCE	918 AA;	103522 MW; DB13F3672DD10D53 CRC64;
Query Match 14.1%; Score 323; DB 1; Length 918;			
Best Local Similarity 28.2%; Pred. No. 8.7e-16;			
Matches 87; Conservative 52; Mismatches 151; Indels 18; Gaps 8;			
QY	ISPODPTLLISSILATCSYHG---DPGGAATAEGLYWLTLNGRLPELSRYLNASTTLA	98	
DB	ISPSPPVQLNSNFAVCLVLEKCMDDYHNANVYVMTNHTFLPEKDYTIINRASSVT	90	
QY	LANNGSRORSQDNLVCHARDGSIAGSLCYVGLPEKRPVNIICSMKMKDLTCRWTFGA	158	
DB	FTDIASLNIQTCLNLTFCQLEQNVYGIITISGLPEKPKHLSCLVNSGKMGRCMDGR	150	
QY	HGRFTPLATNYSLKTKLRMYGDDNTCEBYHTVGPSSCHI PKDLALFTPEIIVCATNRIGS	218	
DB	--ETHLENTPLTKSEWATHKPADCKAKRDT--PTSCYDVSITVYFVNIEVWEAENALGK	206	
QY	ARSDVLTLDILDVYTTDPBPVHYSRVSGLEDDQSVKRVSPALKDFLQAKYQIARVE	278	
DB	VTSHINFDPVYKAKNPNNHLSVNSSELSILCLTNTN--PSISVIT-LKYNQYTK	264	
QY	DSVPMKVY---DVSNNQTSCLAGLPETVYFVQVRCNPFGIYSKKAGIEMSHPTAA	335	
DB	DAGTWSQIPEPDDTASTRSSFTVQDLKPTVEYFRIRC-----MEDGKGYSDMSEASG	319	
QY	336 STEPSERP 343		
DB	320 ITFYEDRP 326		
RESULT 15			
IL6B	MOUSE	STANDARD;	PRT; 917 AA.
ID	IL6B_MOUSE		
AC	Q00560;		
DT	01-FEB-1995 (Rel. 31, Created)		
DT	01-FEB-1995 (Rel. 31, Last sequence update)		
DT	05-JUL-2004 (Rel. 44, Last annotation update)		
DE	Interleukin-6 receptor beta chain precursor (IL-6R-beta) (Interleukin		
DE	6 signal transducer) (Membrane glycoprotein I30) (GP130).		
GN	Name=il6et;		
OS	Mus musculus (Mouse).		
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;		
OC	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Mus.		
OX	NCBI_TaxID=10090;		
RN	(1)		
RP	SEQUENCE FROM N.A.		
RC	STRAIN=ICR; TISSUE=Macrophage;		
RX	MEDLINE=92291532; PubMed=1602143;		
RA	Saito M., Yoshida K., Hibi M., Iga T., Kishimoto T.;		
RT	"Molecular cloning of a murine Il-6 receptor-associated signal		
RT	transducer, gp130, and its regulated expression in vivo."		
RL	J. Immunol. 148:4066-4071(1992).		
CC	-1- FUNCTION: Signal-transducing molecule. The receptor systems for		
CC	IL6, ILF, OSN, CNTF, IL11 and CRT can utilize gp130 for initiating		
CC	signal transduction. Binds to IL6/IL6R (alpha chain) complex,		
CC	resulting in the formation of high-affinity IL6 binding sites, and		
CC	transduces the signal. Does not bind IL6. May have a role in		
CC	embryonic development.		
CC	-1- SUBUNIT: Heterodimer of an alpha and a beta chain.		
CC	-1- SUBCELLULAR LOCATION: Type I membrane protein.		
CC	epitope, kidney, lung and liver. Found in all the cell lines tested		
CC	except BAF-B03. Expression not restricted to IL6-responsive cells.		
CC	-1- DEVELOPMENTAL STAGE: In embryonic stem cells it is found from day		
CC	6 of gestation. It reaches a peak on day 8 and gradually declines		
CC	during the rest of embryogenesis.		
CC	-1- DOMAIN: The WSXWS motif appears to be necessary for proper protein		

CC folding and thereby efficient intracellular transport and cell-
CC surface receptor binding.
CC -1- DOMAIN: The box 1 motif is required for JAK interaction and/or
CC activation.
CC -1- SIMILARITY: Belongs to the type I cytokine family of receptors.
CC Subfamily 2.
CC -1- SIMILARITY: Contains 5 fibronectin type III domains.
CC -1- SIMILARITY: Contains 1 immunoglobulin-like C2-type domain.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL; X62646; CAA44515.1; -;
DR EMBL; M83336; AAA37723.1; -;
DR PIR; I49699; I49699.
DR HSSP; P40189; IBOU.
DR MGD; MGI.96560; I166t.
DR GO; GO:0008593; P:regulation of Notch signaling pathway; IDA.
DR GO; GO:0007165; P:signal transduction; IDA.
DR InterPro; IPRO02996; Cytln_recept_B/G.
DR InterPro; IPRO03961; FN_III.
DR InterPro; IPRO08957; FN_III-like.
DR InterPro; IPRO03529; Hemprecept_102.
DR InterPro; IPRO10457; Lep_receptor_Ig.
DR Pfam; PRO0041; fn3; 4.
DR Pfam; PF06328; Lep_receptor_Ig; 1.
DR PROSITE; PSS0583; FN3; 5.
DR PROSITE; PS01353; HEMATOPO_REC_L_P2; 1.
KW Glycoprotein; Immunoglobulin domain; Receptor; Signal;
KW Transmembrane.
FT SIGNAL 1 22 Potential.
FT CHAIN 23 917 Interleukin-6 receptor beta chain.
FT DOMAIN 23 617 Extracellular (Potential).
FT TRANSMEM 618 639 Potential.
FT DOMAIN 640 917 Cytoplasmic (Potential).
FT DOMAIN 26 120 Ig-like C2-type.
FT DOMAIN 125 214 Fibronectin type-III 1.
FT DOMAIN 220 319 Fibronectin type-III 2.
FT DOMAIN 324 416 Fibronectin type-III 3.
FT DOMAIN 421 512 Fibronectin type-III 4.
FT DOMAIN 514 608 Fibronectin type-III 5.
FT DOMAIN 723 741 Ser-rich.
FT SITE 308 312 WSXWS motif.
FT SITE 649 657 Box 1 motif.
FT DISULFID 28 54 By similarity.
FT DISULFID 48 103 By similarity.
FT DISULFID 134 144 By similarity.
FT DISULFID 172 180 By similarity.
FT DISULFID 456 464 By similarity.
FT CARBOHYD 43 43 N-linked (GLCNAC. .) (Potential).
FT CARBOHYD 61 61 N-linked (GLCNAC. .) (Potential).
FT CARBOHYD 83 83 N-linked (GLCNAC. .) (Potential).
FT CARBOHYD 131 131 N-linked (GLCNAC. .) (Potential).
FT CARBOHYD 157 157 N-linked (GLCNAC. .) (Potential).
FT CARBOHYD 225 225 N-linked (GLCNAC. .) (Potential).
FT CARBOHYD 388 388 N-linked (GLCNAC. .) (Potential).
FT CARBOHYD 476 476 N-linked (GLCNAC. .) (Potential).
FT CARBOHYD 551 551 N-linked (GLCNAC. .) (Potential).
SQ SEQUENCE 917 AA; 102452 MW; FCEPDD220BC2466F4 CRC64;
Query Match 13.9%; Score 317.5; DB 1; Length 917;
Best Local Similarity 29.6%; Pred. No. 2,3e-15;
Matches 92; Conservative 50; Mismatches 146; Indels 23; Gaps 10;
42 ISPODPTLIGSSILATCSVHG---DPGATAGLWTLNGRLPELRSVLNASTLALA 98
31 IYEPFVVGKSNFTALCVLKEACLOHYVYMASIYWKTNHAAVPRBOYTVINRTTSSVT 90

QY 99 IANLNGSRORSBDNLVCHARDGSIAGSCLYVGLPPEKPVNISGWSKNMIDLTCRWTPGA 158
Db 91 FTDVVLBSVOLTCNIIISFGQIBQNVYGVYMLSGFPDPKPTNLTICIVNEGKNMLCQMDPGR 150
QY 159 HGETFLHTNYSLKXKJLWYGOD-NTCEBYHTVGPBHGCHIPKDLALFTPYEIWWEATNRLG 217
Db 151 --ETYLETNYTLKSE--WATEKEFPDQSKHGT--SCWVSVMPTYYNIEWWEAENALG 203
QY 218 SARSDVLTLDLIDVYTTDPPPDVHVSRRVGLLEDQLSVRWVSPFALKDFLQAKYQIRYRV 277
Db 204 KVSSESINFPDVKXKPTPPYNLSVTNSEBLSITLKLWVSSGL--GGLDLKSDIOYRT 261
QY 278 EDSVDMKVY--DDVSNQTSCLAGLKRGTYYFVQVRCNPFGIYGSKKAGIWSWSHPTA 334
Db 262 KDASTWIOVPLEDITMSPTISFTYQDLKFTFYVFRIR---SIKDSGK-GYMSDWSSEAS 316
QY 335 AST--PRSERP 343
Db 317 GTTYEDRPSRP 327

Search completed: February 24, 2005, 03:36:05
Job time : 175 secs

Result No.	Score	Query Match	Length	DB	ID	Description
1	1572.4	75.6	1716		A97100	A97100 Sequence 24
2	1572.4	75.6	1716		BD138607	BD138607 Novel cyt
3	1572.4	75.6	1716		AF059293	AF059293 Homo sapi
4	1572.4	75.6	1740		AX205028	AX205028 Sequence
5	1572.4	75.6	1740		AX205046	AX205046 Sequence
6	1572.4	75.6	1787		BD204628	BD204628 U4 belong
7	1572.4	75.6	1790		BD140543	BD140543 PolyPepti
8	1572.4	75.6	1790		AR429062	AR429062 Sequence
9	1572.4	75.6	1790		AR549953	AR549953 Sequence
10	1572.4	75.6	1802		AY358291	AY358291 Homo sapi
11	1572.4	75.6	1804		AF073515	AF073515 Homo sapi
12	1572	75.6	1813		AR164089	AR164089 Sequence
13	1570.8	75.6	1650		AF178684	AF178684 Homo sapi
14	1570.8	75.6	1690		AR164088	AR164088 Sequence
15	1570.8	75.6	1744		BC044634	BC044634 Homo sapi
16	1511.6	72.7	1579		BD204627	BD204627 U4 belong
17	1511.6	72.7	1491		BD056970	BD056970 Member of
18	1450.4	69.8	1459		CQ726242	CQ726242 Sequence
19	1425	68.5	1498		BD221766	BD221766 Human rec

20	1308.4	62.2	9	1391	6	A70394	A70394 Sequence 24
21	1308.4	62.9	1	1391	6	BD010521	BD010521 A novel h
22	1308.4	62.9	1	1391	6	BD010552	BD010552 A novel h
23	1254.4	60.3	1	1930	6	AX205026	AX205026 Sequence
24	1254.4	60.3	1	1930	6	AX205044	AX205044 Sequence
25	1219.6	58.7	2	2162	6	AX364938	AX364938 Sequence
26	1167.4	56.2	1	1347	6	AR139798	AR139798 Sequence
27	1167.4	56.2	1	1347	6	BD246926	BD246926 Novel orp
28	1128.6	54.3	1	1305	6	AR139797	AR139797 Sequence
29	1128.6	54.3	1	1305	6	BD246925	BD246925 Novel orp
30	1128.6	54.3	1	1305	6	BD131585	BD131585 Orphan re
31	1011.2	48.6	1	1646	10	AB040038	AB040038 Mub muscu
32	1010.2	48.6	1	1673	6	A70384	A70384 Sequence 14
33	1010.2	48.6	1	1673	6	BD010515	BD010515 A novel h
34	1010.2	48.6	1	1673	6	BD010546	BD010546 A novel h
35	1008	48.5	1	1656	6	BD204626	BD204626 U4 belong
36	1008	48.5	1	1656	6	BD056959	BD056959 Member of
37	1006	48.4	1	1754	6	AR164090	AR164090 Sequence
38	972.4	46.8	1	1218	6	AR139796	AR139796 Sequence
39	972.4	46.8	1	1218	6	BD246924	BD246924 Novel orp
40	972.4	46.8	1	1218	6	BD131564	BD131564 Orphan re
41	959.4	46.1	1	1629	6	A70382	A70382 Sequence 12
42	959.4	46.1	1	1629	6	BD010514	BD010514 A novel h
43	959.4	46.1	1	1629	6	BD010545	BD010545 A novel h
44	958	46.1	1	1930	6	A70392	A70392 Sequence 22
45	958	46.1	1	1930	6	BD010519	BD010519 A novel h

ALIGNMENTS

RESULT 1

```

LOCUS       A97100               1716 bp    DNA    linear    PAT 26-JAN-2000
DEFINITION  Sequence 24 from Patent WO920755.
ACCESSION   A97100
VERSION     A97100.1  GI:6780518
KEYWORDS
SOURCE
ORGANISM
REFERENCE   1 (bases 1 to 1716)
AUTHORS    Kosco-Vilbois,M. and Gauchat,J.
TITLE       NOVEL CYTOKINE RECEPTORS
JOURNAL     Patent: WO 920755-A 24 29-APR-1999;
            KOSCO VILBOIS MARIE (CH); GAUCHAT JEAN FRANCOIS (FR)
FEATURES
     source
         1..1716
            /organism="unidentified"
            /mol_type="unassigned DNA"
            /db_xref="taxon:32644"

```

ORIGIN

[illegible]

QY	727	CCCTCTATGGAACCTCTAAATGGGGCGCGCTGCCCCCTGAGCTCTCCCGTATCTCAAG	786
Db	336	GCCTCTATGGAACCTCTAAAGGGGCGCGCTGCCCCCTGAGCTCTCCCGTATCTCAAG	395
QY	787	CCTCACCTTGGCTCTGGCCCTGGCCCAACTCAATGGGTCAGAGCAACGGTCCGGGGACA	846
Db	396	CCTCACCTTGGCTCTGGCCCTGGCCCAACTCAATGGGTCAGAGCAACGGTCCGGGGACA	455
QY	847	ACCTGTGTGCAGCGCCCGTGAACGGCAGACATCTGTGTGGCTCTGGCTCTATGTTGGCC	906
Db	456	ACCTGTGTGCAGCGCCCGTGAACGGCAGACATCTGTGTGGCTCTGGCTCTATGTTGGCC	515
QY	907	TGCCCCCAGAAAAACCGTCAACATCAAGTCTGTGTCCAAGACATAGAATCACTTGACT	966
Db	516	TGCCCCCAGAAAAACCGTCAACATCAAGTCTGTGTCCAAGACATAGAATCACTTGACT	575
QY	967	GCGCTGAGCGCCAGGGGCCCAAGGGAGACTTCTCTCCACACCACTACTCCCTCAAGT	1026
Db	576	GCGCTGAGCGCCAGGGGCCCAAGGGAGACTTCTCTCCACACCACTACTCCCTCAAGT	635
QY	1027	ACAACTTAAGGTGATGGCCAGGACAAACATGTGAGAGATACACAGTGGGGCCCC	1086
Db	636	ACAACTTAAGGTGATGGCCAGGACAAACATGTGAGAGATACACAGTGGGGCCCC	695
QY	1087	ACTCTGCGCACATGCCCAAGAACCTGAGCTCTTTAAGCCTATGAGATCTGGTGAAG	1146
Db	696	ACTCTGCGCACATGCCCAAGAACCTGAGCTCTTTAAGCCTATGAGATCTGGTGAAG	755
QY	1147	CCATCCACCGCTGGGCTCTGCGGCTCCGATGTATCTCAGCTGGATATCTCTGGAATGG	1206
Db	756	CCATCCACCGCTGGGCTCTGCGGCTCCGATGTATCTCAGCTGGATATCTCTGGAATGG	815
QY	1207	TGACCAACGAGACCCCGCGCCGACGTGACAGTGAAGCGGTCGGGGGCTGAGAGACAGC	1266
Db	816	TGACCAACGAGACCCCGCGCCGACGTGACAGTGAAGCGGTCGGGGGCTGAGAGACAGC	875
QY	1267	TGAGGTTGGCTGGGTTGTGCAACCCGCGCTCAAGATTTCTCTTCAACCCAAATACC	1326
Db	876	TGAGGTTGGCTGGGTTGTGCAACCCGCGCTCAAGATTTCTCTTCAACCCAAATACC	935
QY	1327	AGATCCGCTAACCGAGTGGAGACATGTGTGACTGGAGAGTGGATGACATGTGACAAAC	1386
Db	936	AGATCCGCTAACCGAGTGGAGACATGTGTGACTGGAGAGTGGATGACATGTGACAAAC	995
QY	1387	AAGCTCTCTGCGCGCTGCGCGGCTGAAAACCGGACCTGTATCTTGTGAATGGCGCT	1446
Db	996	AAGCTCTCTGCGCGCTGCGCGGCTGAAAACCGGACCTGTATCTTGTGAATGGCGCT	1055
QY	1447	GCACCCCTTTGGCATCTATGGCTCCAGAAAAAGCGGAGATCTGAGTGAATGAGACACC	1506
Db	1056	GCACCCCTTTGGCATCTATGGCTCCAGAAAAAGCGGAGATCTGAGTGAATGAGACACC	1115
QY	1507	CCACAGCCGCTCTCACTCCCGCAGTGAAGCGCGCGGACCGGGCCGGGCGGCGTGCAGAC	1566
Db	1116	CCACAGCCGCTCTCACTCCCGCAGTGAAGCGCGCGGACCGGGCCGGGCGGCGTGCAGAC	1175
QY	1567	CGGCGGGCGGAGACCGGACATCGGGGCGCGGTGCGGCGGAGCTCAAGAGATTCCGGGCT	1626
Db	1176	CGGCGGGCGGAGACCGGACATCGGGGCGCGGTGCGGCGGAGCTCAAGAGATTCCGGGCT	1235
QY	1627	GGCTCAAGAGACGCGGTACTGTCTCCACCTTAGCTTCGCTCTTACGACAGTGGCGAG	1686
Db	1236	GGCTCAAGAGACGCGGTACTGTCTCCACCTTAGCTTCGCTCTTACGACAGTGGCGAG	1295
QY	1687	CTTGATTCAGAAATTTGCAACAAGCCCGAACCTAGAGAGAGATCTCTGCTCTGGGCA	1746
Db	1296	CTTGATTCAGAAATTTGCAACAAGCCCGAACCTAGAGAGAGATCTCTGCTCTGGGCA	1355
QY	1747	GACGGGCAACGGGAGAGGTCCTGCGCAGATTAAGCTGTAGGGCTCAGGCAACCTCTCGT	1806
Db	1356	GACGGGCAACGGGAGAGGTCCTGCGCAGATTAAGCTGTAGGGCTCAGGCAACCTCTCGT	1415
QY	1807	CCAAGTGAAGACGAGAGGCCGAACCAACTGGGGCACTCTGTATCCCTCACTTCAAG	1866

Accession	Sequence	Length
Db	1416 CGACGTGAGACGCGAGAGCCGAAACCCAACTGGGGCCACTCTGTACCTTCACCTTCAGG	1475
Qy	1867 GCACTGAGCCACCCCTCAGCAGAGCTGGGGGTGCCCCCTGAGCTTCACACGGGCAATACAG	1926
Db	1476 GCACCTGAGCCACCCCTCAGCAGAGCTGGGGGTGCCCCCTGAGCTTCACACGGGCAATACAG	1535
Qy	1927 CTCTGACTCCACAGTGAAGGCCACCTTTGGGTGACACCCAGTGGTGTGTGTGTGTGTG	1986
Db	1536 CTCTGACTCCACAGTGAAGGCCACCTTTGGGTGACACCCAGTGGTGTGTGTGTGTGTG	1595
Qy	1987 AGGGT	2046
Db	1596 AGGGT	1655
Qy	2047 CTCCCATTAAGTGAAGGCCCTCTCAAAAAGA	2076
Db	1656 CTCCCATTAAGTGAAGGCCCTCTCAAAAAGA	1685

RESULT 2				
BD138607				
LOCUS	BD138607	1716 bp	DNA	linear
DEFINITION	Novel cytokine receptors.			
ACCESSION	BD138607			
VERSION	BD138607.1	GI:23233552		
KEYWORDS	JP 2002508922-A/14.			
SOURCE	unidentified			
ORGANISM	unidentified			
REFERENCE	1 (bases 1 to 1716)			
AUTHORS	Elson,G., Gauchat,J.F. and Vilbois,M.K.			
TITLE	Novel cytokine receptors			
JOURNAL	Patent: JP 2002508922-A 14 26-MAR-2002;			
	GLAXO GROUP LTD			
COMMENT	OS Unidentified			

COMMENT	OS	Unidentified
PN	JP	2002508922-A/14
PD	26-MAR-2002	
PR	14-OCT-1998	JP 2000517076
PF	16-OCT-1997	GB 9721961.2
PI	GREG ELSON, JEAN FRANCOIS GAUCHAT, MARIE KOSCO VIBOIS	PC
C12N15/00, A61K31/7088, A61K38/00, A61K39/395, A61K45/00, A61K48/00,		PC
PC	A61P3/04, A61P35/00, A61P37/02, C07K14/775, C07K16/28, C12P21/02//	
PC	C12P21/04,	
PC	C12N15/00, A61K37/02	
CC	Novel cytokine receptors	
FH	Key	Location/Qualifiers
FT	Source	1. .1716
FT		/organism='Unidentified'.

FEATURES	Location/Qualifiers
source	1..1716
	/organism="unidentified"
	/mol_type="genomic DNA"
	/db_xref="taxon:3264"

ORIGIN

Query Match 75.6%; Score 1572.4; DB 6; Length 1716;

```

Best Local Similarity  59.76;  1200;  10;  2000;
Matches 1586;  Conservative  0;  Mismatches  1;  Indels  3;  Gaps  1

```

490 GAGGACCGCCGGCCTCATGCCTGGCCGGCCGGGCCGCCGCCAATCCG 549

96ATGCGCCGGCCGCCCATCCG 155

606

215

[illegible]

12

[illegible]

OY	667	GCTCTCCCTCTGGCCACCTGCTCAGTGCAGGAGACCCACACAGAGACCAACCGCCAGG	726
Db	276	GCTCTCCCTCTGGCCACCTGCTCAGTGCAGGAGACCCACACAGAGACCAACCGCCAGG	335
OY	727	GCTCTACTGGAACCTCTCAATGGAGCGCGCTGCCCCCTGAGCTCTCCCTGTACTCAACG	786
Db	336	GCCTTACTGGAACCTCTCAACGGAGCGCGCTGCCCCCTGAGCTCTCCCTGTACTCAACG	395
OY	787	CCTCCACCTTGGCTCTGGCCCTTGGCCAACTTCAATGGGTCCAGGACAGCGGTCCGGGGACA	846
Db	396	CCTCCACCTTGGCTCTGGCCCTTGGCCAACTTCAATGGGTCCAGGACAGCGGTCCGGGGACA	455
OY	847	ACCTGATGAGCCACGCGCTGACGGACAGATCTTGAGTGAGCTTCCGCTCATGTGAGCC	906
Db	456	ACCTGATGAGCCACGCGCTGACGGACAGATCTTGAGTGAGCTTCCGCTCATGTGAGCC	515
OY	907	TGCCCCCAGAGAAACCCGTCAACATCAAGCTGTGTCCAAAGACATGAAAGACTTGAACCT	966
Db	516	TGCCCCCAGAGAAACCCGTCAACATCAAGCTGTGTCCAAAGACATGAAAGACTTGAACCT	575
OY	967	GCCGCTGGAACGTCAGGGGCCACAGGGGAGACTTCTTCCACACCAACTTCCCTCAAGT	1026
Db	576	GCCGCTGGAACGTCAGGGGCCACAGGGGAGACTTCTTCCACACCAACTTCCCTCAAGT	635
OY	1027	ACAAGCTTAAGGTGGTATGATGCCAGGACAAACATGTGAAGATGACACACATGGGGCCCC	1086
Db	636	ACAAGCTTAAGGTGGTATGATGCCAGGACAAACATGTGAAGATGACACACATGGGGCCCC	695
OY	1087	ACTCTGCGCAACATCCCCCAAGGACCTGGCTCTTTTACCCGCTATGAGATCTTGGGTGAGG	1146
Db	696	ACTCTGCGCAACATCCCCCAAGGACCTGGCTCTTTTACCCGCTATGAGATCTTGGGTGAGG	755
OY	1147	CCACCAACCGCTGGGCTCTGCGCGCTCCGATGTACTCACGCTGAGATCTTGAATGTGG	1206
Db	756	CCACCAACCGCTGGGCTCTGCGCGCTCCGATGTACTCACGCTGAGATCTTGAATGTGG	815
OY	1207	TGACCAAGGACCCCCCGGCCGACGTCACAGGACGAGCGCGGTGGGGGCTTGGAGACCAAG	1266
Db	816	TGACCAAGGACCCCCCGGCCGACGTCACAGGACGAGCGCGGTGGGGGCTTGGAGACCAAG	875
OY	1267	TGAGCGTACGCTGGGTGTGCGCACCCGCGCTCAAGAGATTTCTCTTTCAAGCCAAATATCC	1326
Db	876	TGAGCGTACGCTGGGTGTGCGCACCCGCGCTCAAGAGATTTCTCTTTCAAGCCAAATATCC	935
OY	1327	AGATCCGCTACCGAGTGGAGGACAGTGTGACTGGAGGTGGTGGACGATGTGACCAAC	1386
Db	936	AGATCCGCTACCGAGTGGAGGACAGTGTGACTGGAGGTGGTGGACGATGTGACCAAC	995
OY	1387	AGACTCTCTGCGCGCTTGGCCGCGCTGAAACCCGCGACCTGTATCTTGTGCAATGGCT	1446
Db	996	AGACTCTCTGCGCGCTTGGCCGCGCTGAAACCCGCGACCTGTATCTTGTGCAATGGCT	1055
OY	1447	GCAACCCCTTGGCACTTATGGCTCCAAAGAAAGCCGGATCTGAGGTAGTGGAGCCAC	1506
Db	1056	GCAACCCCTTGGCACTTATGGCTCCAAAGAAAGCCGGATCTGAGGTAGTGGAGCCAC	1115
OY	1507	CCACAGCCGCTTCACTCCCGCCAGTGAAGCGCCCGGCGCCGAGCGCGCGCGCTGTGCAAC	1566
Db	1116	CCACAGCCGCTTCACTCCCGCCAGTGAAGCGCCCGGCGCCGAGCGCGCGCGCTGTGCAAC	1175
OY	1567	CGCGGGGCGAGAGCCGAGACTTGGGGGCGGATGCGGAGCTCAAGCAGATTCTTGAGCT	1626
Db	1176	CGCGGGGCGAGAGCCGAGACTTGGGGGCGGATGCGGAGCTCAAGCAGATTCTTGAGCT	1235
OY	1627	GGCTCAAGAGACGCGTATCTGCTCAACCTCAAGTTCCGCTTACGACCAAGTGGCGAG	1686
Db	1236	GGCTCAAGAGACGCGTATCTGCTCAACCTCAAGTTCCGCTTACGACCAAGTGGCGAG	1295
OY	1687	CCTGATCAGAGATGCGACAAAGACCCGCAACAGAGACGAGGGAGTCTTGCCTTCGGGCA	1746
Db	1296	CCTGATCAGAGATGCGACAAAGACCCGCAACAGAGACGAGGGAGTCTTGCCTTCGGGCA	1355
OY	1747	GACGGGGACGCGAGAGGTCTTGCACAGATATAGTGAAGGCTTCAGGACCACTTCCCTG	1806

QY	Db	LOCUS	DEFINITION	ACCESSION	VERSION	KEYWORDS	ORGANISM	REFERENCE	AUTHORS	TITLE	JOURNAL	MEETING	PUBMED	REFERENCE	AUTHORS	TITLE	JOURNAL	FEATURES	SOURCE
QY	1356	GAAGGGGAGAGGAGGATCTGCGACGATTAAGCTGTAGAGGGCTCAGGCCACCCCTCGT	1716 bp mRNA linear PRI 03-MAY-2001	AF059293	AF059293		Homo sapiens (human)	Homo sapiens cytokine-1-like factor-1 precursor (CLF-1) mRNA, complete cds.											
QY	1807	CCACGTGAGACGACGAGAGCCGAACCCAACTGGGGCCACTCTGTACCTCTCACTTCAGG		AF059293	AF059293		Homo sapiens (human)												
Db	1416	CCAGGTGAGACGACGAGAGCCGAACCCAACTGGGGCCACTCTGTACCTCTCACTTCAGG																	
QY	1667	GCACCTGAGCAACCTCAGACGAGGCTGTGGGGTGGCCCTGTAGGCTCCAAACGGCCATTAACAG																	
Db	1476	GCACCTGAGCAACCTCAGACGAGGCTGTGGGGTGGCCCTGTAGGCTCCAAACGGCCATTAACAG																	
QY	1927	CTCTGACTCCACGCTGAGGCCACTTTTGGGTGACCCCAAGTGGTGTGTGTGTGTGTGTGTGTG	1986																
Db	1536	CTCTGACTCCACGCTGAGGCCACTTTTGGGTGACCCCAAGTGGTGTGTGTGTGTGTGTGTGTG	19595																
QY	1987	AGGGTTGGTGAAGTTGCTTAGAACCCCTGCGCAGGGCTGGGGGTGAGAAAGGGAGTCATTTA	2046																
Db	1596	AGGGTTGGTGAAGTTGCTTAGAACCCCTGCGCAGGGCTGGGGGTGAGAAAGGGAGTCATTTA	16555																
QY	2047	CTCCCAATTACTTATGAGGGCCCTCCAAAAGA	2016																
Db	1656	CTCCCAATTACTTATGAGGGCCCTCCAAAAGA	1695																
RESULT 3																			
LOCUS	AF059293																		
DEFINITION	Homo sapiens cytokine-1-like factor-1 precursor (CLF-1) mRNA,																		
ACCESSION	AF059293																		
VERSION	AF059293.1																		
KEYWORDS	GI:3372626																		
ORGANISM	Homo sapiens (human)																		
REFERENCE	1 (bases 1 to 1716)																		
AUTHORS	Elson,G.C.A., Graber,P., Losberger,P., Herren,S., Gretener,D., Menoud,L.N., Wells,T.N.C., Kosco-Vilbois,M.H. and Gauchat,J.F.																		
TITLE	Cytokine-like factor-1, a novel soluble protein, shares homology with members of the cytokine type I receptor family																		
JOURNAL	J. Immunol. 161 (3), 1371-1379 (1998)																		
MEETING	98349389																		
PUBMED	9686600																		
REFERENCE	2 (bases 1 to 1716)																		
AUTHORS	Elson,G.C.A., Graber,P., Losberger,P., Herren,S., Gretener,D., Menoud,L.N., Wells,T.N.C., Kosco-Vilbois,M.H. and Gauchat,J.F.																		
TITLE	Direct Submission																		
JOURNAL	Submitted (14-APR-1998) Dept. of Immunology, SeroPharmaceutical Research Institute, 14, Chemin des Aulx, Plan-les-Ouates, CH 1228, Switzerland																		
FEATURES	location/Qualifiers																		

/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
131..1399
/note="unamed protein product; CLF-1"

/codon_start=1
/protein_id="CAG60177.1"
/db_xref="GI:15394264"
/translation="MPAGRRGPAQASARRPPPLPLLLLCVLPAGAPAGAGATVAVIS
PODPTLLIGSLATGSHVDPGATAGVLYMTLNGRLPRLSRVLAATLALAN
LNGRSRSGDNLVCHADGSIAGSCLVGLPREKPNISCSNMKDLTCRTPGAH
GRTFLTNISLKTLMYGDNTCEETHVGPSCILPKDLATPELIVEATNRLG
SASDVLTLDILVYTTDPPDVHVSIVGLDQLSVRNVPALPKFLVAKTOIRY
RVEDSDVMKYVDVNSQTSCLAKPQTVYFVQVRCPNGISKKAGIIMSESHPT
AASPRSERPGGACERPGSGSPVRELKQFLGMLKKHAYCSNLSFRLYDQWR
AMWQSKHTNODGILPSGRRTGRRGPAR"

ORIGIN

Query Match 75.6%; Score 1572.4; DB 6; Length 1740;
Best Local Similarity 99.7%; Pred. No. 1.8e-288;
Matches 1586; Conservative 0; Mismatches 1; Indels 3; Gaps 1;
QY 490 GCGCCCCCGGAGCGCGGCGCCCATGCCCCCGCGCGCGCGCGCGCGCAATCCG 549
DB 108 GCGCCCCCGGAGCGCGGCGCCCATGCCCCCGCGCGCGCGCGCGCAATCCG 167
QY 550 CGGCG 606
DB 168 CGGCG 227
QY 607 GAGCGCGATGAGAGCCCAACAGCTGTGATCAATCCCAAGATCCCAAGCTTCTACG 666
DB 228 GAGCGCGATGAGAGCCCAACAGCTGTGATCAATCCCAAGATCCCAAGCTTCTACG 287
QY 667 GCT 726
DB 288 GCT 347
QY 727 GCT 786
DB 348 GCT 407
QY 787 CCTCACTTGGCTGTGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCA 846
DB 408 CCTCACTTGGCTGTGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCA 467
QY 847 ACTCTGTGTGCG 906
DB 468 ACTCTGTGTGCG 527
QY 907 TGGCCCCAGAGAACCCGTCACATCACTGTGCTGTGCTGTGCTGTGCTGTGCTGTG 966
DB 528 TGGCCCCAGAGAACCCGTCACATCACTGTGCTGTGCTGTGCTGTGCTGTGCTGTG 587
QY 967 GCGGCTGAGAGCGCGAGGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG 1026
DB 588 GCGGCTGAGAGCGCGAGGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG 647
QY 1027 ACAAGCTTGT 1086
DB 648 ACAAGCTTGT 707
QY 1087 ACTCTGTGCGCAATCCCAAGAGCTGTGCTGTGCTGTGCTGTGCTGTGCTGTGCTGT 1146
DB 708 ACTCTGTGCGCAATCCCAAGAGCTGTGCTGTGCTGTGCTGTGCTGTGCTGTGCTGT 767
QY 1147 CCAACCAAGCGCTGTGCTGTGCTGTGCTGTGCTGTGCTGTGCTGTGCTGTGCTGT 1206
DB 768 CCAACCAAGCGCTGTGCTGTGCTGTGCTGTGCTGTGCTGTGCTGTGCTGTGCTGT 827
QY 1207 TGAACCAAGCG 1266
DB 828 TGAACCAAGCG 887

QY 1267 TGAACCGTGGCTGGGTGTGCGCCACCGCGCTCAAGAGATTCTCTTCAAGCCAATACC 1326
DB 888 TGAACCGTGGCTGGGTGTGCGCCACCGCGCTCAAGAGATTCTCTTCAAGCCAATACC 947
QY 1327 AGATCCGCTACCGAGTGAAGAGACAGTGTGATCTGAAAGGTGTGTGAGACATGCAAC 1386
DB 948 AGATCCGCTACCGAGTGAAGAGACAGTGTGATCTGAAAGGTGTGTGAGACATGCAAC 1007
QY 1387 AGATCCGCTACCGAGTGAAGAGACAGTGTGATCTGAAAGGTGTGTGAGACATGCAAC 1446
DB 1008 AGATCCGCTACCGAGTGAAGAGACAGTGTGATCTGAAAGGTGTGTGAGACATGCAAC 1067
QY 1447 GCAACCCCTTGGATCTATGCTCTCAAGAAAGCGCGGATCTGGAGTGAAGTGAAGCACC 1506
DB 1068 GCAACCCCTTGGATCTATGCTCTCAAGAAAGCGCGGATCTGGAGTGAAGTGAAGCACC 1127
QY 1507 CCAACGCGCTCTCACTCCCGAGTGAAGCGCGCGCGCGCGCGCGCGCGCGCGCGCG 1566
DB 1128 CCAACGCGCTCTCACTCCCGAGTGAAGCGCGCGCGCGCGCGCGCGCGCGCGCGCG 1187
QY 1567 CGCGGCGCGAGAGCGGAGCTCGGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG 1626
DB 1188 CGCGGCGCGAGAGCGGAGCTCGGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG 1247
QY 1627 GCGCTCAAGAGCAAGCGTATGCTCCCAAGCTTCAAGCTTCAAGCTTCAAGCTTCAAG 1686
DB 1248 GCGCTCAAGAGCAAGCGTATGCTCCCAAGCTTCAAGCTTCAAGCTTCAAGCTTCAAG 1307
QY 1687 CTTGATGCAAGAGTGCACACAGACCGCGCAACGAGAGAGATCTGCGCTCGGCGCA 1746
DB 1308 CTTGATGCAAGAGTGCACACAGACCGCGCAACGAGAGAGATCTGCGCTCGGCGCA 1367
QY 1747 GAGCGGCGAGCGGAGAGTCTCTGCGAGATTAAGCTGTAGGGGCTCAAGGCCACTCTG 1806
DB 1368 GAGCGGCGAGCGGAGAGTCTCTGCGAGATTAAGCTGTAGGGGCTCAAGGCCACTCTG 1427
QY 1807 CCAAGTGAAGAGCGCAGAGCGCGCAACCTGAGGCGCACTGTATCCCTCACTTCAAG 1866
DB 1428 CCAAGTGAAGAGCGCAGAGCGCGCAACCTGAGGCGCACTGTATCCCTCACTTCAAG 1487
QY 1867 GCACTGAGAGCACTTCAAGAGAGTGGGGTGGCGCTGAGCTCCACCGCATTAACAG 1926
DB 1488 GCACTGAGAGCACTTCAAGAGAGTGGGGTGGCGCTGAGCTCCACCGCATTAACAG 1547
QY 1927 CTCTGACTCCACGTAGAGCGCACTTGGGGTGAACCCCAAGTGGGTGTGTGTGTGTG 1986
DB 1548 CTCTGACTCCACGTAGAGCGCACTTGGGGTGAACCCCAAGTGGGTGTGTGTGTGTG 1607
QY 1987 AGGGTGTGTGATTTGCTTGAAGACCCCTGCGCAGAGGCTGGGGTGAAGAGGGAGTCA 2046
DB 1608 AGGGTGTGTGATTTGCTTGAAGACCCCTGCGCAGAGGCTGGGGTGAAGAGGGAGTCA 1667
QY 2047 CTCCCATTTACTAGAGGCGCGCTCCAAAGA 2076
DB 1668 CTCCCATTTACTAGAGGCGCGCTCCAAAGA 1697

RESULT 5
AX205046 1740 bp DNA linear PAT 30-AUG-2001
LOCUS AX205046
DEFINITION Sequence 5 from Patent WO0155219.
ACCESSION AX205046
VERSION AX205046.1 GI:15394282
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
1. Elson, G. and Gauchat, J.F.
Scsctfz/mt-1 fusion protein
Patent: WO 0155219-A 5 02-AUG-2001.

[illegible]

QY	967	GC	CGCTGAGAGCCACGGGGGCCACAGGGAGACCTTCCCTCCACACCAATACATCCCTCAAGT	1026
Db	576	GC	CGCTGAGAGCCACGGGGGCCACAGGGAGAGACCTTCCCTCCACACCAATACATCCCTCAAGT	635
QY	1027	ACA	AGCTTAAAGTGTATAGGCGACGACCAACATATGTAGAGATACACACAGTGGGGCCC	1086
Db	636	ACA	AGCTTAAAGTGTATAGGCGACGACCAACATATGTAGAGATACACACAGTGGGGCCC	695
QY	1087	ACT	CTCTGCGACATTCGCCAAGGACCTGGCTCTTTTACGCCCTTATGAGATCTGGGTGAGG	1146
Db	696	ACT	CTCTGCGACATTCGCCAAGGACCTGGCTCTTTTACGCCCTTATGAGATCTGGGTGAGG	755
QY	1147	CC	ACCAACCGCGCTGGGCTCTGCGCGCTCCGATGACTCAGCTGAGTAATCTGGATGTGG	1206
Db	756	CC	ACCAACCGCGCTGGGCTCTGCGCGCTCCGATGACTCAGCTGAGTAATCTGGATGTGG	815
QY	1207	TG	ACCAACGGACCCCCCGCGCGACGTGACAGTGAACCGCGCTCGGGGGCTTGAGAGCAAGC	1266
Db	816	TG	ACCAACGGACCCCCCGCGCGACGTGACAGTGAACCGCGCTCGGGGGCTTGAGAGCAAGC	875
QY	1267	TG	ACCGTGGCGGTGGGTGTGCGACCCGCGCTCAAGAGATTCTCTTTCAAGCCAAATACC	1326
Db	876	TG	ACCGTGGCGGTGGGTGTGCGACCCGCGCTCAAGAGATTCTCTTTCAAGCCAAATACC	935
QY	1327	AG	ATCCGCTACCGAGTGGAGGACAGTGTGACCTGGAAGGTGTGACGATGTGACCAAC	1386
Db	936	AG	ATCCGCTACCGAGTGGAGGACAGTGTGACCTGGAAGGTGTGACGATGTGACCAAC	995
QY	1387	AG	ACTCTCTGCGCGCTGGCGCTTGAAACCCCGGACCCGTGTACTTGTGTCAAGTGGCT	1446
Db	996	AG	ACTCTCTCTGCGCGCTGGCGCTTGAAACCCCGGACCCGTGTACTTGTGTCAAGTGGCT	1055
QY	1447	GCA	ACCCTTTGGGATCTATGTGCTCCAAAGACCGGGATCTGGAAGTGTGAGCCACC	1506
Db	1056	GCA	ACCCTTTGGGATCTATGTGCTCCAAAGAACCGGGATCTGGAAGTGTGAGCCACC	1115
QY	1507	CC	ACAGCGCGCTCCACTCCCGCGAGTGAAGCGCCCGCGCGCGCGCGCGCGCGCGCGAC	1566
Db	1116	CC	ACAGCGCGCGCTCCACTCCCGCGAGTGAAGCGCCCGCGCGCGCGCGCGCGCGCGAC	1175
QY	1567	CG	CGGGCGCGAGAGCCGAGCTCGGGGGCGGTGGCGCGCGCGAGCTCAACAGTCTCGGGCT	1626
Db	1176	CG	CGGGGGGGAGAACCCGAGCTCGGGGGCGGGCGCGAGCTTCAGCAAGTTCCTGGAGCT	1235
QY	1627	GG	CTCAAGAGCAAGCGCTACTGCTCCAACTCAAGCTTCGCGCTCTACAGCAAGTGGGAG	1686
Db	1236	GG	CTCAAGAGCAAGCGCTACTGCTCCAACTCAAGCTTCGCGCTCTACAGCAAGTGGGAG	1295
QY	1687	CT	TGAGATGTGAGAAATCGGCACAAGCCCGCAACCGAGACGAGGGGATCTCTCGGGGCA	1746
Db	1296	CT	TGAGATGTGAGAAATCGGCACAAGCCCGCAACCGAGACGAGGGGATCTCTCGGGGCA	1355
QY	1747	GA	CGGGGCGAGAGGTCTTCCAGATTAAGCTTGAAGGGGCTCAGAGCAACCTCCCTG	1806
Db	1356	GA	CGGGGCGAGAGGTCTTCCAGATTAAGCTTGAAGGGGCTCAGAGCAACCTCCCTG	1415
QY	1807	CC	ACGTGAGAGCGAGAGGCCGAACCCAAACTGGGGCCACTCTGTACCTCACTTCAGG	1866
Db	1416	CC	ACGTGAGAGCGAGAGGCCGAACCCAAACTGGGGCCACTCTGTACCTCACTTCAGG	1475
QY	1867	GC	ACTGACCAACCTTCAAGAGAGGCTGGGGTGGCGCTGAGCTCCAAAGGCCATTAACAG	1926
Db	1476	GC	ACTGACCAACCTTCAAGAGAGGCTGGGGTGGCGCTGAGCTCCAAAGGCCATTAACAG	1535
QY	1927	CT	CTGACTCCCAAGTGAAGCCACTTTGGGTGACCCCAAGTGGGTGTGTGTGTGTGTG	1986
Db	1536	CT	CTGACTCCCAAGTGAAGCCACTTTGGGTGACCCCAAGTGGGTGTGTGTGTGTGTGTG	1595
QY	1987	AG	GGTGTGTGAATGTTCCCTAGAACCTCTGCGACGAGGCTGGGGGTGAGAAAGGAGTCACTTA	2046
Db	1596	AG	GGTGTGTGAATGTTCCCTAGAACCTCTGCGACGAGGCTGGGGGTGAGAAAGGAGTCACTTA	1655

Oy	2047	CTCCCATTAAGGCGCCCTCCAAAGA	2016
Dd	1668	CTCCCATTAAGGCGCCCTCCAAAGA	1697
RESULT 11			
LOCUS	AF073515	1804 bp	mRNA linear PRI 20-JUN-1999
DEFINITION	Homo sapiens cytokine type I receptor CRP-1 precursor, mRNA,		
ACCESSION	AF073515		
VERSION	AF073515.1	GI:5106394	
KEYWORDS			
SOURCE	Homo sapiens (human)		
ORGANISM	Homo sapiens		
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;		
AUTHORS	Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.		
TITLE	Magrangeas, F., Jacques, Y. and Minvielle, S. Cloning and expression of a novel soluble protein containing hematopoietic cytokine receptor domains		
JOURNAL	Unpublished		
REFERENCE	2 (bases 1 to 1804)		
AUTHORS	Magrangeas, F., Jacques, Y. and Minvielle, S.		
TITLE	Direct Submission		
JOURNAL	Submitted (18-JUN-1998) Institut de Biologie, INSERM U463, 9 Quai Monodou, Nantes 44035, France		
FEATURES	Location/Qualifiers		
source	1..1804		
	/organism="Homo sapiens"		
	/mol_type="mRNA"		
	/db_xref="taxon:9606"		
	/chromosome="19"		
	/map="19p12"		
	204..1472		
CDS	/note="soluble hematopoietic cytokine receptor"		
	/codon_start=1		
	/product="cytokine type I receptor CRP-1 precursor"		
	/protein_id="AAB3681.1"		
	/db_xref="GI:5106395"		
	/translation="MPAGRPPAQAQARRPPLPLLLLCVLGAAPRAGSAHTAVIS PODPIILIGSSILLATCSVHPDPATIAEGLWYTLNGRLPELRSVNASTALALANA LNGSORSGDNLYGHARDGSIIAGSCIVGAPPEKPAVVISCSNMMDLTGRTPGAH GETPLHTNYSIKYLIRWGDMTNCBEHYTHPSCHLPKDIALTPYEIWEANTNRG SARSVFLITLDLVTTDDPTPRPDVHRYSRGIGLEDLSARVSPPALPKDFLRKQIQRY RVESVDVKVVDDVSNQTSCLAGLKPEVTIVFVOVRCPFGIYGSKAGIASENSHPT AASIPRSRPGRPGAGCPRGBSPBSGRBELKQFLGMLEKHAVCNSLSPRLYDWMER AMMOKSHTRNQDBEGILPSGRRTARGPAR"		
ORIGIN			
Query Match	75.6%; Score 1572.4; DB 9; Length 1804;		
Best Local Similarity	99.7%; Pred. No. 1.8e-286;		
Matches 1586; Conservative	0; Mismatches 1; Indels 3; Gaps 1;		
Oy	490	GCGCCCCGGCAAGCGCCGCCGCCGCCGCCGCCGCCGCCGCCGCCGC	549
Dd	181	GCGCCCCGGCAAGCGCCGCCGCCGCCGCCGCCGCCGCCGCCGCCGC	240
Oy	550	GCGGGCGGCGCGCGCGGTGGTGCCC--CTGGCTGCTGCTGCGTCTCGGGGCGCCGC	606
Dd	241	GCGGGCGGCGCGCGCGGTGGTGCCCCTGGCTGCTGCTGCGTCTCGGGGCGCCGC	300
Oy	607	GAGCGGATCAAGAACCCACAAGCTGTGATCAATGCCAGATGCCAGCTTCATCG	666
Dd	301	GAGCGGATCAAGAACCCACAAGCTGTGATCAATGCCAGATCCAAGCTTCATCG	360
Oy	667	GCTCTCTCCCTGTGGCCACTGCTCAGTAGCACGAGACCACCAAGAACCAACCGCCAGG	726
Dd	361	GCTCTCTCCCTGTGGCCACTGCTCAGTAGCACGAGACCACCAAGAACCAACCGCCAGG	420
Oy	727	GCTCTACTGAACTCAATGGGCGCGGCTGCCCCCTGAGCTTCCTCGGTACTCAACG	786

Db	421	GCCTCTACTGGAACCTCTCAAGGGGCGCGCCTGCCCTCTGAGCTCTCCCTGTACTCAACG	480
Qy	787	CCTCCACCTTGGCTCTGGCCTCTGGCCCAACTCAATGGGTCAGGCAAGCGGTCCGGGGACA	846
Db	481	CCTCCACCTTGGCTCTGGCCTCTGGCCCAACTCAATGGGTCAGGCAAGCGGTCCGGGGACA	540
Qy	847	ACTCTGTGTGCCACGCCCCGTGACGGGCAAGCATCTGTGGTGTGGCTCTGTGCTTATGTGGCC	906
Db	541	ACTCTGTGTGCCACGCCCCGTGACGGGCAAGCATCTGTGGTGTGGCTCTGTGCTTATGTGGCC	600
Qy	907	TGCCCCAGAGAAACCCGTCAACATCGAGCTGTGGTCCAAAGAACATGAGGACTTGAAGCT	966
Db	601	TGCCCCAGAGAAACCCGTCAACATCGAGCTGTGGTCCAAAGAACATGAGGACTTGAAGCT	660
Qy	967	GCCGCTGGACGCGCAAGGGGCCCAAGGGAGACCTTCTCTCCACCAACTACTCCCTCAAGT	1026
Db	661	GCCGCTGGACGCGCGCAAGGGGCCCAAGGGAGACCTTCTCTCCACCAACTACTCCCTCAAGT	720
Qy	1027	ACAAGCTTAGGTGTATGGCCAGAACACATATGTGAGAGTACCAACAGTGGGGCCCC	1086
Db	721	ACAAGCTTAGGTGTATGGCCAGAACACATATGTGAGAGTACCAACAGTGGGGCCCC	780
Qy	1087	ACTCTGTGCATCCCCCAAGGACCTGTGCTCTTTAAGCCCTAAGACATCGGGTGGAGG	1146
Db	781	ACTCTGTGCATCCCCCAAGGACCTGTGCTCTTTAAGCCCTAAGACATCGGGTGGAGG	840
Qy	1147	CCACCAACCGGCTGTGGGCTCTGCCCGCTCCGATGTACTCAACGTGGATATCTGGATGTGG	1206
Db	841	CCACCAACCGGCTGTGGGCTCTGCCCGCTCCGATGTACTCAACGTGGATATCTGGATGTGG	900
Qy	1207	TGACCAAGGAACCCCCCGCCGACGTGCACGTGAGCCGCTGTGGGGGCTTGAAGACCAAGC	1266
Db	901	TGACCAAGGAACCCCCCGCCGACGTGCACGTGAGCCGCTGTGGGGGCTTGAAGACCAAGC	960
Qy	1267	TGAAGGTGTGCGTGGGTGTGCGCACCGGCGCTCAAGGATTTCTCTTTCAAGCCAAATATAC	1326
Db	961	TGAAGGTGTGCGTGGGTGTGCGCACCGGCGCTCAAGGATTTCTCTTTCAAGCCAAATATAC	1020
Qy	1327	AGATTCGGTACCGAGTGGAGGACAGTGTGACCTGGAAGGTGTGGACGATGTGAGCAACC	1386
Db	1021	AGATTCGGTACCGAGTGGAGGACAGTGTGACCTGGAAGGTGTGGAGATGTGAGCAACC	1080
Qy	1387	AGACTCTCTGCGCCTGTGGCCGGGCTTGAACCCGGGACCCGTGTACTTGTGTCAAGTGTGCT	1446
Db	1081	AGACTCTCTGCGCCTGTGGCCGGGCTTGAACCCGGGACCCGTGTACTTGTGTCAAGTGTGCT	1140
Qy	1447	GCAACCCCTTTGGGATCTATGGGCTCCAAAGAACCGGGATCTGTGAGTGAAGTGGAGCCACC	1506
Db	1141	GCAACCCCTTTGGGATCTATGGGCTCCAAAGAACCGGGATCTGTGAGTGAAGTGGAGCCACC	1200
Qy	1507	CCAACAGCCGCTCACTCTCCCGCAGTGAAGCGCCCGGGCCCGGGCGGCGGGGCGTGCAGAC	1566
Db	1201	CCAACAGCCGCTCACTCTCCCGCAGTGAAGCGCCCGGGCCCGGGCGGCGGGGCGTGCAGAC	1260
Qy	1567	CGCGGGGCGAGAGGCGAGGCTCGGGGGCGGATGCGGGCGGAGCTGAAGCAAGTTCTTGGGCT	1626
Db	1261	CGCGGGGCGAGAGGCGAGGCTCGGGGGCGGATGCGGGCGGAGCTTCAGCAAGTTCTTGGGCT	1320
Qy	1627	GGCTCAAGAACACAGCGGTATGCTTCMAACCTCAAGCTTCGGCTCTTAAGACCAAGTGGGAG	1686
Db	1321	GGCTCAAGAACACAGCGGTATGCTTCMAACCTCAAGCTTCGGCTCTTAAGACCAAGTGGGAG	1380
Qy	1687	CCTGATTCAGAAATCTGCAAGAACCCGCAACCAAGACGAGGAGATCTTGCCCTCGGGACA	1746
Db	1381	CCTGATTCAGAAATCTGCAAGAACCCGCAACCAAGACGAGGAGATCTTGCCCTCGGGACA	1440
Qy	1747	GACGGGGGCAAGAGGTCTTCCAGATTAAGCTGTAGGGGCTCAGGCCACCTCTCCTG	1806
Db	1441	GACGGGGGCAAGAGGTCTTCCAGATTAAGCTGTAGGGGCTCAGGCCACCTCTCCTG	1500
Qy	1807	CCAGCTGGAGACGAGAGGCGGAACCAAAATGGGGGCAACTCTGTACCTCACTTCAAG	1866
Db	1501	CCAGCTGGAGACGAGAGGCGGAACCAAAATGGGGGCAACTCTGTACCTCACTTCAAG	1560

OY		1867	GCACCTGAGCCACCCTCAGCAGAAGCTGGGGTGGGCCCTGAGACTCCACAACCGCATAAACG	1928			
Db		1409	GCACTTGAGCACCCCTCAGCAGAAGCTGGGGTGGGCCCTGAGACTCCACAACCGCATAAACG	1468			
OY		1927	CTCTGACTCCCACTGAGGCCACCTTTGGGTGCACCCAGTAGGTGTGTGTGTGTG	1988			
Db		1469	CTCTGACTCCCACTGAGGCCACCTTTGGGTGCACCCAGTAGGTGTGTGTGTGTG	1528			
OY		1987	AGGGTTGGTTGATGGTTCCTTAAGAACCCCTGCCCAGGGCTGGGGGTGAAGAGGGAGTCATTA	2048			
Db		1529	AGGGTTGGTTGATGGTTCCTTAAGAACCCCTGCCCAGGGCTGGGGGTGAAGAGGGAGTCATTA	1588			
OY		2047	CTCCCCATTACCTAAGGGCCCCCTCCAAAAAGA	2076			
Db		1589	CTCCCCATTACCTAAGGGCCCCCTCCAAAAAGA	1618			
<hr/>							
RESULT 14							
LOCUS	AR164088	1690 bp	DNA	linear PAT 17-OCT-2001			
DEFINITION	Sequence 1 from patent US 6271343.						
ACCESSION	AR164088						
VERSION	AR164088.1	GI:16235032					
KEYWORDS							
SOURCE	Unknown.						
ORGANISM	Unknown.						
REFERENCE	Unclassified.						
AUTHORS	1 (bases 1 to 1690) Lok,S., Presnell,S.R., Jelineberg,A.C., Gilbert,T., Whitmore,T.E., Foester,D.C., Adams,R.L. and Lehner,J.M. Mammalian cytokine-like receptor 5 Patent: US 6271343-A 1 07-MUG-2001; location/Qualifiers 1..1690 /organism="unknown" /mol_type="unasigned DNA"						
TITLE							
JOURNAL							
FEATURES							
source							
<hr/>							
ORIGIN							
<hr/>							
Query_Match	75.6%;	Score 1570.8;	DB 6;	Length 1690;			
Best Local Similarity	99.7%;	Pred.No. 3.6e-286;					
Matches 1585;	Conservative 0;	Mismatches 2;	Indels 3;	Gaps 1;			
<hr/>							
OY	490	GGGCCCCCGGCGAGCGCCGGCCCATAGCCCGCGCGCCGCGCGGCCCGCCGCCCATTCG	549				
Db	29	GGGCCCCCGGCGAGCGCCGGCCCATAGCCCGCGCGCCGCGCGGCCCGCCGCCCATTCG	88				
OY	550	CGGCGCGCGCGCGCGCGCTTGCTGCC--CTGCTGCTGCTTGCGTCTTGCGGGCGCGCG	606				
Db	89	CGGCGCGCGCGCGCGCGCTTGCTGCC--CTGCTGCTGCTTGCGTCTTGCGGGCGCGCG	148				
OY	607	GAGCGCGATCAGGAGCCCAACAGCTGTGATAGTCCCAAGATCCCAAGCTTCATACG	666				
Db	149	GAGCGCGATCAGGAGCCCAACAGCTGTGATAGTCCCAAGATCCCAAGCTTCATACG	208				
OY	667	GCTCCTCCTGCTGCGCACTGCTCAGTGCAGGAGACCCAACAAGACCAACCGCGAGG	726				
Db	209	GCTCCTCCTGCTGCGCACTGCTCAGTGCAGGAGACCCAACAAGACCAACCGCGAGG	268				
OY	727	GCTTACTGAGACCTCAATGGGGCGCGCTGCCCCCTGAGTCTCCCTGTACTCAAAG	786				
Db	269	GCTTACTGAGACCTCAATGGGGCGCGCTGCCCCCTGAGTCTCCCTGTACTCAAAG	328				
OY	787	CCTCACCTGGCTGTGGCGCCGCGCAACCTCAATGGGTCCAGGACAGGAGTGGGGGACA	846				
Db	329	CCTCACCTGGCTGTGGCGCCCTGCGCAACCTCAATGGGTCCAGGACAGGAGTGGGGGACA	388				
OY	847	ACCTGTGTGCCACGCCCGGTGAACGGACAGATCTGGCTGTGCTCTCTATGTGTGCC	906				
Db	389	ACCTGTGTGCCACGCCCGGTGAACGGACAGATCTGGCTGTGCTCTCTATGTGTGCC	448				
OY	907	TGCCCCCAGAAAACCGGTCAACATCACTGTGTGTCATAAATATGAAGAATTGAACT	966				

[illegible]

Db	1589	CTCCCATATTACTTAGGGCCCTCCCAAAAAGA	1618
RESULT 15			
LOCUS	BC044634	1744 bp	mRNA linear PRI 30-JUN-2004
DEFINITION	Homo sapiens cytokine receptor-like factor 1, mRNA (cDNA clone MGC:52126 IMAGE:5926400), complete cds.		
ACCESSION	BC044634		
VERSION	BC044634.1	GI:27882443	
KEYWORDS	MGC.		
SOURCE	Homo sapiens (human)		
ORGANISM	Homo sapiens		
REFERENCE	Mumtazota, Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Eumalia; Eutheria; Primates; Carnivora; Homnidae; Homo. 1 (bases 1 to 1744)		
AUTHORS	Klausner R.D., Collins F.S., Wagner L.H., Derge J.G., Altschul S.F., Zeeberg B., Buettow K.H., Schaefer C.F., Bhattacharya N.K., Hopkins R.F., Jordan H., Moore T., Wax S.I., Wang J., Hsieh F., Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L., Stopleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheer T.E., Brownstein M.J., Udell T.B., Toshyaki S., Carninci P., Prange C., Raha S.S., Loguigliano N.A., Peters G.U., Abramson R.D., Mullany S.J., Bosak S.A., McEwan P.J., Wexlerman K.J., Malek U.A., Gunaratne P.H., Richards S., Wolley K.C., Hale S., Garcia A.M., Gay L.J., Huliyil S.W., Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A., Fahney J., Helton E., Ketterman M., Madan A., Young A.C., Shevchenko Y., Sanchez A., Whiting M., Madan A., Touchman J.W., Green E.D., Bouffard G.G., Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C., Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butlerfield Y.S., Krzywnicki M.I., Skalska U., Smalls D.E., Schermer A., Schein J.E., Jones S.J., and Marra M.A.		
TITLE	Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences		
JOURNAL	Proc. Natl. Acad. Sci. U.S.A. 99 (26), 16939-16903 (2002)		
PUBMED	12477932		
REFERENCE	2 (bases 1 to 1744)		
AUTHORS	Straussberg R.		
TITLE	Direct Submission		
JOURNAL	Submitted (17-JUN-2003) National Institutes of Health, Mammalian Gene Collection (MGC), Cancer Genomics Office, National Cancer Institute, 31 Center Drive, Room 11A03, Bethesda, MD 20892-2590, USA		
REMARK	NIH-MGC Project URL: http://mgc.nci.nih.gov		
COMMENT	Contact: MGC help desk Email: cgapbs-re@mail.nih.gov Tissue Procurement: Lou Stroud cDNA Library Preparation: Rubin Laboratory cDNA library Arrayed by: The I.M.A.G.E. Consortium (LNL) DNA Sequencing by: National Institutes of Health Intramural Sequencing Center (NISC), Gaithersburg, Maryland; Web site: http://www.nisc.nih.gov/ Contact: nisc.mgc@nih.gov		
	Akhter, N., Ayale, K., Beckerrom-Sternberg, S.M., Benjamin, B., Blakesley, R.W., Bouffard, G.G., Breun, K., Brinkley, C., Brooks, S., Dieterich, N.L., Granite, S., Guan, X., Gupta, U., Haghighi, P., Hansen, N., Ho, S.-L., Karlins, E., Kwong, P., Laric, P., Legaspi, R., Mandru, Q.L., Masello, C., Maskeri, B., Mastrian, S.D., McCloskey, J.C., McDowell, J., Pearson, R., Stanitropo, S., Thomas, P.J., Touchman, J.W., Tsougen, C., Vogt, U.L., Walker, M.A., Wechtery, K.D., Wiggins, L., Young, A., Zhang, L.-H. and Green, E.D.		
FEATURES	Clone distribution: MGC clone distribution information can be found through the I.M.A.G.E. Consortium/LNL at: http://image.llnl.gov		
SOURCE	Series: ITAL Plate: 44 Row: O Column: 22. Location/Qualifiers 1..1744		

[illegible]

Db ~ 645 ACAAGCTTAGTGTGATGCGCAGACACATGTGAGAGTACCAACAGTGGGGCCCC 704
QY 1087 ACTCCCTGGCAATCCCCAAGGACTGTCTTTACGCCCTATGAGATCTGGGTGGAGG 1146
Db 705 ACTCTGCGCAATCCCCAAGGACTGTCTTTACGCCCTATGAGATCTGGGTGGAGG 764
QY 1147 CCACCAACCGCTTGGGCTGTGCGGCTCCGATGTACTCAGCTGATATCTTGGATGTGG 1206
Db 765 CCACCAACCGCTTGGGCTGTGCGGCTCCGATGTACTCAGCTGATATCTTGGATGTGG 824
QY 1207 TGAACCAAGGACCCCGCGCGACGTGACGTGAGCCGCTCGGGGCTTGAGAGACCAAGC 1266
Db 825 TGAACCAAGGACCCCGCGCGACGTGACGTGAGCCGCTCGGGGCTTGAGAGACCAAGC 884
QY 1267 TGAAGCGTGTGGGTGTGGCCACCGGCGCTCAAGATTTCTCTTCAAGCCAAATACC 1326
Db 885 TGAAGCGTGTGGGTGTGGCCACCGGCGCTCAAGATTTCTCTTCAAGCCAAATACC 944
QY 1327 AGATCCGCTACCGAGTGAAGACAGTGTGACTGGAAGTGTGACGATGTGACCAACC 1386
Db 945 AGATCCGCTACCGAGTGAAGACAGTGTGACTGGAAGTGTGACGATGTGACCAACC 1004
QY 1387 AGACTCTCTGCGCGCTGGCGCGCTGTAAACCGGACACCTGTACTTCTGTCAAGTGGCT 1446
Db 1005 AGACTCTCTGCGCGCTGGCGCGCTGTAAACCGGACACCTGTACTTCTGTCAAGTGGCT 1064
QY 1447 GCAACCCCTTTGGCATCTATGAGCTCAAGAAACCGGGATCTGAGATGTGAGCCACC 1506
Db 1065 GCAACCCCTTTGGCATCTATGAGCTCAAGAAACCGGGATCTGAGATGTGAGCCACC 1124
QY 1507 CCACAGCCGCTCCACTCCCGCAGTGAAGCGCCGGGCGGGGCGGGGCGTGCAGAC 1566
Db 1125 CCACAGCCGCTCCACTCCCGCAGTGAAGCGCCGGGCGGGGCGGGGCGTGCAGAC 1184
QY 1567 CGGGGGGCGAGAGCCGAGCTCGGGGCGGGTGCAGGCTCAAGCACTTCTGGGCT 1626
Db 1185 CGGGGGGCGAGAGCCGAGCTCGGGGCGGGTGCAGGCTCAAGCACTTCTGGGCT 1244
QY 1627 GGGTCAAGAAAGCAAGGTACTGTCTCAACTCACTTCCGCTCTTACGACCACTGGGAG 1686
Db 1245 GGGTCAAGAAAGCAAGGTACTGTCTCAACTCACTTCCGCTCTTACGACCACTGGGAG 1304
QY 1687 CCTGATGCAAGAGTGCACAAAGCCGCAACGAGGAGATCTGCGGCGCA 1746
Db 1305 CCTGATGCAAGAGTGCACAAAGCCGCAACGAGGAGATCTGCGGCGCA 1364
QY 1747 GACGGGGCAAGGAGAGGTCTTGCAATAGCTGAGGGGCTCAGGCCACCTCCTG 1806
Db 1365 GACGGGGCAAGGAGAGGTCTTGCAATAGCTGAGGGGCTCAGGCCACCTCCTG 1424
QY 1807 CCACGTGAGAGCGCAAGGCGCAACCCAACTGGGGCACCTGTACTCTCACTTCAGG 1866
Db 1425 CCACGTGAGAGCGCAAGGCGCAACCCAACTGGGGCACCTGTACTCTCACTTCAGG 1484
QY 1867 GCACTGAGGCAACCTCAGCAGAGGTGGGGTGGCCCTGAGCTCCAAAGGCCATTAACAG 1926
Db 1485 GCACTGAGGCAACCTCAGCAGAGGTGGGGTGGCCCTGAGCTCCAAAGGCCATTAACAG 1544
QY 1927 CTCTGACTCCACGTAGGGCACTTTGGGTGCAACCAGTGGGTGTGTGTGTGTG 1986
Db 1545 CTCTGACTCCACGTAGGGCACTTTGGGTGCAACCAGTGGGTGTGTGTGTGTG 1604
QY 1987 AGGGTTGGTTGAGTTGCTTAGAACCTCTGCAAGGCTGGGGGTGAGAAAGGGAGTCATTA 2046
Db 1605 AGGGTTGGTTGAGTTGCTTAGAACCTCTGCAAGGCTGGGGGTGAGAAAGGGAGTCATTA 1664
QY 2047 CTCCCATTAACCTAGGGGCCCTCCAAAAGA 2076
Db 1665 CTCCCATTAACCTAGGGGCCCTCCAAAAGA 1694

mis Page Blank (uspto)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: February 25, 2005, 07:35:16 : Search time 1045 Seconds
(without alignments)
11777.170 Million cell updates/sec

Title: US-09-037-657-43

Perfect score: 2079

Sequence: 1 gcgcattctgtgttcaaat.....aggcccccctcaaatgattcc 2079

Scoring table: IDENTITY_NUC

Gapop 10.0 , Gapext 1.0

Searched: 4390206 seqs, 2959870667 residues

Total number of hits satisfying chosen parameters: 8780412

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

N_Geneseq_16Dec04:*

- 1: geneseqn1980s:*
- 2: geneseqn1980s:*
- 3: geneseqn2000s:*
- 4: geneseqn2001as:*
- 5: geneseqn2001bs:*
- 6: geneseqn2002as:*
- 7: geneseqn2002bs:*
- 8: geneseqn2003as:*
- 9: geneseqn2003bs:*
- 10: geneseqn2003cs:*
- 11: geneseqn2003ds:*
- 12: geneseqn2004as:*
- 13: geneseqn2004bs:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	2079	100.0	2079	4 AAD04199	Aad04199 Murine ha
2	1572.4	75.6	1716	2 Aax25489	Aax25489 Human typ
3	1572.4	75.6	1716	6 ABQ88149	Abq88149 Human ost
4	1572.4	75.6	1716	8 ABX14013	Abx14013 Human cyt
5	1572.4	75.6	1716	13 ADR25220	Adr25220 Breast ca
6	1572.4	75.6	1740	4 AAH74486	Aah74486 Nucleotid
7	1572.4	75.6	1789	2 AAX90754	Aax90754 Human U4
8	1572.4	75.6	1789	2 AAX80050	Aax80050 Human PRO
9	1572.4	75.6	1789	10 ADH27451	Adh27451 Human cdn
10	1572.4	75.6	1790	2 AAX87256	Aax87256 cDNA clon
11	1572.4	75.6	1790	3 AAA49558	Aaa49558 Human PRO
12	1572.4	75.6	1790	8 ABX96790	Abx96790 Human cdn
13	1572.4	75.6	1790	8 ABX78444	Abx78444 DNA encod
14	1572.4	75.6	1790	8 ABX77078	Abx77078 cDNA sequ
15	1572.4	75.6	1790	8 ABX75909	Abx75909 Human cdn
16	1572.4	75.6	1790	8 ABX89620	Abx89620 Human enco
17	1572.4	75.6	1790	8 ABX34106	Abx34106 cDNA enco
18	1572.4	75.6	1790	9 ACA04326	Aca04326 Human PRO
19	1572.4	75.6	1790	10 ADC52787	Adc52787 Human cdn
20	1572.4	75.6	1790	10 ADC55545	Adc55545 Human cdn

ALIGNMENTS

21	1572.4	75.6	1790	10 ADC25666	Adc25666 Human cdn
22	1572.4	75.6	1790	10 ABX75462	Abx75462 Human sec
23	1572.4	75.6	1790	10 ABX89453	Abx89453 Human PRO
24	1572.4	75.6	1790	12 ADE71500	Adel71500 Human cdn
25	1572.4	75.6	1790	12 ADG63443	Adg63443 Human cdn
26	1572.4	75.6	1790	12 ADH43172	Adh43172 Human cdn
27	1572.4	75.6	1790	12 ADN00410	Adn00410 Human cdn
28	1572.4	75.6	1802	3 AAA46902	Aaa46902 cDNA enco
29	1572.4	75.6	1804	6 ABQ88147	Abq88147 Human ost
30	1572.4	75.6	1804	10 ADL13624	Adl13624 Osteoarth
31	1572.4	75.6	1804	12 ADN04231	Adn04231 Antipsoit
32	1572.4	75.6	1804	12 ADQ18850	Adq18850 Human sof
33	1572.4	75.6	2154	12 ADQ23242	Adq23242 Human sof
34	1572	75.6	1813	2 AAV70895	Aav70895 cDNA enco
35	1570.8	75.6	1650	6 ABQ88148	Abq88148 Human ost
36	1570.8	75.6	1650	2 AAV70894	Aav70894 cDNA enco
37	1511.6	72.7	1579	2 AAV41689	Aav41689 Nucleotid
38	1511.6	72.7	1579	2 AAX90753	Aax90753 Human U4
39	1511.6	72.7	1594	7 ADR41329	Adr41329 Human CD-
40	1433.8	69.0	1882	10 ADF71799	Adf71799 cDNA for
41	1425	68.5	1498	3 AAZ34614	Aaz34614 Human rec
42	1308.4	62.9	1391	2 AAV27144	Aav27144 Nucleotid
43	1308.4	62.9	1391	4 AAD04196	Aad04196 cDNA clon
44	1254.4	60.3	1930	4 AAH74485	Aah74485 Nucleotid
45	1251.4	60.2	1269	10 ADL13625	Adl13625 Osteoarth

RESULT 1

AAAD04199	standard; DNA; 2079 BP.
ID	AAAD04199
XX	AAAD04199;
AC	AAAD04199;
XX	AAAD04199;
DT	09-SEP-2004 (revised)
DT	02-JUL-2001 (first entry)
XX	
DE	Murine haemopoietin receptor, NR6 DNA.
XX	
KM	Murine; biologically active complex; haemopoietin receptor; NR6;
KW	cardiotrophin-like cytokine; CLC; therapy; prophylaxis; proliferation;
KX	differentiation; cell survival; neutrophilic activity; ds.
XX	
OS	Mus sp.
XX	Unidentified.
XX	
FT	Key
FT	Location/Qualifiers
FT	CDS
FT	/*tag= a
FT	/product= "Murine haemopoietin receptor, NR6 protein"
XX	
PN	W0200127157-A1.
XX	
PD	19-APR-2001.
XX	
PF	06-OCT-2000; 2000WO-AU001216.
XX	
PR	08-OCT-1999; 99AU-00003327.
XX	
PR	12-MAY-2000; 2000AU-00007489.
XX	
XX	(AMRA-) AMRAD OPERATIONS PTY LTD.
PA	
XX	
PI	Nash A., Jachno KM, Fabri LJ, Reid K, Bartlett PF, Hilton DJ;
XX	Nakata Y., Hasegawa M,
XX	WPI, 2001-281978/29.
DR	P-PSDB; AAE00826.
XX	
PT	New biologically active complex comprising NR6 and cardiotrophin-like-
PT	cytokine for facilitating proliferation, differentiation and/or survival
PT	of a cell.

XX Claim 22; Page 102-106; 123pp; English.

PS The present invention relates to a biologically active complex comprising
CC a haemopoietin receptor, NR6 and cardiotrophin-like cytokine (CLC). The
CC complex is useful in the manufacture of a medicament for the treatment
CC and/or prophylaxis of a subject, as it is involved in facilitating
CC proliferation, differentiation and/or survival of a cell. The complex or
CC its components have neurotrophic activity. The present sequence is murine
CC haemopoietin receptor, NR6 DNA

CC Revised record issued on 09-SEP-2004 : Correction to Organism field
CC
CC Sequence 2079 BP; 412 A; 667 C; 602 G; 398 T; 0 U; 0 Other;

Query Match 100.0%; Score 2079; DB 4; Length 2079;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 2079; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GGGGTATTTGTGTTCAAAATCTATCTACAGAAAAGATTGAGAACAGAACCCCTTTCTGT 60
DB 1 GGGGTATTTGTGTTCAAAATCTATCTACAGAAAAGATTGAGAACAGAACCCCTTTCTGT 60
QY 61 TTTTGAAGAGTAGCTGACTCACTGTTCAAGAAAGAGAACACTTTCAATTATGCTGTTT 120
DB 61 TTTTGAAGAGTAGCTGACTCACTGTTCAAGAAAGAGAACACTTTCAATTATGCTGTTT 120
QY 121 GACTGAGAGTCAAGGAGATCCAAAGAAATGACTCCATCCCTTCCATTCACCACTTC 180
DB 121 GACTGAGAGTCAAGGAGATCCAAAGAAATGACTCCATCCCTTCCATTCACCACTTC 180
QY 181 AGTGAACAGAAATTCATGATGTGCTGAGGGTTGGCTTGTGAAGAGATCTAGAAATTC 240
DB 181 AGTGAACAGAAATTCATGATGTGCTGAGGGTTGGCTTGTGAAGAGATCTAGAAATTC 240
QY 241 TGCCTAAGCCATAGCCGATGAGAAAGATGTATCCTATGGTGTGATTTTCTGTGCCCC 300
DB 241 TGCCTAAGCCATAGCCGATGAGAAAGATGTATCCTATGGTGTGATTTTCTGTGCCCC 300
QY 301 CTCAGAGGAAAGTTGTCAATGAGAGAGTGTATCTATAGCAAAACAGAACTTAATA 360
DB 301 CTCAGAGGAAAGTTGTCAATGAGAGAGTGTATCTATAGCAAAACAGAACTTAATA 360
QY 361 GGTACACAGATTAATCTGATGCTGATGCTTACAGAACTGTGCTATTTGAAGAGGGA 420
DB 361 GGTACACAGATTAATCTGATGCTGATGCTTACAGAACTGTGCTATTTGAAGAGGGA 420
QY 421 AGGTTCATGCTCAGGGGGCAACTGTGTGGTTAGATTGAAGTTGAAGAGCTTCTGCT 480
DB 421 AGGTTCATGCTCAGGGGGCAACTGTGTGGTTAGATTGAAGTTGAAGAGCTTCTGCT 480
QY 481 CATATTTCAGCCGCCCGGAGGCGGCCCATGCGCCCGCGCGCGCGCGCGCGCGCGCG 540
DB 481 CATATTTCAGCCGCCCGGAGGCGGCCCATGCGCCCGCGCGCGCGCGCGCGCGCGCG 540
QY 541 CCCAATCCGCGCGCGCGCGCGCGCGCGCTGTGCTGCTGCTGCTGCTGCTGCTGCTG 600
DB 541 CCCAATCCGCGCGCGCGCGCGCGCGCGCTGTGCTGCTGCTGCTGCTGCTGCTGCTG 600
QY 601 CGCGCGAGCCGAGATCAGAGAGCCACACAGCTGTGATCACTCCAGAGATCCAGCTTC 660
DB 601 CGCGCGAGCCGAGATCAGAGAGCCACACAGCTGTGATCACTCCAGAGATCCAGCTTC 660
QY 661 TCATGCGGCTCTCTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 720
DB 661 TCATGCGGCTCTCTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 720
QY 721 CCGAGGGGCTCTACTGAGAGCCCTCAATGAGGAGCGCGCTGAGCTCTCCGCTGATC 780
DB 721 CCGAGGGGCTCTACTGAGAGCCCTCAATGAGGAGCGCGCTGAGCTCTCCGCTGATC 780
QY 781 TCACGCGCTTCACCTTGTGCTGTGAGCCCTGAGCAACTCAATGAGGATCAGAGCAGGATCG 840
DB 781 TCACGCGCTTCACCTTGTGCTGTGAGCCCTGAGCAACTCAATGAGGATCAGAGCAGGATCG 840

DB 781 TCACGCGCTTCACCTTGTGCTGTGAGCCCTGAGCAACTCAATGAGGATCAGAGCAGGATCG 840
QY 841 GGGACAACTCGTGTGCGCACCGCGGAGCGAGAGATCCGTGCTGCTGCTGCTGCTGCTG 900
DB 841 GGGACAACTCGTGTGCGCACCGCGGAGCGAGAGATCCGTGCTGCTGCTGCTGCTGCTG 900
QY 901 TTGGCTGCGCCCGCAGAGAAACCGCTCAATCAGCTGCTGCTGCTGCTGCTGCTGCTG 960
DB 901 TTGGCTGCGCCCGCAGAGAAACCGCTCAATCAGCTGCTGCTGCTGCTGCTGCTGCTG 960
QY 961 TGAAGTGAAGCTTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTG 1020
DB 961 TGAAGTGAAGCTTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTG 1020
QY 1021 TGAAGTGAAGCTTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTG 1080
DB 1021 TGAAGTGAAGCTTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTG 1080
QY 1081 GGGCCCACTCTGCGACATCCCAAGAGACTGCTCTTTACGCGCTTATGAGATCTGG 1140
DB 1081 GGGCCCACTCTGCGACATCCCAAGAGACTGCTCTTTACGCGCTTATGAGATCTGG 1140
QY 1141 TGAAGGCGACCAACCGCTGCGCTGCGCTGCGCTGCGCTGCGCTGCGCTGCGCTGCG 1200
DB 1141 TGAAGGCGACCAACCGCTGCGCTGCGCTGCGCTGCGCTGCGCTGCGCTGCGCTGCG 1200
QY 1201 ATGTGAGTGAAG 1260
DB 1201 ATGTGAGTGAAG 1260
QY 1261 ACCAGTGAAGCTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAG 1320
DB 1261 ACCAGTGAAGCTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAG 1320
QY 1321 AATTAACAGATCCGCTTACCGAGTGAAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 1380
DB 1321 AATTAACAGATCCGCTTACCGAGTGAAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 1380
QY 1381 GGAACAGAGCTTCGCGCGCTGCGCGCTGCGCGCTGCGCGCTGCGCGCTGCGCGCTGCG 1440
DB 1381 GGAACAGAGCTTCGCGCGCTGCGCGCTGCGCGCTGCGCGCTGCGCGCTGCGCGCTGCG 1440
QY 1441 TGCCTGCAACCCCTTTGCGATCTATGCTCCAAAGAACCGGAGATCTGAGATGAG 1500
DB 1441 TGCCTGCAACCCCTTTGCGATCTATGCTCCAAAGAACCGGAGATCTGAGATGAG 1500
QY 1501 GGCACCCCAACAGCCGCTTCACTCCCGGAGTGAAGCGCCCGGAGCCGCGCGCGCGCT 1560
DB 1501 GGCACCCCAACAGCCGCTTCACTCCCGGAGTGAAGCGCCCGGAGCCGCGCGCGCGCT 1560
QY 1561 GCGAACCGCGGGGCGGAGAGCGGAGCTGCGGGGCGGAGTGGCGGAGCTCAAGCAGTTCC 1620
DB 1561 GCGAACCGCGGGGCGGAGAGCGGAGCTGCGGGGCGGAGTGGCGGAGCTCAAGCAGTTCC 1620
QY 1621 TGGGCTGAGCTCAAGAGAGAGCGGATCTGCTCCAACTCAGCTTCCGCTCTAGCAAGT 1680
DB 1621 TGGGCTGAGCTCAAGAGAGAGCGGATCTGCTCCAACTCAGCTTCCGCTCTAGCAAGT 1680
QY 1681 GCGAGAGCTGATGAGAGAGTGTGCAACAGAGCCCGGAGCAAGAGAGAGAGAGAGAG 1740
DB 1681 GCGAGAGCTGATGAGAGAGTGTGCAACAGAGCCCGGAGCAAGAGAGAGAGAGAGAG 1740
QY 1741 CCGGAG 1800
DB 1741 CCGGAG 1800
QY 1801 TCCCTGCGACCTGAG 1860
DB 1801 TCCCTGCGACCTGAG 1860
QY 1861 TTCAAGGGGAGCTTGAAGCAGCTTCAAGAGAGAGTGGAGTGGCCCTGAGCTTCAAGCGGCA 1920
DB 1861 TTCAAGGGGAGCTTGAAGCAGCTTCAAGAGAGAGTGGAGTGGCCCTGAGCTTCAAGCGGCA 1920

QY	1921	TAAACGCTCTGATCCCAAGAGGCAACCTTGGGATGACACCCAGATGAGTGTG	1980
Db	1921	TAAACGCTCTGATCCCAAGAGGCAACCTTGGGATGACACCCAGATGAGTGTG	1980
QY	1981	TGTGTGAGGGTGTGTGAGTTGCTTGAACCCCTGACCAGGCTGGGGGTGAGAAAGGGAG	2040
Db	1981	TGTGTGAGGGTGTGTGAGTTGCTTGAACCCCTGACCAGGCTGGGGGTGAGAAAGGGAG	2040
QY	2041	TCATTACTCTCCATTACTTACCTAGGGCCCCCTTCCAAGATCC	2079
Db	2041	TCATTACTCTCCATTACTTACCTAGGGCCCCCTTCCAAGATCC	2079
RESULT 2			
ID	AAK25489	standard; cDNA, 1716 BP.	
AC	AAK25489;		
DT	02-AUG-1999	(first entry)	
DE	Human type I cytokine receptor GBRI-ILR cDNA.		
XX	GBRI-ILR; hGBR-ILR; cytokine receptor; human; cancer; obesity;		
KW	inflammation; septic shock; AIDS; embryo development; lung infection;		
KW	cytostatic; anorectic; immunosuppressive; antibacterial; antiviral;		
KW	antiinflammatory; therapy; ss.		
OS	Homo sapiens.		
XX			
FH	Key	Location/Qualifiers	
FT	CDS	119..1387	
FT		/*tag= a	
FT	sig_peptide	119..229	
FT		/*tag= b	
FT	mat_peptide	230..1384	
FT		/*tag= c	
XX			
PN	MO9920755-A2.		
PD	29-APR-1999.		
XX			
PF	14-OCT-1998;	98WO-EP006497.	
XX			
PR	16-OCT-1997;	97GB-00021961.	
XX			
PA	(GLAXO) GLAXO GROUP LTD.		
XX			
PI	Elson G, Gauchat J, Kosco-Villbois M,		
DR	WPI; 1999-288305/24.		
XX	P-PSDB; AAY05782.		
PT	Novel human or mouse type I cytokine receptors hGBRI-ILR or mGBRI-ILR,		
XX	useful for treating e.g. cancer, immune disorders, obesity and AIDS.		
PS	Claim 23; Fig 3; 41pp; English.		
XX			
CC	This is the nucleotide sequence of a cDNA clone encoding a novel type I		
CC	cytokine receptor (see AAY05782) that has been termed human GBRI-ILR as		
CC	it is believed to be an interleukin receptor, or at least a substantial		
CC	part of such a receptor. To clone the cDNA, a 310 bp PCR product was		
CC	amplified from human lung cDNA using primers designed from human ESTs		
CC	that had been identified using the WEXMS motif of the mouse IL-13		
CC	receptor alpha 1 as query, and used as a probe to screen a human		
CC	placental cDNA library. The GBRI-ILR receptor has also been identified in		
CC	mice (see AAY05783), and the high degree of conservation of amino acids		
CC	between the human and murine polypeptides indicates that this receptor is		
CC	functionally important. GBRI-ILR nucleic acids are used for the		
CC	recombinant production of GBRI-ILR polypeptides, in antisense therapy and		
CC	as probes and primers. GBRI-ILR polypeptides, nucleic acids, agonists,		
CC	antagonists and antibodies can be used to treat e.g. cancer, immune		

[illegible]

QY	1447	GCACCCCTTTGGATCTGATGAGCTCCAGAAAGAGCCGGGATATCTGGAGTGAAGTGAAGCAACC	1506
Db	1056	GCAACCCCTTTGGATCTGATGAGCTCCAGAAAGAGCCGGGATATCTGGAGTGAAGTGAAGCAACC	1115
QY	1507	CCACAGCCGAGCTCCACTCCCCCGCAGTGAACGCCGCCGAGCCCGGAGCGCGGGCGTTCGAAAC	1566
Db	1116	CCACAGCCGAGCTCCACTCCCCCGCAGTGAACGCCGCCGAGCCCGGAGCGCGGGCGTTCGAAAC	1175
QY	1567	CGCGGGCGGAGAGACCCGAGCTCTGGGGGGCGGTGTGGCGCGGAGCTCAAGAGTTCCGTGGGCT	1626
Db	1176	CGCGGGCGGAGAGACCCGAGCTCTGGGGGGCGGTGTGGCGCGGAGCTCAAGAGTTCCGTGGGCT	1235
QY	1627	GGCTCAAGAAACAGCGGCTACTGTCTCCAACTCCAGCTTCGAGCTTCGACGACCAAGTTCGAGAG	1686
Db	1236	GGCTCAAGAAACAGCGGCTACTGTCTCCAACTCCAGCTTCGAGCTTCGAGCTTCGAGAG	1235
QY	1687	CCTGGAATGCAGAAAGTTCGCAACAAGACCCGCAACCAAGAGAGAGGATCTCTGCTTCGAGCA	1746
Db	1296	CCTGGAATGCAGAAAGTTCGCAACAAGACCCGCAACCAAGAGAGAGGATCTCTGCTTCGAGCA	1355
QY	1747	GACGGGGGACGGGCCGAGAGTCTCTCGAATTAAGCTGTGGGGGCTCAGGGCCACCCCTCCCTG	1806
Db	1356	GACGGGGGACGGGCCGAGAGTCTCTCGAATTAAGCTGTGGGGGCTCAGGGCCACCCCTCCCTG	1415
QY	1807	CCACGTGAGAGCGCAGAGGCGGAACCCAACTGGGGGCCACCTCTGTACCTCACTTCAGG	1866
Db	1416	CCACGTGAGAGCGCAGAGGCGGAACCCAACTGGGGGCCACCTCTGTACCTCACTTCAGG	1475
QY	1867	GCACCTGAGCAACCCCTCAGCAGAGAGCTGGGTGGTCCCTTGAGCTCCAAACGGCATTAACG	1926
Db	1476	GCACCTGAGCAACCCCTCAGCAGAGAGCTGGGTGGTCCCTTGAGCTCCAAACGGCATTAACG	1535
QY	1927	CTGTGACTCCACCGTAGAGGCCACCTTTGGGTGACCCCGAGTGGAGTGTGTGTGTGTG	1986
Db	1536	CTGTGACTCCACCGTAGAGGCCACCTTTGGGTGACCCCGAGTGGAGTGTGTGTGTGTGTG	1595
QY	1987	AGGGTGGTGTGAGTGTCTTAGAACCCCTGCCAGAGGCTGGGGGTGAGAAAGGGAGTCAATTA	2046
Db	1596	AGGGTGGTGTGAGTGTCTTAGAACCCCTGCCAGAGGCTGGGGGTGAGAAAGGGAGTCAATTA	1655
QY	2047	CTCCCATTAATCTTAGAGGCGCCCTCCAAAAAGA	2076
Db	1656	CTCCCATTAATCTTAGAGGCGCCCTCCAAAAAGA	1685
RESULT 3			
ABQ88149			
AC	ABQ88149	standard; cDNA; 1716 BP.	
XX	ABQ88149;		
DT	18-SEP-2002	(first entry)	
XX			
DE	Human osteoblast differentiation related cDNA SEQ ID NO 56.		
XX			
KW	Human; osteoblast; stem cell differentiation; bone tissue deposition;		
XX	osteoporosis; osteopathic; ss.		
OS	Homo sapiens.		
XX			
PN	WO200250301-A2.		
XX			
PD	27-JUN-2002.		
XX			
PF	18-DEC-2001; 2001WO-US048276.		
XX			
PR	18-DEC-2000; 2000US-0255882P.		
XX			
PA	24-APR-2001; 2001US-0285691P.		
XX			
XX	(GENE-) GENE LOGIC INC.		
XX	(PROC) PROCTER & GAMBLE CO.		
XX			

[illegible]

Db 636 ACAAGCTTAGTGTATGCGCAGAGCAACATGATGAGAGTACCAACAGTGGGGCCCC 695
 Qy 1087 ACTGCTGCAATCCCAAGGACCTGGCTCTTTAGCCCTTAAGATCTGGGTGAGG 1146
 Db 696 ACTCTGCAATCCCAAGGACCTGGCTCTTTAGCCCTTAAGATCTGGGTGAGG 755
 Qy 1147 CCACCAACCGGCTGGCTGCTCCGCTCCGATGATCAACGCTGGATCTCTGGATGTG 1206
 Db 756 CCACCAACCGGCTGGCTGCTCCGCTCCGATGATCAACGCTGGATGTG 815
 Qy 1207 TGACACGAGACCCCCCGCCGACGTGACGTGAGCCGCTGGGGGGCTGAGAGACAGC 1266
 Db 816 TGACACGAGACCCCCCGCCGACGTGACGTGAGCCGCTGGGGGGCTGAGAGACAGC 875
 Qy 1267 TGAGCGTGGCTGGGTGTGCGCACCCGCTCAAGATTTCTTTCAACCAAAATACC 1326
 Db 876 TGAGCGTGGCTGGGTGTGCGCACCCGCTCAAGATTTCTTTCAACCAAAATACC 935
 Qy 1327 AGATCCGCTACCGAGTGAAGACAGTGTGACTGGAAGTGTGAGCAATGTGAGCAAC 1386
 Db 936 AGATCCGCTACCGAGTGAAGACAGTGTGACTGGAAGTGTGAGCAATGTGAGCAAC 995
 Qy 1387 AGACTCTCTGCGGCTGTGCGGCTGAAACCCGGCACCGTGTACTTGTGCAAGTGGCT 1446
 Db 996 AGACTCTCTGCGGCTGTGCGGCTGAAACCCGGCACCGTGTACTTGTGCAAGTGGCT 1055
 Qy 1447 GCACCCCTTTGGATCTATGCTCCCAAGAAAGCCGGATTTGGAGTGAAGTGAAGCCACC 1506
 Db 1056 GCACCCCTTTGGATCTATGCTCCCAAGAAAGCCGGATTTGGAGTGAAGTGAAGCCACC 1115
 Qy 1507 CCACAGCGGCTCCACTCCCGCAGTGAAGCCCGGACCGGGGCGGCGGCGGTGCGGAC 1566
 Db 1116 CCACAGCGGCTCCACTCCCGCAGTGAAGCCCGGACCGGGGCGGCGGCGGTGCGGAC 1175
 Qy 1567 CGCGGGCGGAGAGCCGAGCTCGGAGCGGTGCGGCGGAGCTCAAGCATTTCTTGGGCT 1626
 Db 1176 CGCGGGCGGAGAGCCGAGCTCGGAGCGGTGCGGCGGAGCTCAAGCATTTCTTGGGCT 1225
 Qy 1627 GGCTCAAGAGAGCGGCTATGCTCTCCCAACTCCGCTTCAAGCAAGTGGGAG 1686
 Db 1236 GGCTCAAGAGAGCGGCTATGCTCTCCCAACTCCGCTTCAAGCAAGTGGGAG 1295
 Qy 1687 CTTGATGCAAGATGCGACCAAGACCCGCAACAGAGAGGATCTGCGCTCGGGACA 1746
 Db 1296 CTTGATGCAAGATGCGACCAAGACCCGCAACAGAGAGGATCTGCGCTCGGGACA 1355
 Qy 1747 GACGGGGCAGCGGCGAGAGTCTGCGCATTAAGCTGTAGGGGCTCAAGGCCACTTCCCTG 1806
 Db 1356 GACGGGGCAGCGGCGAGAGTCTGCGCATTAAGCTGTAGGGGCTCAAGGCCACTTCCCTG 1415
 Qy 1807 CCACGTGAGACCGAGAGGCGGCAACCAACTGGGGGCACTCTGTACCTCTCATTTCAAG 1866
 Db 1416 CCACGTGAGACCGAGAGGCGGCAACCAACTGGGGGCACTCTGTACCTCTCATTTCAAG 1475
 Qy 1867 GCACCTGAGCACCCTGACGAGAGTGGGGTGGCCCTGAGCTCAACGGCCATAACAG 1926
 Db 1476 GCACCTGAGCACCCTGACGAGAGTGGGGTGGCCCTGAGCTCAACGGCCATAACAG 1535
 Qy 1927 CTCTGACTCCACGTGAGGCCACTTTTGGGTGACCCCAAGTGTGTGTGTGTGTG 1986
 Db 1536 CTCTGACTCCACGTGAGGCCACTTTTGGGTGACCCCAAGTGTGTGTGTGTGTG 1595
 Qy 1987 AGGGTTGGTGAAGTGGCTTGAAGACCTCTGCGCAGGGGCTGAGGAGGAGTCAATTA 2046
 Db 1596 AGGGTTGGTGAAGTGGCTTGAAGACCTCTGCGCAGGGGCTGAGGAGGAGTCAATTA 1655
 Qy 2047 CTCCCAATTAAGTGGGCGCCCTCAAAAGA 2076
 Db 1656 CTCCCAATTAAGTGGGCGCCCTCAAAAGA 1685

ID ABX14013 standard; cDNA; 1716 BP.
 XX
 AC ABX14013;
 XX
 DT 20-FEB-2003 (first entry)
 XX
 DE Human cytokine receptor-like factor 1 (CLF-1 or CLRF-1) cDNA.
 XX
 KW Human; gene; ss; gene expression; bone formation; cartilage formation;
 KW embryonic development; cytokine receptor-like factor 1; CLF-1; CLRF-1;
 KW mesenchymal cell differentiation; matrix metalloproteinase 23; MMP23;
 KW bone development; antagonist; agonist; cadherin; CD68; cytokine;
 KW diagnosis; osteodystrophy; osteopetrosis; osteoblastoma;
 KW osteopetrosis; osteogenesis imperfecta; osteoporosis; osteopenia;
 KW osteoma; osteoblastoma; periodontal disease; hyperparathyroidism;
 KW hypercalcaemia of malignancy; Paget's disease; osteolytic lesion;
 KW bone metastasis; bone loss; immobilisation; sex hormone deficiency;
 KW inflammatory disease; rheumatoid arthritis; osteoarthritis;
 KW bone fracture.
 XX
 OS Homo sapiens.
 XX
 FH Key Location/Qualifiers
 FH CDS 119..1387
 FT /*tag= a
 FT /product= "CLF-1"
 FT
 XX W0200285285-A2.
 PN
 XX
 PD 31-OCT-2002.
 XX
 PF 18-APR-2002; 2002M0-US012149.
 XX
 PR 18-APR-2001; 2001US-0284786P.
 XX
 PA (AMHP) WYETH.
 XX
 PI Clancy B, Pittman DM;
 XX WPI; 2003-103384/09.
 DR P-PSDB; ABG72776.
 XX
 DR
 XX
 PT Determining the difference between levels of expression of a number of
 PT genes; useful for diagnosing and treating disorders associated with bone
 PT or cartilage formation or resorption such as osteoporosis and bone
 PT fractures.
 XX
 PS Disclosure; Page 190-192; 197pp; English.
 XX
 CC The invention discloses a method for determining the difference between
 CC the levels of expression of a number of, at least 500 genes, during bone
 CC or cartilage formation. The method comprises determining levels of RNA
 CC from the genes to obtain levels of expression and comparing these to a
 CC set of reference levels for each of the genes. Bone formation is an
 CC essential process in embryonic development and plays a critical role in
 CC many diseases and conditions in humans. Two genes found to be regulated
 CC during bone and cartilage formation are the cytokine receptor-like factor
 CC 1 (CLF-1 or CLRF-1), which is specifically regulated during mesenchymal
 CC cell differentiation, and matrix metalloproteinase 23 (MMP23), which is
 CC specifically regulated during bone development. Also disclosed is a
 CC computer program for analysing levels of expression of a number of genes,
 CC comprising a number of antagonists or agonists of the genes,
 CC and methods for determining whether a subject has, or is likely to
 CC develop, a disease related to bone or cartilage resorption or formation,
 CC for determining the effectiveness of a treatment intended to stimulate
 CC bone or cartilage formation or resorption, for identifying a compound for
 CC treating, modulating or stimulating a disease related to bone or
 CC cartilage formation possibly acting as a cadherin or CD68 agonist or a
 CC cytokine antagonist. The methods and compositions are useful for
 CC diagnosing and treating disorders associated with bone or cartilage
 CC formation or resorption such as osteodystrophy, osteopetrosis,
 CC osteoblastoma, osteopetrosis, osteogenesis imperfecta, osteoporosis,
 CC osteopenia, osteoma and osteoblastoma, periodontal disease,

QY 967 GCCGCTGAGAGCCAGGGGGCCACGAGGAGACCTTCTTCAACCACTACTCCCTCAAGT 1026
DB 576 GCCGCTGAGAGCCAGGGGGCCACGAGGAGACCTTCTTCAACCACTACTCCCTCAAGT 635
QY 1027 ACAAGCTTAGTGGTATGACCAAGACAATGTAGAGATACCAACAGTGGGGCCC 1086
DB 636 ACAAGCTTAGTGGTATGACCAAGACAATGTAGAGATACCAACAGTGGGGCCC 695
QY 1087 ACTCTGACCAATCTCCCAAGAGACTGCTCTTTAGCCCTATGAGATCTGGTGGAGG 1146
DB 696 ACTCTGACCAATCTCCCAAGAGACTGCTCTTTAGCCCTATGAGATCTGGTGGAGG 755
QY 1147 CCACCAACCCGCTGGGCTTGCCTCCGATGACTCAGCGTGGAGATCTGGATGG 1206
DB 756 CCACCAACCCGCTGGGCTTGCCTCCGATGACTCAGCGTGGAGATCTGGATGG 815
QY 1207 TGAACCAAGACCCCGCCGACGCTGACGTCGACCGCTGCGGGGCTGAGAGACCAGC 1266
DB 816 TGAACCAAGACCCCGCCGACGCTGACGTCGACCGCTGCGGGGCTGAGAGACCAGC 875
QY 1267 TGAAGCTGCGCTGGGCTTGCCTCCGATGACTCAGCGTGGAGATCTGGATGG 1326
DB 876 TGAAGCTGCGCTGGGCTTGCCTCCGATGACTCAGCGTGGAGATCTGGATGG 935
QY 1327 AGATCGGCTACCGAGTGGAGAGACAGTGTGAGTGGAGAGTGGAGAGTGGAGAAC 1386
DB 936 AGATCGGCTACCGAGTGGAGAGACAGTGTGAGTGGAGAGTGGAGAGTGGAGAAC 995
QY 1387 AGACCTCTGCTCGCTGCTGCTGCTGAAACCCGACCGTGTACTTCTGTCAGATGGCT 1446
DB 996 AGACCTCTGCTCGCTGCTGCTGCTGAAACCCGACCGTGTACTTCTGTCAGATGGCT 1055
QY 1447 GCAACCCCTTTGGCATTTATGCTTCAAGAAAGCCGGATCTGGAGTGAAGTGAAC 1506
DB 1056 GCAACCCCTTTGGCATTTATGCTTCAAGAAAGCCGGATCTGGAGTGAAGTGAAC 1115
QY 1507 CCAAGCGCTCTCACTCCCGCAGTGAAGGCGCGGGCCGGGGGGGGGGGGGGGGGCAAC 1566
DB 1116 CCAAGCGCTCTCACTCCCGCAGTGAAGGCGCGGGCCGGGGGGGGGGGGGGGGGCAAC 1175
QY 1567 CGCGGGCGGAGAGCCGAGTCTGGGAGCGGGTGCAGCGAGTCAACAGTCTTCTGGGCT 1626
DB 1176 CGCGGGCGGAGAGCCGAGTCTGGGAGCGGGTGCAGCGAGTCAACAGTCTTCTGGGCT 1235
QY 1627 GGGCTCAAGAAAGCAGCGTACTGCTCAACTCACTTCCGCTCTTACGACCAAGTGGAG 1686
DB 1236 GGGCTCAAGAAAGCAGCGTACTGCTCAACTCACTTCCGCTCTTACGACCAAGTGGAG 1295
QY 1687 CTTGATGACGAAGTGGCAACAAGCCCGCAACGAGGAGATCTTCCCTCGGAGCA 1746
DB 1296 CTTGATGACGAAGTGGCAACAAGCCCGCAACGAGGAGATCTTCCCTCGGAGCA 1355
QY 1747 GACGGGGCAGGAGAGTCTTGCAGATAGTGTAGGGGCTCAGGCGCACTTCCCTG 1806
DB 1356 GACGGGGCAGGAGAGTCTTGCAGATAGTGTAGGGGCTCAGGCGCACTTCCCTG 1415
QY 1807 CCAAGTGGAGAGCAGAGGCGGAACTGGGGGCACTTCTGTACCTTCACTTCAAG 1866
DB 1416 CCAAGTGGAGAGCAGAGGCGGAACTGGGGGCACTTCTGTACCTTCACTTCAAG 1475
QY 1867 GCAACCTGAGGACCTTCAAGAGAGTGGGGTGGCCCTTGAATCTTCAACGCGCATTAAG 1926
DB 1476 GCAACCTGAGGACCTTCAAGAGAGTGGGGTGGCCCTTGAATCTTCAACGCGCATTAAG 1535
QY 1927 CTCTGACTCCACGTAGGAGCACTTTGGGTGACCCCAAGTGGTGTGTGTGTGTGTGTG 1986
DB 1536 CTCTGACTCCACGTAGGAGCACTTTGGGTGACCCCAAGTGGTGTGTGTGTGTGTGTG 1595
QY 1987 AGGGT 2046
DB 1596 AGGGT 1655

QY 2047 CTCCTTACTTACTTGGGCCCCCTCCAAAGA 2076
DB 1656 CTCCTTACTTACTTGGGCCCCCTCCAAAGA 1685
RESULT 9
ID ADH27451
ADH27451 standard; cDNA; 1789 BP.
AC ADH27451;
XX 11-MAR-2004 (first entry)
XX
DE Human cDNA encoding secreted/transmembrane PRO polypeptide #6.
KW ser; gene; human; sports-related joint problem;
KW articular cartilage defect; osteoarthritis; rheumatoid arthritis; cancer;
KW PRO; secreted protein; transmembrane protein.
XX
OS Homo sapiens.
XX
PN US2003083479-A1.
PD 01-MAY-2003.
XX
PF 31-AUG-2001; 2001US-00944852.
XX 03-DEC-1997; 97US-0067411P.
PR 11-DEC-1997; 97US-0069278P.
PR 11-DEC-1997; 97US-0069334P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 16-DEC-1997; 97US-0069694P.
PR 16-DEC-1997; 97US-0069696P.
PR 16-DEC-1997; 97US-0069702P.
PR 17-DEC-1997; 97US-0069870P.
PR 17-DEC-1997; 97US-0069873P.
PR 18-DEC-1997; 97US-0068017P.
PR 05-JAN-1998; 98US-0070440P.
PR 09-FEB-1998; 98US-0074086P.
PR 25-FEB-1998; 98US-0075945P.
PR 16-SEP-1998; 98MO-US019330.
PR 01-DEC-1998; 98MO-US025108.
PR 16-DEC-1998; 98US-0112850P.
PR 22-DEC-1998; 98US-0113296P.
PR 02-JUN-1999; 99US-0146222P.
PR 28-JUL-1999; 99MO-US021090.
PR 15-SEP-1999; 99MO-US028313.
PR 30-NOV-1999; 99MO-US028313.
PR 30-NOV-1999; 99MO-US028409.
PR 01-DEC-1999; 99MO-US028301.
PR 16-DEC-1999; 99MO-US030095.
PR 11-FEB-2000; 2000MO-US003565.
PR 22-FEB-2000; 2000MO-US004414.
PR 02-MAR-2000; 2000MO-US005841.
PR 30-MAR-2000; 2000MO-US008439.
PR 22-MAY-2000; 2000MO-US014042.
PR 28-JUL-2000; 2000MO-US020710.
PR 01-DEC-2000; 2000MO-US032678.
PR 28-FEB-2001; 2001MO-US006520.
PR 25-MAY-2001; 2001US-00866028.
XX
XX (GENTECH) GENENTECH INC.
XX
XX Baker KP, Botstein D, Baton DL, Ferrara N, Filvaroff E,
PI Gerlitsen ME, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL,
PI Hillan KJ, Kijaviri ID, Napier MA, Roy MA, Tumas D, Wood WI;
XX WPI; 2003-801132/75.
XX P-FSDB; ADH27452.
XX
XX New isolated nucleic acid encoding a secreted and transmembrane (PRO)

Db	1176	CGCGGGGGCGAGAGGCCGAGCTTCGGGGCCGGTGCGGGCGGAGCTCAAGCAGTTTCTGGGCT	12335
OY	1627	GGCTTCAGAGGCA CGCGTACTGCTCTCAACCTTCAGCTTC CGCCTCTACGACAGTGGCGAG	1688
Db	1236	GGCTCAAGAACACCGCGTACTGCTCAACCTCAGCTTC CGCCTTACGACAGTGGCGAG	12395
OY	1687	CCTGGATCCAGAAAGTCGACAAAGACCCGCAACAGAGAGAGATCTCTGCCCTTCGGGCA	1746
Db	1296	CCTGGATCCAGAAAGTCGACAAAGACCCGCAACAGAGAGAGATCTCTGCCCTTCGGGCA	13555
OY	1747	GACGGGGGACGGCGAGAGGTCTCGTCCAGATTAAGCTGTAGGGGCTCAGGCCAACCTCCCTG	1808
Db	1356	GACGGGGGACGGCGAGAGGTCTCGTCCAGATTAAGCTGTAGGGGCTCAGGCCAACCTCCCTG	1415
OY	1807	CGACGTGGAGACGCAAGAGCCGGAACCCAACTGGGGCCA CTTCTGTACCTTCATCTTCAGG	1866
Db	1416	CCACGTGGAGACGCAAGAGCCGGAACCCAACTGGGGCCA CTTCTGTACCTTCATCTTCAGG	14757
OY	1867	GCACTGAGGCCACCTTCAGCAAGGAGCTGGGGGGCCCTTGAGCTCCAAAGCCCAATTAAG	1928
Db	1476	GCACTGAGGCCACCTTCAGCAAGGAGCTGGGGGGCCCTTGAGCTCCAAAGCCCAATTAAG	1535
OY	1927	CTCTGACTCCACAGTGAAGGCCACTTTTGGGTGACCCCAAGTGGGTGTGTGTGTGTGTG	1986
Db	1536	CTCTGACTCCACAGTGAAGGCCACTTTTGGGTGACCCCAAGTGGGTGTGTGTGTGTGTG	15595
OY	1987	AGGGTGGTTGAGTTTGCTTAAGACCCCTTGCCAGAGGCTGGGGGTGAGAAAGGGAGTCAATTA	2046
Db	1596	AGGGTGGTTGAGTTTGCTTAAGACCCCTTGCCAGAGGCTGGGGGTGAGAAAGGGAGTCAATTA	16555
OY	2047	CTCCCCATTA CTTAGGGGCCCTCCCAAAAGA 2076	
Db	1656	CTCCCCATTA CTTAGGGGCCCTCCCAAAAGA 1685	

RESULT 12	ID	ABX96790 standard; cDNA; 1790 BP.
ABX96790	AC	ABX96790;
XX	DT	15-MAY-2003, (first entry)
XX	DE	Human cDNA encoding secreted/transmembrane protein PRO327.
XX	KW	Human; ss; gene; PRO; secreted protein; transmembrane protein;
KW	KW	Cornelia de Lange syndrome; gene therapy; immune disorder;
KW	KW	inflammatory disease; organ failure; atherosclerosis; cardiac injury;
KW	KW	fertility; birth defect; premature aging; cardiac injury; AIDS; cancer;
XX	XX	diabetic complication.
OS	XX	Homo sapiens.
XX	XX	US2002173463-A1.
XX	XX	21-NOV-2002.
XX	XX	31-AUG-2001; 2001US-00944944.
XX	XX	03-DEC-1997; 97US-0067411P.
XX	XX	11-DEC-1997; 97US-0069278P.
XX	XX	11-DEC-1997; 97US-0069334P.
XX	XX	11-DEC-1997; 97US-0069335P.
XX	XX	12-DEC-1997; 97US-0069425P.
XX	XX	16-DEC-1997; 97US-0069594P.
XX	XX	16-DEC-1997; 97US-0069596P.
XX	XX	16-DEC-1997; 97US-0069702P.
XX	XX	17-DEC-1997; 97US-0069870P.
XX	XX	17-DEC-1997; 97US-0069873P.
XX	XX	18-DEC-1997; 97US-0068017P.
XX	XX	05-JAN-1998; 98US-0070440P.
XX	XX	09-FEB-1998; 98US-0074086P.

PR	09-FEB-1998;	98US-0074092P.
PR	25-FEB-1998;	98US-0075945F.
PR	16-SEP-1998;	98WO-US019330.
PR	01-DEC-1998;	98WO-US025108.
PR	16-DEC-1998;	98US-0112850P.
PR	22-DEC-1998;	98US-0113296P.
PR	02-JUN-1999;	99WC-US01225Z.
PR	28-JUL-1999;	99US-0146222P.
PR	15-SEP-1999;	99WO-US021090.
PR	30-NOV-1999;	99WO-US028313.
PR	01-DEC-1999;	99WO-US028409.
PR	16-DEC-1999;	99WC-US028301.
PR	11-FEB-2000;	2000WO-US00356S.
PR	22-FEB-2000;	2000WO-US004414.
PR	02-MAR-2000;	2000WO-US005843.
PR	30-MAR-2000;	2000WO-US008439.
PR	22-MAY-2000;	2000WO-US01404Z.
PR	28-JUL-2000;	2000WO-US020710.
PR	01-DEC-2000;	2000WO-US032678.
PR	28-FEB-2001;	2001WO-US006520.
PR	25-MAY-2001;	2001US-00866028.
XX	(GETH) GENENTECH INC.	
PA	Baker KP, Borestein D, Eaton DL, Ferrara N, Filvaroff E;	
P1	Gerritsen ME, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL;	
P1	Hillam KJ, Kljavin IJ, Napier MA, Roy MA, Tumas D, Wood WJ;	
XX	WPI: 2003-311003/30.	
DR	P-PSDB; ABU64921.	
XX	New transmembrane polypeptides and polynucleotides useful for chromosome	
PT	identification, tissue typing, gene therapy, in chromosome and gene	
PT	mapping, or as molecular weight markers.	
XX	Claim 2; Fig 13; 172pp; English.	
PS	The invention relates to an isolated nucleic acid encoding a secreted/ transmembrane polypeptide (designated as PRO proteins). 15 PRO polypeptides and their encoding polynucleotides are disclosed. Also included are a vector comprising the PRO nucleic acid, a host cell comprising the vector, a process for producing a PRO polypeptide (by culturing the host cell under conditions for the expression of the PRO polypeptide, and recovering the PRO polypeptide from the cell culture), an isolated polypeptide having at least 80% amino acid sequence identity to the PRO polypeptides, a chimeric molecule comprising PRO fused to a heterologous amino acid sequence and an antibody which specifically binds to PRO. The PRO nucleotide sequences are useful as hybridisation probes, in chromosome and gene mapping, in generating sense and antisense RNA or DNA, in generating transgenic or knock-out animals which can be used in the development and screening of therapeutically useful reagents, and in gene therapy. The polypeptides may be used as molecular weight markers for protein electrophoresis purposes. The PRO polypeptides and nucleic acids may also be used for chromosome identification, and tissue typing. PRO241 (identified as Chordin) is a candidate gene for Cornelia de Lange syndrome. Other PRO proteins are variously implicated in immune disorders, inflammatory disease, organ failure, atherosclerosis, cardiac injury, infertility, birth defects, premature aging, cardiac injury, AIDS, cancer and diabetic complications. The present sequence encodes a PRO protein	
CC	Sequence 1790 BP; 359 A; 624 C; 529 G; 278 T; 0 U; 0 Other;	
SQ		
OY	Query Match	75.6%; Score 1572.4; DB 8; Length 1790;
	Best Local Similarity	99.7%; Pied. No. 0;
Dn	Matches 1586; Conservative	0; Mismatches 1; Indels 3; Gaps 1
490	GGCGCCCCGAGCAGCGCGGAGCCCAATGCCGCGCGGCGCGCGGAGCGCCGCACCAATCCG	549
96	GGCGCCCCGAGCAGCGCGGAGCCCAATGCCGCGCGGCGCGCGGAGCGCCGCACCAATCCG	155
550	CGGAGCGAGCGCGCGCGCTTTGTGTCGCC---CTGCTGCTGCTTGTGCGTCTCGGAGCGCGCG	606

Db 876 TGAAGTCGCGTGGGTTCGCGACCCGCGCTCAAGATTCTCTTTCMAAGCAATAATACC 935
 Qy 1327 AGATCCGCTACCGAGTGAAGGACAGTGTGACTGGAAGTGTGAGACGATGTGAGCAACC 1386
 Db 936 AGATCCGCTACCGAGTGAAGGACAGTGTGACTGGAAGTGTGAGACGATGTGAGCAACC 995
 Qy 1387 AGACCTTCCTGCGCGCTGCGCGCTGAAACCCGCGCACCGTGTACTTGTGTGCAAGTGTGCGCT 1446
 Db 996 AGACCTTCCTGCGCGCTGCGCGCTGAAACCCGCGCACCGTGTACTTGTGTGCAAGTGTGCGCT 1055
 Qy 1447 GCAACCCCTTTTGGATCTTATGTGCTTCAAGAAAGCCGCGGATTTGTGAGTGTGAGCAACC 1506
 Db 1056 GCAACCCCTTTTGGATCTTATGTGCTTCAAGAAAGCCGCGGATTTGTGAGTGTGAGCAACC 1115
 Qy 1507 CCAAGACCGCTCCACTCCCGCGAGTGTGAGCGCCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG 1566
 Db 1116 CCAAGACCGCTCCACTCCCGCGAGTGTGAGCGCCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG 1175
 Qy 1567 CCGCGCGCGCGAGAGCCGAGCTCGGCT 1626
 Db 1176 CCGCGCGCGCGAGAGCCGAGCTCGGCT 1235
 Qy 1627 GCGCTCAAGAAAGCAGCGCTATGCTCTCAAGCTTCCGCTCTTACGACCAAGTGTGCGAG 1686
 Db 1236 GCGCTCAAGAAAGCAGCGCTATGCTCTCAAGCTTCCGCTCTTACGACCAAGTGTGCGAG 1295
 Qy 1687 CCGTATGACGAAAGTGTGCAAGACCCGCGCAACGAGGAGGATCTGCGCTCGCGGCA 1746
 Db 1296 CCGTATGACGAAAGTGTGCAAGACCCGCGCAACGAGGAGGATCTGCGCTCGCGGCA 1355
 Qy 1747 GACGCGGCGACGCGGAGAGTCTTCCAGATTAAGCTGTAGGGGCTCAGGCGCAACCTCCCTG 1806
 Db 1356 GACGCGGCGACGCGGAGAGTCTTCCAGATTAAGCTGTAGGGGCTCAGGCGCAACCTCCCTG 1415
 Qy 1807 CCAAGTGAAGACCGAGAGCCGCAACCCAACTGCGGCTCACTCTGTAACCTCACTTCAAG 1866
 Db 1416 CCAAGTGAAGACCGAGAGCCGCAACCCAACTGCGGCTCACTCTGTAACCTCACTTCAAG 1475
 Qy 1867 GCACTGAGGCGACCGCTGAGAGGAGCTGGGGTGGCGCTGAGCTCCCAACCGGCAATTAACAG 1926
 Db 1476 GCACTGAGGCGACCGCTGAGAGGAGCTGGGGTGGCGCTGAGCTCCCAACCGGCAATTAACAG 1535
 Qy 1927 CTCTGACTCCAGGTGAGGCGACCTTTGGGTGACCCCAATGGGTGTGTGTGTGTGTG 1986
 Db 1536 CTCTGACTCCAGGTGAGGCGACCTTTGGGTGACCCCAATGGGTGTGTGTGTGTGTG 1595
 Qy 1987 AGCGTTGGTTGAGTGTGCTTAAGAACCCCTGTCAGGGCTGGGGGTGAGAAAGGAGTCAATTA 2046
 Db 1596 AGCGTTGGTTGAGTGTGCTTAAGAACCCCTGTCAGGGCTGGGGGTGAGAAAGGAGTCAATTA 1655
 Qy 2047 CTCCCAATTAAGGAGGCGCGCTCCAAAGA 2076
 Db 1656 CTCCCAATTAAGGAGGCGCGCTCCAAAGA 1685
 RESULT 15
 ABX75909
 ID ABX75909 standard; cDNA; 1790 BP.
 AC ABX75909;
 XX 31-MAR-2003 (first entry)
 DT
 XX
 DE Human cDNA encoding secreted/transmembrane protein, PRO327.
 XX
 XX Human; ss; gene; PRO; antiinflammatory; antiarteriosclerotic; cardiac;
 KW gynecological; anti-HIV; cytostatic; antidiabetic; inflammatory disease;
 KW organ failure; atherosclerosis; cardiac injury; infertility;
 KW birth defect; premature aging; AIDS; acquired immunodeficiency syndrome;
 KW cancer; diabetic complication.
 XX
 XX Homo sapiens.
 OS
 XX

PN US2002132981-A1.
 XX
 PD 19-SEP-2002.
 XX
 PF 30-AUG-2001; 2001US-00944396.
 XX
 PR 03-DEC-1997; 97US-0067411P.
 PR 11-DEC-1997; 97US-0069278P.
 PR 11-DEC-1997; 97US-0069334P.
 PR 11-DEC-1997; 97US-0069335P.
 PR 12-DEC-1997; 97US-0069425P.
 PR 16-DEC-1997; 97US-0069694P.
 PR 16-DEC-1997; 97US-0069696P.
 PR 16-DEC-1997; 97US-0069702P.
 PR 17-DEC-1997; 97US-0069870P.
 PR 17-DEC-1997; 97US-0069873P.
 PR 18-DEC-1997; 97US-0068017P.
 PR 05-JAN-1998; 98US-0070440P.
 PR 09-FEB-1998; 98US-0074086P.
 PR 09-FEB-1998; 98US-0074092P.
 PR 25-FEB-1998; 98US-0075945P.
 PR 16-SEP-1998; 98WO-US019330.
 PR 01-DEC-1998; 98WO-US025108.
 PR 16-DEC-1998; 98US-0112850P.
 PR 22-DEC-1998; 98US-0113296P.
 PR 02-JUN-1999; 99WO-US012252.
 PR 28-JUL-1999; 99US-0146222P.
 PR 15-SEP-1999; 99WO-US021090.
 PR 30-NOV-1999; 99WO-US028313.
 PR 30-NOV-1999; 99WO-US028409.
 PR 01-DEC-1999; 99WO-US028301.
 PR 16-DEC-1999; 99WO-US030095.
 PR 11-FEB-2000; 2000WO-US003565.
 PR 22-FEB-2000; 2000WO-US004414.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 28-JUL-2000; 2000WO-US020710.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 25-MAY-2001; 2001US-00866028.
 XX
 PA (GENTH) GENENTECH INC.
 XX
 PI Baker KP, Botstein D, Eaton DL, Ferrara N, Flvaroff E,
 PI Gerltsen ME, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL;
 PI Hillan KJ, Kijavini JV, Napier MA, Roy MA, Tumas D, Wood WI;
 XX WPI; 2003-147446/14.
 DR P-PSDB; ABUS6306.
 XX
 PT New isolated PRO polypeptide and encoding nucleic acids, useful for the
 PT diagnosis and treatment of disorders such as inflammatory disease,
 PT atherosclerosis, cardiac injury, infertility, AIDS, cancer and diabetic
 PT complications.
 XX
 PS Claim 2; Fig 13; 171pp; English.
 XX
 CC The invention relates to an isolated PRO polypeptide having at least 80%
 CC amino acid sequence identity to and scoring at least 80% positives when
 CC compared to any of 15 fully defined sequences of 235-954 amino acids,
 CC given in the specification. Also included are: (1) an isolated PRO
 CC nucleic acid having at least 80% nucleic acid sequence identity to a
 CC nucleotide sequence that encodes PRO or its extracellular domain, and
 CC comprising any of 15 fully defined nucleotide sequences of 957-3441 bp,
 CC given in the specification and deposited under ATCC accession number
 CC 209526, 209508, 209524, 209528, 209530, 209532, 209533, 209534, 209531,
 CC 209529, 209527, 209570, 209618, 209621 and 209619; (2) a vector
 CC comprising the PRO nucleic acid; (3) a host cell comprising the vector;
 CC (4) producing PRO polypeptides, comprising culturing the cell for
 CC expression of the PRO polypeptide and recovering the PRO polypeptide from
 CC the cell culture; (5) a chimeric molecule comprising PRO fused to a
 CC heterologous amino acid sequence; and (6) an anti-PRO antibody. The

Sequence ID	Sequence	Sequence ID	Sequence
1	US-09-037-657-43	1	Sequence 1
2	Patent No. US20020045741A1	2	Sequence 2
3	GENERAL INFORMATION:	3	Sequence 3
4	APPLICANT: Hilton, Douglas J.	4	Sequence 4
5	APPLICANT: Nicola, Nicos A.	5	Sequence 5
6	APPLICANT: Farley, Allison	6	Sequence 6
7	APPLICANT: Wilson, Tracy	7	Sequence 7
8	APPLICANT: Zhang, Jian-Guo	8	Sequence 8
9	APPLICANT: Alexander, Warren	9	Sequence 9
10	APPLICANT: Rakar, Steven	10	Sequence 10
11	APPLICANT: Fabri, Louis	11	Sequence 11
12	APPLICANT: Kojima, Tetsuo	12	Sequence 12
13	APPLICANT: Maeda, Maatsugu	13	Sequence 13
14	APPLICANT: Kikuchi, Yasutomi	14	Sequence 14
15	APPLICANT: Naeh, Andrew	15	Sequence 15
16	TITLE OF INVENTION: A NOVEL HAEMPOIETTIN RECEPTOR AND GENETIC SEQUENCES	16	Sequence 16
17	FILE REFERENCE: DAVIES COLLISON SAME	17	Sequence 17
18	CURRENT APPLICATION NUMBER: US/09/037,657A	18	Sequence 18
19	CURRENT FILING DATE: 1998-03-10	19	Sequence 19
20	EARLIER APPLICATION NUMBER: 08/928,720	20	Sequence 20
21	NUMBER OF SEQ ID NOS: 54	21	Sequence 21
22	SOFTWARE: PatentIn Ver. 2.0	22	Sequence 22
23	SEQ ID NO 43	23	Sequence 23
24	LENGTH: 2079	24	Sequence 24
25	TYPE: DNA	25	Sequence 25
26	ORGANISM: Unknown	26	Sequence 26
27	FEATURE:	27	Sequence 27
28	NAME/KEY: CDS	28	Sequence 28
29	LOCATION: (513)..(1775)	29	Sequence 29
30	FEATURE:	30	Sequence 30
31		31	Sequence 31
32		32	Sequence 32
33		33	Sequence 33
34		34	Sequence 34
35		35	Sequence 35
36		36	Sequence 36
37		37	Sequence 37
38		38	Sequence 38
39		39	Sequence 39
40		40	Sequence 40
41		41	Sequence 41
42		42	Sequence 42
43		43	Sequence 43
44		44	Sequence 44
45		45	Sequence 45

OTHER INFORMATION: Description of Unknown Organism: Nucleotide Sequence of NR6
US-09-037-657-43

Query Match	100.0%;	Score 2079;	DB 9;	Length 2079;
Best Local Similarity	100.0%;	Pred. No. 0;		
Matches 2079;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;
QY 1	GGGGTATTTGTGTTTAAATCTATCTACAGAAAAGATGTGAACCGAAGCCCTTTTCCT	60		
DB 1	GGGGTATTTGTGTTTAAATCTATCTACAGAAAAGATGTGAACCGAAGCCCTTTTCCT	60		
QY 61	TTTTGAAGCTAGCTGACTCACTGTTCAAGAAAGAAACACTTTCAATTAATGCTGTTT	120		
DB 61	TTTTGAAGCTAGCTGACTCACTGTTCAAGAAAGAAACACTTTCAATTAATGCTGTTT	120		
QY 121	GACTGCAGTGTGAGGGATCCAAAGAAATGATCTCATCCCTTCCTTTCATCCCAACCTC	180		
DB 121	GACTGCAGTGTGAGGGATCCAAAGAAATGATCTCATCCCTTCCTTTCATCCCAACCTC	180		
QY 181	AGTGAAGCAAAATTTGATGTGACTGAGGGTGGCTTTGGAAGAGTCAATAGAAATTC	240		
DB 181	AGTGAAGCAAAATTTGATGTGACTGAGGGTGGCTTTGGAAGAGTCAATAGAAATTC	240		
QY 241	TGCTTAAGCCATAGCCGATGAGAAAGATGTATCTATGCTGCTGATTTTCTGTGCCCC	300		
DB 241	TGCTTAAGCCATAGCCGATGAGAAAGATGTATCTATGCTGCTGATTTTCTGTGCCCC	300		
QY 301	CTTGAAGGAAAGTTGTCAATGAGAGAGTGAATTTCTATAGCAACAGCAAGCTAATA	360		
DB 301	CTTGAAGGAAAGTTGTCAATGAGAGAGTGAATTTCTATAGCAACAGCAAGCTAATA	360		
QY 361	GGTTACACAGATTAATCTCTGACTTGGCTTACAGAACCTGCTATTTAGCCTTAGGGCA	420		
DB 361	GGTTACACAGATTAATCTCTGACTTGGCTTACAGAACCTGCTATTTAGCCTTAGGGCA	420		
QY 421	AGGTTATGCTCAAGGGGGCCAACTGTGGGTTAGATTGAATTTAGAGCTTTCGTCT	480		
DB 421	AGGTTATGCTCAAGGGGGCCAACTGTGGGTTAGATTGAATTTAGAGCTTTCGTCT	480		
QY 481	CATATTTCAAGCCCCCGGAGCGCCCATGCCCCCGGCGCCCGGCGCGCCCGCGCG	540		
DB 481	CATATTTCAAGCCCCCGGAGCGCCCATGCCCCCGGCGCCCGGCGCGCCCGCGCG	540		
QY 541	CCCAATCCGCGGCGCGCGCGCGCGCTGGCTGCTGCTGCTGCTGCTGCTGCTGCTG	600		
DB 541	CCCAATCCGCGGCGCGCGCGCGCGCTGGCTGCTGCTGCTGCTGCTGCTGCTGCTG	600		
QY 601	CGCGCGAGCCGAGATGAGAGCCCAACAGCTGTGATCACTCCAGATCCCAAGCTTC	660		
DB 601	CGCGCGAGCCGAGATGAGAGCCCAACAGCTGTGATCACTCCAGATCCCAAGCTTC	660		
QY 661	TCAATGAGCTCTCTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG	720		
DB 661	TCAATGAGCTCTCTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG	720		
QY 721	CCGAGGAGCTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG	780		
DB 721	CCGAGGAGCTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG	780		
QY 781	TCAAAGCTCTCACTTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG	840		
DB 781	TCAAAGCTCTCACTTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG	840		
QY 841	GGGACAACCTCTGTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG	900		
DB 841	GGGACAACCTCTGTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG	900		
QY 901	TTGGCTGCCCCAGAGAAACCGCTCAATCACTGCTGCTGCTGCTGCTGCTGCTGCTG	960		
DB 901	TTGGCTGCCCCAGAGAAACCGCTCAATCACTGCTGCTGCTGCTGCTGCTGCTGCTG	960		
QY 961	TGACTGCGCTGAGCGCAGGGGCCACAGGGAGACTTCTCTCAACCACTACTCCC	1020		

DB 961	TGACTGCGCTGAGCGCAGGGGCCACAGGGAGACTTCTCTCAACCACTACTCCC	1020		
QY 1021	TCAAGTACAACTTGTAGTGTGTATGTGCCAGAGCAACATGTGAGAGTACCAACAGTGG	1080		
DB 1021	TCAAGTACAACTTGTAGTGTGTATGTGCCAGAGCAACATGTGAGAGTACCAACAGTGG	1080		
QY 1081	GGCCCCACTCTGACCATCCCCAAGAGACTGAGCTCTCTTTACGGCCCTATGAGATCTGGG	1140		
DB 1081	GGCCCCACTCTGACCATCCCCAAGAGACTGAGCTCTCTTTACGGCCCTATGAGATCTGGG	1140		
QY 1141	TGAGGGCAACCAACCGCTGTGGCTGTGCCGCTCCGATGTACTCAAGCTGATATCTTGG	1200		
DB 1141	TGAGGGCAACCAACCGCTGTGGCTGTGCCGCTCCGATGTACTCAAGCTGATATCTTGG	1200		
QY 1201	ATGTGTGACCAAGAACCCCGCCGACGTGCAAGTGAAGCCGCTGCGGGGCTGAGAG	1260		
DB 1201	ATGTGTGACCAAGAACCCCGCCGACGTGCAAGTGAAGCCGCTGCGGGGCTGAGAG	1260		
QY 1261	ACGAGTGAAGGTGGGCTGGGCTGTGGCCACCGGCTCCAGGATTTCTTTCAAGGCA	1320		
DB 1261	ACGAGTGAAGGTGGGCTGGGCTGTGGCCACCGGCTCCAGGATTTCTTTCAAGGCA	1320		
QY 1321	AATACCAATCCGCTTACCCGATGAGAGCAAGTGTGAATGGAAGGTGTGAGCAATGTGA	1380		
DB 1321	AATACCAATCCGCTTACCCGATGAGAGCAAGTGTGAATGGAAGGTGTGAGCAATGTGA	1380		
QY 1381	GCAACGAACTCTCTGCGCTGTGGCGGCTGTGAACCCGCGCACCTGTATCTTGTGCAAG	1440		
DB 1381	GCAACGAACTCTCTGCGCTGTGGCGGCTGTGAACCCGCGCACCTGTATCTTGTGCAAG	1440		
QY 1441	TGCGCTGCAACCCCTTTGGCATCTATGTGCTCAAGAAAGCCGAGATCTGAGTGTGGA	1500		
DB 1441	TGCGCTGCAACCCCTTTGGCATCTATGTGCTCAAGAAAGCCGAGATCTGAGTGTGGA	1500		
QY 1501	GCCAACCACCAAGCCGCTTCACTCCCGAGTGAAGCCCGGCGCCCGGCGGCGGCGCT	1560		
DB 1501	GCCAACCACCAAGCCGCTTCACTCCCGAGTGAAGCCCGGCGCCCGGCGGCGGCGCT	1560		
QY 1561	GGGAAACCGCGGGGCGGAGAGCCGAGCTGCGGGGCGGCTGCGGCGGCAAGCTTCC	1620		
DB 1561	GGGAAACCGCGGGGCGGAGAGCCGAGCTGCGGGGCGGCTGCGGCGGCAAGCTTCC	1620		
QY 1621	TGGGCTGAGCTCAAGAAAGCAAGGCTACTGCTCAACCTGAGCTTCCGCTCTTCAAGCACT	1680		
DB 1621	TGGGCTGAGCTCAAGAAAGCAAGGCTACTGCTCAACCTGAGCTTCCGCTCTTCAAGCACT	1680		
QY 1681	GGCGAGCTGTATGAGAAAGTGCACAAGACCCGCAACCGAGACGAGGGATCTGCGCT	1740		
DB 1681	GGCGAGCTGTATGAGAAAGTGCACAAGACCCGCAACCGAGACGAGGGATCTGCGCT	1740		
QY 1741	CGGGGAGAGCGGGGCAAGGAGAGTCTGTGCAATTAAGCTTGAAGGCTTCAAGGCTTCC	1800		
DB 1741	CGGGGAGAGCGGGGCAAGGAGAGTCTGTGCAATTAAGCTTGAAGGCTTCAAGGCTTCC	1800		
QY 1801	TCCCTGCAACGTGAGAGAGCAAGAGCCGAAACCAACTGAGGCGCACTTGTATACCTGAC	1860		
DB 1801	TCCCTGCAACGTGAGAGAGCAAGAGCCGAAACCAACTGAGGCGCACTTGTATACCTGAC	1860		
QY 1861	TTCAAGGGCACTTGAAGCAACCTTCAAGAGAGTGTGGGTGTGAGCTTCCAAAGGCA	1920		
DB 1861	TTCAAGGGCACTTGAAGCAACCTTCAAGAGAGTGTGGGTGTGAGCTTCCAAAGGCA	1920		
QY 1921	TAAACAGCTCTGACTCCACGTGAGGCGCACTTTTGGGTGCAACCCGAGGTGTGTGTG	1980		
DB 1921	TAAACAGCTCTGACTCCACGTGAGGCGCACTTTTGGGTGCAACCCGAGGTGTGTGTG	1980		
QY 1981	TGTGTGAGGTTGTGTTGATTGCTTGAAGACCTTGCAGGGGTGTGGGAGGAGGAG	2040		
DB 1981	TGTGTGAGGTTGTGTTGATTGCTTGAAGACCTTGCAGGGGTGTGGGAGGAGGAG	2040		
QY 2041	TCATTACTCCCATTAACCTAGGGCCCTTCAAAAGATCC	2079		
DB 2041	TCATTACTCCCATTAACCTAGGGCCCTTCAAAAGATCC	2079		

```

RESULT 2
US-10-125-691-1
: Sequence 1, Application US/10125691
: Publication NO. US20030087259A1
: GENERAL INFORMATION:
: APPLICANT: CLANCY, BRIAN M.
: APPLICANT: PITTMAN, DEBRA M.
: TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR REGULATING BONE AND
: TITLE OF INVENTION: CARTILAGE FORMATION
: FILE REFERENCE: G1A-002.01
: CURRENT APPLICATION NUMBER: US/10/125,691
: CURRENT FILING DATE: 2002-04-18
: PRIOR APPLICATION NUMBER: 60/284,786
: PRIOR FILING DATE: 2001-04-18
: NUMBER OF SEQ. ID NOS: 4
: SOFTWARE: PatentIn Ver. 2.1
: SEQ. ID NO. 1
: LENGTH: 1716
: TYPE: DNA
: ORGANISM: Homo sapiens
: FEATURE:
: NAME/KEY: CDS
: LOCATION: (119)..(1384)
: US-10-125-691-1

```

[illegible]

Db	696	ACTCTGCGCAATCCCAAGAGACTGGCTCTTTACGCCCTATGAGATCTGGGTGAGG	755
Oy	1147	CCACCAACCGCTGAGGCTTGTCCCGCTCCGATGTACTCAGGCTGAGATATCTTGGATGTGG	1206
Db	756	CCACCAACCGCTGGGCTTGTCCCGCTCCGATGTACTCAGGCTGAGATATCTTGGATGTGG	815
Oy	1207	TGACCAAGGAGACCCCGCGCCGAGCGTGCAGCGTGCAGCGCGCTGTCCGGGGGCTCGAGAGACGAC	1266
Db	816	TGACCAAGGAGACCCCGCGCCGAGCGTGCAGCGTGCAGCGCGCTGTCCGGGGGCTCGAGAGACGAC	875
Oy	1267	TGACCGTGCAGCTGGGGTGTGCACCCCGCGCTCAAGAGATTTCTCTTTCAAGCCAAATACC	1326
Db	876	TGACCGTGCAGCTGGGGTGTGCACCCCGCGCTCAAGAGATTTCTCTTTCAAGCCAAATACC	935
Oy	1327	AGATCCGCTACCGAGTGTGAGAGACAGTGTGACTGTGAAGTGTGTGTGAGACAGATGTAGCAACC	1386
Db	936	AGATCCGCTACCGAGTGTGAGAGACAGTGTGACTGTGAAGTGTGTGTGAGACAGATGTAGCAACC	995
Oy	1387	AGACCTCTGCGCGGCTGTGAGCGGCGCTTGAAACCCGCGCACCGTGATCTTGTCGAAATGCGCT	1446
Db	996	AGACCTCTGCGCGGCTGTGAGCGGCGCTTGAAACCCGCGCACCGTGATCTTGTCGAAATGCGCT	1055
Oy	1447	GCAACCCCTTTGGCATGTAGCTTCAAGAAAGCCGGGATCTGAGTGAATGAGCCACC	1506
Db	1056	GCAACCCCTTTGGCATGTAGCTTCAAGAAAGCCGGGATCTGAGTGAATGAGCCACC	1115
Oy	1507	CCAAAGCCGCTCCACTCTCCCGCAGTGAAGGCGCCCGGCGCCGGGGCGGGCGGCGTGGCAAC	1566
Db	1116	CCAAAGCCGCTCCACTCTCCCGCAGTGAAGGCGCCCGGCGCCGGGGCGGGCGGCGTGGCAAC	1175
Oy	1567	CGCGGGCGGAGAGACCGAGCTCGGGGCGCGGTGCAGCGCTCAACAGTCTCTGGGCT	1626
Db	1176	CGCGGGCGGAGAGACCGAGCTCGGGGCGCGGTGCAGCGCTCAACAGTCTCTGGGCT	1235
Oy	1627	GAGCTCAAGAAACACGCGTACTGTCTCAACCTCAGCTTCCGCTCTACGACCAAGTGGCGAG	1686
Db	1236	GAGCTCAAGAAACACGCGTACTGTCTCAACCTCAGCTTCCGCTCTACGACCAAGTGGCGAG	1295
Oy	1687	CTTGTGATGCAGAGTGTGCCACAAAGACCCGCAACCAAGACAGAGGGATCTCTGCGCTCGGGCA	1746
Db	1296	CTTGTGATGCAGAGTGTGCCACAAAGACCCGCAACCAAGACAGAGGGATCTCTGCGCTCGGGCA	1355
Oy	1747	GACGGGCGACGGCGAGAGGTCTGTCCAGATTAAGCTGTAGGGGCTCAGAGCCACTTCCCTG	1806
Db	1356	GACGGGCGACGGCGAGAGGTCTGTCCAGATTAAGCTGTAGGGGCTCAGAGCCACTTCCCTG	1415
Oy	1807	CCACGTGAGAGACGACAGAGGCGGAAACCCAAACTGGGGCAACTCTGTACCTCAGCTTCAAG	1866
Db	1416	CCACGTGAGAGACGACAGAGGCGGAAACCCAAACTGGGGCAACTCTGTACCTCAGCTTCAAG	1475
Oy	1867	GCACCTGAGGCACTCTCAGACGAGAGCTGGGGTGGCCCTGTAGCTTCAACGGCCATTAACAG	1926
Db	1476	GCACCTGAGGCACTCTCAGACGAGAGCTGGGGTGGCCCTGTAGCTTCAACGGCCATTAACAG	1535
Oy	1927	CTTGTGATCCCAAGTGAAGCCACTTTTGGGTGACCCCAAGTGGGTGTGTGTGTGTGTGTG	1986
Db	1536	CTTGTGATCCCAAGTGAAGCCACTTTTGGGTGACCCCAAGTGGGTGTGTGTGTGTGTGTG	1595
Oy	1987	AGGGTTGGTGTGATGTGCTTGAAGACCCCTGTCCAGGGCTGGGGGTGAGAAAGGGAGTCAATTA	2046
Db	1596	AGGGTTGGTGTGATGTGCTTGAAGACCCCTGTCCAGGGCTGGGGGTGAGAAAGGGAGTCAATTA	1655
Oy	2047	CTTCCCATTAACCTTGGGCGCCCTCCAAAAGA 2076	
Db	1656	CTTCCCATTAACCTTGGGCGCCCTCCAAAAGA 1665	

RESULT 3
US-10-172-118-1081
; Sequence 1081, Application US/10172118
; Publication No. US20030224374A1
; GENERAL INFORMATION:
; APPLICANT: Dai, Hongyue


```

1 PRIOR APPLICATION NUMBER: US 60/284,766
2
3 PRIOR FILING DATE: 2001-04-18
4
5 NUMBER OF SEQ ID NOS: 4
6
7 SOFTWARE: PatentIn version 3.1
8
9 SEQ ID NO 1
10
11 LENGTH: 1716
12
13 TYPE: DNA
14
15 ORGANISM: Homo sapiens
16
17 FEATURE:
18
19 NAME/KEY: CDS
20
21 LOCATION: (119)..(1387)
22
23 OTHER INFORMATION:
24
25 US-10-329-056-1

```

Query Match	75.6%	Score 1572.4;	DB 17;	Length 1716;
-------------	-------	---------------	--------	--------------

Matches 1586; Conservative 0; Mismatches 1; Indels 3; Gaps 1;

[illegible]

QY	1327	AGATCCGCTACCGAGTGTGAAGACAGTGTGACCTGGAAAGGTGGTGGAGAGATGTGACCAAC	1386
Db	936	AGATCCGCTACCGAGTGTGAAGACAGTGTGACCTGGAAAGGTGGTGGAGAGATGTGACCAAC	995
QY	1387	AGACCTCCTGCGCGCTTGGCGCGGCTGTAAACCCGAGCACCGTGTACTTCGTGTCAAGTGCGCT	1446
Db	996	AGACCTCCTGCGCGCTTGGCGCGGCTGTAAACCCGAGCACCGTGTACTTCGTGTCAAGTGCGCT	1055
QY	1447	GCAACCCCTTTGGGATTTATGGCTCCAAAGAAAGCCGGGATCTGTGAGTGAAGTGAACCAAC	1506
Db	1056	GCAACCCCTTTGGGATTTATGGCTCCAAAGAAAGCCGGGATCTGTGAGTGAAGTGAACCAAC	1115
QY	1507	CCAAAGCGCGCTCCACCTCCCGGAGTGAAGGCGCCGGGCGCGGGCGCGCGGGCGCGGCAAC	1566
Db	1116	CCAAAGCGCGCTCCACCTCCCGGAGTGAAGGCGCCGGGCGCGGGCGCGGGCGCGGCAAC	1175
QY	1567	CGCGGGCGGAGAGACCGAGCTCGGGGCGGTGTGCGCGCGAGCTCAAGCAGTGTCTTGAGGCT	1626
Db	1176	CGCGGGCGGAGAGACCGAGCTCGGGGCGGTGTGCGCGCGAGCTCAAGCAGTGTCTTGAGGCT	1235
QY	1627	GGCTCAAGAAAGCAGCGGTACTGCTCCAACTCAGCTTCGCGCTCTACGACCAAGTGCGAG	1686
Db	1236	GGCTCAAGAAAGCAGCGGTACTGCTCCAACTCAGCTTCGCGCTCTACGACCAAGTGCGAG	1295
QY	1687	CTGGAGTGCAGAGTGTGSCACAACAACCCGCAACAGAGACGAGGGGATCTGCGCCCTCGGGCA	1746
Db	1296	CTGGAGTGCAGAGTGTGSCACAACAACCCGCAACAGAGACGAGGGGATCTGCGCCCTCGGGCA	1355
QY	1747	GACGGGCGCAGGCGAGAGGTCTGTGCGCAGATTAAGCTGTAGGGGCTCAGGCCACCTCCCTG	1806
Db	1356	GACGGGCGCAGGCGAGAGGTCTGTGCGCAGATTAAGCTGTAGGGGCTCAGGCCACCTCCCTG	1415
QY	1807	CCACGTGTGAAGACGACAGAGGCCGAAACCCAACTGGGGCGACCTCTGTATCCCTCACTTCAGG	1866
Db	1416	CCACGTGTGAAGACGACAGAGGCCGAAACCCAACTGGGGCGACCTCTGTATCCCTCACTTCAGG	1475
QY	1867	GCACCTGAGGCAACCTTCAGAGGAGGCTGGGGTGGCCCCCTGAGTCCAAACGGCCCATTAACG	1926
Db	1476	GCACCTGAGGCAACCTTCAGAGGAGGCTGGGGTGGCCCCCTGAGTCCAAACGGCCCATTAACG	1535
QY	1927	CTCTGACTCCACAGTGAAGCCACTTTGGGTGTGACCCACAGTGGGTGTGTGTGTGTGTG	1986
Db	1536	CTCTGACTCCACAGTGAAGCCACTTTGGGTGTGACCCACAGTGGGTGTGTGTGTGTGTGTG	1595
QY	1987	AGGGTTGGTTGAAGTTGCTTAGAACCCCTGCGAGGAGCTGGGGGTGAAGAGGGAGTCAATTA	2046
Db	1596	AGGGTTGGTTGAAGTTGCTTAGAACCCCTGCGAGGAGCTGGGGGTGAAGAGGGAGTCAATTA	1655
QY	2047	CTCCCCAATTACCTTAGGGCCCCCTCCAAAAGA	2076
Db	1656	CTCCCCAATTACCTTAGGGCCCCCTCCAAAAGA	1685

RESULT 6
US-10-450-826-56
Sequence 56, Application US/10450826
Publication No. US20040101818A1
GENERAL INFORMATION:
APPLICANT: Ji, Darren
APPLICANT: Axelrod, Douglas W.
APPLICANT: Cook, Jonathan S.
APPLICANT: Ustswal, Neelam
APPLICANT: Eistein, Richard
APPLICANT: Houghton, Adam
APPLICANT: Mertz, Lawrence
TITLE OF INVENTION: Gene Expression Profiles Associated with Osteoblast Differentiation
FILE REFERENCE: 044921-5039-WO
CURRENT APPLICATION NUMBER: US/10/450,826
CURRENT FILING DATE: 2003-06-18
PRIOR APPLICATION NUMBER: US 60/255,882
PRIOR FILING DATE: 2000-12-18
PRIOR APPLICATION NUMBER: US 60/285,691


```

1 TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEI
2 TITLE OF INVENTION: ACIDS ENCODING THE SAME
3 FILE REFERENCE: P2548P1C1
4 CURRENT APPLICATION NUMBER: US/09/944,449
5 CURRENT FILING DATE: 2001-09-26
6 PRIOR APPLICATION NUMBER: 09/866, 028
7 PRIOR FILING DATE: 2001-05-25
8 PRIOR APPLICATION NUMBER: 60/067,411
9 PRIOR FILING DATE: December 3, 1997
10 PRIOR APPLICATION NUMBER: 60/069,334
11 PRIOR FILING DATE: December 11, 1997
12 PRIOR APPLICATION NUMBER: 60/069335
13 PRIOR FILING DATE: December 11, 1997
14 PRIOR APPLICATION NUMBER: 60/069,278
15 PRIOR FILING DATE: December 11, 1997
16 PRIOR APPLICATION NUMBER: 60/069,425
17 PRIOR FILING DATE: December 12, 1997
18 PRIOR APPLICATION NUMBER: 60/069,696
19 PRIOR FILING DATE: December 16, 1997
20 PRIOR APPLICATION NUMBER: 60/069,694
21 PRIOR FILING DATE: December 16, 1997
22 PRIOR APPLICATION NUMBER: 60/069,702
23 PRIOR FILING DATE: December 16, 1997
24 PRIOR APPLICATION NUMBER: 60/069,870
25 PRIOR FILING DATE: December 17, 1997
26 PRIOR APPLICATION NUMBER: 60/069,873
27 PRIOR FILING DATE: December 17, 1997
28 PRIOR APPLICATION NUMBER: 60/068,017
29 PRIOR FILING DATE: December 18, 1997
30 PRIOR APPLICATION NUMBER: 60/070,440
31 PRIOR FILING DATE: January 5, 1998
32 PRIOR APPLICATION NUMBER: 60/074,086
33 PRIOR FILING DATE: February 9, 1998
34 PRIOR APPLICATION NUMBER: 60/074,092
35 PRIOR FILING DATE: February 9, 1998
36 PRIOR APPLICATION NUMBER: 60/075,945
37 PRIOR FILING DATE: February 25, 1998
38 PRIOR APPLICATION NUMBER: 60/112,850
39 PRIOR FILING DATE: December 16, 1998
40 PRIOR APPLICATION NUMBER: 60/113,296
41 PRIOR FILING DATE: December 22, 1998
42 PRIOR APPLICATION NUMBER: 60/146,222
43 PRIOR FILING DATE: July 28, 1999
44 PRIOR APPLICATION NUMBER: PCT/US98/19330
45 PRIOR FILING DATE: September 16, 1998
46 PRIOR APPLICATION NUMBER: PCT/US98/25108
47 PRIOR FILING DATE: December 1, 1998
48 PRIOR APPLICATION NUMBER: 09/216,021
49 PRIOR FILING DATE: December 16, 1998
50 PRIOR APPLICATION NUMBER: 09/218,517
51 PRIOR FILING DATE: December 22, 1998
52 PRIOR APPLICATION NUMBER: 09/254,311
53 PRIOR FILING DATE: March 3, 1999
54 PRIOR APPLICATION NUMBER: PCT/US99/12252
55 PRIOR FILING DATE: June 22, 1999
56 PRIOR APPLICATION NUMBER: PCT/US99/21090
57 PRIOR FILING DATE: September 15, 1999
58 PRIOR APPLICATION NUMBER: PCT/US99/28409
59 PRIOR FILING DATE: No. US20020102647a1member 30, 1999
60 PRIOR APPLICATION NUMBER: PCT/US99/28313
61 PRIOR FILING DATE: No. US20020102647a1member 30, 1999
62 PRIOR APPLICATION NUMBER: PCT/US99/28301
63 PRIOR FILING DATE: December 1, 1999
64 PRIOR APPLICATION NUMBER: PCT/US99/310095
65 PRIOR FILING DATE: December 16, 1999
66 PRIOR APPLICATION NUMBER: PCT/US00/03565
67 PRIOR FILING DATE: February 11, 2000
68 PRIOR APPLICATION NUMBER: PCT/US00/04414
69 PRIOR FILING DATE: February 22, 2000
70 PRIOR APPLICATION NUMBER: PCT/US00/05641
71 PRIOR FILING DATE: March 2, 2000
72 PRIOR APPLICATION NUMBER: PCT/US00/08439
73 PRIOR FILING DATE: March 30, 2000

```

	PRIOR APPLICATION NUMBER:	PCT/US00/14042		
	PRIOR FILING DATE:	May 22, 2000		
	PRIOR APPLICATION NUMBER:	PCT/US00/20710		
	PRIOR FILING DATE:	July 28, 2000		
	PRIOR APPLICATION NUMBER:	PCT/US00/32678		
	PRIOR FILING DATE:	December 1, 2000		
	PRIOR APPLICATION NUMBER:	PCT/US01/06520		
	PRIOR FILING DATE:	February 28, 2001		
	NUMBER OF SEQ ID NOS:	120		
	SEQ ID NO 31			
	LENGTH:	1790		
	TYPE:	DNA		
	ORGANISM:	Homo Sapien		
	US-09-944-449-31			
Query Match	75.6%; Score 1572.4; DB 9;	Length 1790;		
Blast Local Similarity	99.7%; Pred. No. 0;			
Matches 1586;	Conservative 0; Mismatches 1;	Indels 3; Gaps 1;		
Oy	490	GCGCCGCCGAGCGGGCCCCCATGTGCCTCCGCGGCCCGGAGCCTTCCCAATCCG	549	
Db	96	GCGCCCCCGAGCGCGCCCACATGCGCGCGCGCGCGCGCGCGCCAAATCCG	155	
Oy	550	C GGCGCGCGCGCGCGCGCGTGTCGCC--CTGCTGCTGTGTTGGTCTTCTCGGGGCGCGC	606	
Db	156	CGCGCGCGCGCGCGCGCGTGTCGCCCTGTGCTGTGCTGTGCGTCTCGGGGCGCGC	215	
Oy	607	GAGCGGATCGAGAAGCCACA CAGCTGTGATCATGCCAGATTCCACGCTTCTCATCG	666	
Db	216	GAGCGGATCGAGAAGCCACA CAGCTGTGATCATGCCAGATTCCACGCTTCTCATCG	275	
Oy	667	GCTCCTCCCTGCTGCTGACCAC TCTCA GTGACGGA GCCACA GAGAAC CGCGCGAGG	726	
Db	276	GCTCCTCCCTGCTGCTGACCAC TCTCA GTGACGGA ACCCA CGAAGCAC CGCGCGAGG	335	
Oy	727	GCTCTACTGGAACCTTCA ATGAGGCGCGCGCTGCGCCCCCTGAGCTTCCCGTGTACTCAACG	786	
Db	336	GCTCTACTGGAACCTTCA ACAGGGGCGCGCGCTGCGCCCCCTGAGCTTCCCGTGTACTCAACG	395	
Oy	787	CCTCACCTTGGCTCTGAGCC CTGGCCA ACGTC AA TGAGGTCCAGGACAGCGGTGGGGAGCA	846	
Db	396	CCTCACCTTGGCTCTGAGCC CTGGCCA ACGTC AA TGAGGTCCAGGACAGCGGTGGGGAGCA	455	
Oy	847	ACTCTGTGTGCA CGCCCGGTGA CGGAGCA TCCTGAGTGCTCTGCTCTATGTTGACC	906	
Db	456	ACTCTGTGTGCA CGCCCGGTGA CGGAGCA TCCTGAGTGCTCTGCTCTATGTTGACC	515	
Oy	907	TGCCCCAGAGAAACCGGTCAA CATCA GCTGCTGCTCA AGA CATGAAGACTTGACCT	966	
Db	516	TGCCCCAGAGAAACCGGTCAA CATCA GCTGCTGCTCA AGA CATGAAGACTTGACCT	575	
Oy	967	GCGCGTGAAGCGCCAGGGG CCCACGGGGAGAC TTTCCTCCACA CCAATA CTCCTCAAGT	1026	
Db	576	GCGCGTGAAGCGCCAGGGG CCCACGGGGAGAC TTTCCTCCACA CCAATA CTCCTCAAGT	635	
Oy	1027	ACAAGCTTAGGTGATATG CCAAGACA CAATGTAGAGTA CCACA GATGGGGCCCC	1086	
Db	636	ACAAGCTTAGGTGATATG CCAAGACA CAATGTAGAGTA CCACA GATGGGGCCCC	695	
Oy	1087	ACTCTGCGCAATCCCAAGAG ACTGACTCTTTTACGCCCTATGAGATCTGGGTGAGG	1146	
Db	696	ACTCTGCGCAATCCCAAGAG ACTGACTCTTTTACGCCCTATGAGATCTGGGTGAGG	755	
Oy	1147	CCACCAACCGCTGGGGCTTG CCGCGTCCATATGATCA CTCAAGTGGATATCTTGATG	1206	
Db	756	CCACCAACCGCTGGGGCTTG CCGCGTCCATATGATCA CTCAAGTGGATATCTTGATG	815	
Oy	1207	TGACCAAGAACCCCGCGCGA CGTGCAGTGA CGCGCTCGGGGCGCTGAGAGACGAG	1266	
Db	816	TGACCAAGAACCCCGCGCGA CGTGCAGTGA CGCGCTCGGGGCGCTGAGAGACGAG	875	
Oy	1267	TGAGCGTGCCTGGGTGTGCG CA CCGCGCTCAAGGATTTCTCTTTCAGGCCAAATACC	1326	

Db 876 TGAGGTGGGCTGGGTGGCCACCCGCCCTCAAGGATTTCTTTCAAGCCAAATACC 935
Qy 1327 AGATCCGCTACCGAGTGGAGGACAGTGTGACTGGAAAGTGGTGGACATGTGAGCAACC 1386
Db 936 AGATCCGCTACCGAGTGGAGGACAGTGTGACTGGAAAGTGGTGGACATGTGAGCAACC 995
Qy 1387 AGACCTCCGCGCCCTGGCCGCGGCTGAAAACCCGCGCACCGGTATCTTGGGCAAGTCGCT 1446
Db 996 AGACCTCCGCGCCCTGGCCGCGGCTGAAAACCCGCGCACCGGTATCTTGGTGAAGTCGCT 1055
Qy 1447 GCACCCCTTTGGCATCTATGGCTCCAGAAAAGCCGGAATCTTGAAGTGGAGCCACC 1506
Db 1056 GCACCCCTTTGGCATCTATGGCTCCAGAAAAGCCGGAATCTTGAAGTGGAGCCACC 1115
Qy 1507 CCACAGCCGCTCTCATCTCCCGGAGTGAAGCCCGCGGCGCGCGCGCGCGCGCGCGCGCG 1566
Db 1116 CCACAGCCGCTCTCATCTCCCGGAGTGAAGCCCGCGGCGCGCGCGCGCGCGCGCGCGCG 1175
Qy 1567 CGCGGCGCGGAGAGCCGAGCTCGGGGCGGGGTCGCGGAGCTCAAGCAGTTCTGGGCT 1626
Db 1176 CGCGGCGCGGAGAGCCGAGCTCGGGGCGGGGTCGCGGAGCTCAAGCAGTTCTGGGCT 1235
Qy 1627 GGCCTAAGAGACACCGCTACTGCTCAACCTTCCGCTCTTCAAGCAGTGGCGAG 1686
Db 1236 GGCCTAAGAGACACCGCTACTGCTCAACCTTCCGCTCTTCAAGCAGTGGCGAG 1295
Qy 1687 CCTGATGCAAGAGTGGCACACACCCGCAACCAAGACAGGAGGATCTGCGCTCGGGCA 1746
Db 1296 CCTGATGCAAGAGTGGCACACACCCGCAACCAAGACAGGAGGATCTGCGCTCGGGCA 1355
Qy 1747 GACGCGGCGACGCGGAGAGTCTGCGAGATTAAGCTTGAAGGAGCTCAGGCGCACCTCCCTG 1806
Db 1356 GACGCGGCGACGCGGAGAGTCTGCGAGATTAAGCTTGAAGGAGCTCAGGCGCACCTCCCTG 1415
Qy 1807 CCACTGAGAGACGACAGAGGCGCAACCAAACTGGGCGCACCTCTGTAACCTCACTTCAAG 1866
Db 1416 CCACTGAGAGAGACGACAGAGGCGCAACCAAACTGGGCGCACCTCTGTAACCTCACTTCAAG 1475
Qy 1867 GCACCTGAGACACCTCTCAGAGAGAGCTGGGCTGGCCCTGAGCTCAAGCGCCATTAACAG 1926
Db 1476 GCACCTGAGACACCTCTCAGAGAGAGCTGGGCTGGCCCTGAGCTCAAGCGCCATTAACAG 1535
Qy 1927 CTCTGACTCCCACTGAGGCGACCTTTGGGTGACCCCAAGTGGGTGTGTGTGTGTGTGTG 1986
Db 1536 CTCTGACTCCCACTGAGGCGACCTTTGGGTGACCCCAAGTGGGTGTGTGTGTGTGTGTG 1595
Qy 1987 AGGGTGTGTTAGTTGCTTGAACCCCTGTCAGGAGCTGGGGGTGAGAAAGGAGATCATTA 2046
Db 1596 AGGGTGTGTTAGTTGCTTGAACCCCTGTCAGGAGCTGGGGGTGAGAAAGGAGATCATTA 1655
Qy 2047 CTCTCCATTAACCTAAGGCGCCCTTCCAAAAGA 2076
Db 1656 CTCTCCATTAACCTAAGGCGCCCTTCCAAAAGA 1685

RESULT 9
US-09-944-457-31
Sequence 31, Application US/09944457
Patent No. US20020110859A1

GENERAL INFORMATION:
APPLICANT: Baker, Kevin

APPLICANT: Botstein, David

APPLICANT: Baton, Dan

APPLICANT: Ferrara, Napoleone

APPLICANT: Filvaroff, Ellen

APPLICANT: Gerlitsen, Mary

APPLICANT: Goddard, Audrey

APPLICANT: Grimaldi, Christopher

APPLICANT: Gurney, Austin

APPLICANT: Hillan, Kenneth

APPLICANT: Kijavlin, Ivar

APPLICANT: Napier, Mary

APPLICANT: Roy, Margaret
APPLICANT: Tumas, Daniel
APPLICANT: Wood, William
TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
FILE REFERENCE: P2548P1C1
CURRENT FILING DATE: 2001-09-26
PRIOR APPLICATION NUMBER: US/09/944,457
PRIOR FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: 60/067,411
PRIOR FILING DATE: December 3, 1997
PRIOR APPLICATION NUMBER: 60/069,334
PRIOR FILING DATE: December 11, 1997
PRIOR APPLICATION NUMBER: 60/069,335
PRIOR FILING DATE: December 11, 1997
PRIOR APPLICATION NUMBER: 60/069,278
PRIOR FILING DATE: December 11, 1997
PRIOR APPLICATION NUMBER: 60/069,425
PRIOR FILING DATE: December 12, 1997
PRIOR APPLICATION NUMBER: 60/069,696
PRIOR FILING DATE: December 16, 1997
PRIOR APPLICATION NUMBER: 60/069,694
PRIOR FILING DATE: December 16, 1997
PRIOR APPLICATION NUMBER: 60/069,702
PRIOR FILING DATE: December 16, 1997
PRIOR APPLICATION NUMBER: 60/069,870
PRIOR FILING DATE: December 17, 1997
PRIOR APPLICATION NUMBER: 60/069,873
PRIOR FILING DATE: December 17, 1997
PRIOR APPLICATION NUMBER: 60/068,017
PRIOR FILING DATE: December 18, 1997
PRIOR APPLICATION NUMBER: 60/070,440
PRIOR FILING DATE: January 5, 1998
PRIOR APPLICATION NUMBER: 60/074,086
PRIOR FILING DATE: February 9, 1998
PRIOR APPLICATION NUMBER: 60/074,092
PRIOR FILING DATE: February 9, 1998
PRIOR APPLICATION NUMBER: 60/075,945
PRIOR FILING DATE: February 25, 1998
PRIOR APPLICATION NUMBER: 60/112,850
PRIOR FILING DATE: December 16, 1998
PRIOR APPLICATION NUMBER: 60/113,296
PRIOR FILING DATE: December 22, 1998
PRIOR APPLICATION NUMBER: 60/146,222
PRIOR FILING DATE: July 28, 1999
PRIOR APPLICATION NUMBER: PCT/US98/19330
PRIOR FILING DATE: September 16, 1998
PRIOR APPLICATION NUMBER: PCT/US98/25108
PRIOR FILING DATE: December 1, 1998
PRIOR APPLICATION NUMBER: 09/216,021
PRIOR FILING DATE: December 16, 1998
PRIOR APPLICATION NUMBER: 09/218,517
PRIOR FILING DATE: December 22, 1998
PRIOR APPLICATION NUMBER: 09/254,311
PRIOR FILING DATE: March 3, 1999
PRIOR APPLICATION NUMBER: PCT/US99/12252
PRIOR FILING DATE: June 22, 1999
PRIOR APPLICATION NUMBER: PCT/US99/21090
PRIOR FILING DATE: September 15, 1999
PRIOR APPLICATION NUMBER: PCT/US99/28409
PRIOR FILING DATE: No. US20020110859A1member 30, 1999
PRIOR APPLICATION NUMBER: PCT/US99/28313
PRIOR FILING DATE: No. US20020110859A1member 30, 1999
PRIOR APPLICATION NUMBER: PCT/US99/28301
PRIOR FILING DATE: December 1, 1999
PRIOR APPLICATION NUMBER: PCT/US99/30095
PRIOR FILING DATE: December 16, 1999
PRIOR APPLICATION NUMBER: PCT/US00/03565
PRIOR FILING DATE: February 11, 2000
PRIOR APPLICATION NUMBER: PCT/US00/04414
PRIOR FILING DATE: February 22, 2000
PRIOR APPLICATION NUMBER: PCT/US00/05841

QY 1207 TGACACGAGACCCCGCCGACGTCAGCCGCTCGGGGGCTGAGAGCAGC 1266
| | | | |
DB 816 TGACACGAGACCCCGCCGACGTCAGCCGCTCGGGGGCTGAGAGCAGC 875
| | | | |
QY 1267 TGAGCGTGCCTGAGTGCACCCGCTCAAGATTTCTTTCAAGCCAAATACC 1326
| | | | |
DB 876 TGAGCGTGCCTGAGTGCACCCGCTCAAGATTTCTTTCAAGCCAAATACC 935
| | | | |
QY 1327 AGATCCGCTACCGAGTGAAGACAGTGTGATGGAAGGTGTGTGAGATGTAGCAAC 1386
| | | | |
DB 936 AGATCCGCTACCGAGTGAAGACAGTGTGATGGAAGGTGTGTGAGATGTAGCAAC 995
| | | | |
QY 1387 AGACCTCTGCGCGCTGAGCGGCTGAAACCGGACCGTGTACTTGTGTCAAGTGGCT 1446
| | | | |
DB 996 AGACCTCTGCGCGCTGAGCGGCTGAAACCGGACCGTGTACTTGTGTCAAGTGGCT 1055
| | | | |
QY 1447 GCAACCCCTTTGGCATCTATATGCTCCAAAGAACCGGAGTGTGAGTGAAGCCACC 1506
| | | | |
DB 1056 GCAACCCCTTTGGCATCTATATGCTCCAAAGAACCGGAGTGTGAGTGAAGCCACC 1115
| | | | |
QY 1507 CCAACGCGCTCTCACTCCCCGAGTGAAGCGCCCGGCGCGGCGGCGGCGTGCAGAC 1566
| | | | |
DB 1116 CCAACGCGCTCTCACTCCCCGAGTGAAGCGCCCGGCGCGGCGGCGGCGTGCAGAC 1175
| | | | |
QY 1567 CGCGGGGCGGAGAGCGGAGCTCGGGGCGGAGTGAAGCGTCAAGCAGTTCTTGGGCT 1626
| | | | |
DB 1176 CGCGGGGCGGAGAGCGGAGCTCGGGGCGGAGTGAAGCGTCAAGCAGTTCTTGGGCT 1235
| | | | |
QY 1627 GGGCTCAAGAGCAAGCGTCTGCTCAACTCAGCTTCGCTCTTCAAGCAGTGGCAG 1686
| | | | |
DB 1236 GGGCTCAAGAGCAAGCGTCTGCTCAACTCAGCTTCGCTCTTCAAGCAGTGGCAG 1295
| | | | |
QY 1687 CCGTGAATGCAAGATGCGCAAGACCCGCAACCAAGACAGAGGAGTCTGCTCGGACA 1746
| | | | |
DB 1296 CCGTGAATGCAAGATGCGCAAGACCCGCAACCAAGACAGAGGAGTCTGCTCGGACA 1355
| | | | |
QY 1747 GACGGGGACAGGGGAGGCTCTGCGCATATAGCTGAGGGGCTCAGGGCACTCCCTG 1806
| | | | |
DB 1356 GACGGGGACAGGGGAGGCTCTGCGCATATAGCTGAGGGGCTCAGGGCACTCCCTG 1415
| | | | |
QY 1807 CCACTGAGAGACGACAGAGCCGAAACCAACTGGGGCACTCTGTACCTTCACTTCAAG 1866
| | | | |
DB 1416 CCACTGAGAGACGACAGAGCCGAAACCAACTGGGGCACTCTGTACCTTCACTTCAAG 1475
| | | | |
QY 1867 GCACTGAGAGACCTCTCAGAGAGAGTGGGGTGGCCCTTGAAGCTCCAGCGCCATAACAG 1926
| | | | |
DB 1476 GCACTGAGAGACCTCTCAGAGAGAGTGGGGTGGCCCTTGAAGCTCCAGCGCCATAACAG 1535
| | | | |
QY 1927 CTTGTACTCCAGTGAAGCCACTTTGGGTGACACCCCATGAGTGTGTGTGTGTG 1986
| | | | |
DB 1536 CTTGTACTCCAGTGAAGCCACTTTGGGTGACACCCCATGAGTGTGTGTGTGTG 1595
| | | | |
QY 1987 AGGGTTGTTGAGTGTGCTAGAACCCCTGACAGGGCTGGGGGTGAGAGAGGAGTCAATTA 2046
| | | | |
DB 1596 AGGGTTGTTGAGTGTGCTAGAACCCCTGACAGGGCTGGGGGTGAGAGAGGAGTCAATTA 1655
| | | | |
QY 2047 CTCTCCCAATTAAGAGGGCCCTCTCAAAAAGA 2076
| | | | |
DB 1656 CTCTCCCAATTAAGAGGGCCCTCTCAAAAAGA 1685
| | | | |

APPLICANT: Godowski, Paul
APPLICANT: Grimaldi, Christopher
APPLICANT: Guiney, Austin
APPLICANT: Hillan, Kenneth
APPLICANT: Hillan, Kenneth
APPLICANT: Kijavlin, Ivar
APPLICANT: Napier, Mary
APPLICANT: Roy, Margaret
APPLICANT: Tumas, Daniel
APPLICANT: Wood, William
TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
FILE REFERENCE: P2548P1C1
CURRENT APPLICATION NUMBER: US/09/945,015
CURRENT FILING DATE: 2001-09-26
PRIOR APPLICATION NUMBER: 09/866,028
PRIOR FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: 60/067,411
PRIOR FILING DATE: December 3, 1997
PRIOR APPLICATION NUMBER: 60/069,334
PRIOR FILING DATE: December 11, 1997
PRIOR APPLICATION NUMBER: 60/069,335
PRIOR FILING DATE: December 11, 1997
PRIOR APPLICATION NUMBER: 60/069,278
PRIOR FILING DATE: December 11, 1997
PRIOR APPLICATION NUMBER: 60/069,425
PRIOR FILING DATE: December 12, 1997
PRIOR APPLICATION NUMBER: 60/069,596
PRIOR FILING DATE: December 16, 1997
PRIOR APPLICATION NUMBER: 60/069,694
PRIOR FILING DATE: December 16, 1997
PRIOR APPLICATION NUMBER: 60/069,702
PRIOR FILING DATE: December 16, 1997
PRIOR APPLICATION NUMBER: 60/069,870
PRIOR FILING DATE: December 17, 1997
PRIOR APPLICATION NUMBER: 60/069,873
PRIOR FILING DATE: December 17, 1997
PRIOR APPLICATION NUMBER: 60/068,017
PRIOR FILING DATE: December 18, 1997
PRIOR APPLICATION NUMBER: 60/070,440
PRIOR FILING DATE: January 5, 1998
PRIOR APPLICATION NUMBER: 60/074,086
PRIOR FILING DATE: February 9, 1998
PRIOR APPLICATION NUMBER: 60/074,092
PRIOR FILING DATE: February 9, 1998
PRIOR APPLICATION NUMBER: 60/075,945
PRIOR FILING DATE: February 25, 1998
PRIOR APPLICATION NUMBER: 60/112,850
PRIOR FILING DATE: December 16, 1998
PRIOR APPLICATION NUMBER: 60/113,296
PRIOR FILING DATE: December 22, 1998
PRIOR APPLICATION NUMBER: 60/146,222
PRIOR FILING DATE: July 28, 1999
PRIOR APPLICATION NUMBER: PCT/US98/19330
PRIOR FILING DATE: September 16, 1998
PRIOR APPLICATION NUMBER: PCT/US98/25108
PRIOR FILING DATE: December 1, 1998
PRIOR APPLICATION NUMBER: 09/216,021
PRIOR FILING DATE: December 16, 1998
PRIOR APPLICATION NUMBER: 09/218,517
PRIOR FILING DATE: December 22, 1998
PRIOR APPLICATION NUMBER: 09/254,311
PRIOR FILING DATE: March 3, 1999
PRIOR APPLICATION NUMBER: PCT/US99/12252
PRIOR FILING DATE: June 22, 1999
PRIOR APPLICATION NUMBER: PCT/US99/21090
PRIOR FILING DATE: September 15, 1999
PRIOR APPLICATION NUMBER: PCT/US99/28409
PRIOR FILING DATE: No. US20020132768A1member 30, 1999
PRIOR APPLICATION NUMBER: PCT/US99/28313
PRIOR FILING DATE: No. US20020132768A1member 30, 1999
PRIOR APPLICATION NUMBER: PCT/US99/28301
PRIOR FILING DATE: December 1, 1999
PRIOR APPLICATION NUMBER: PCT/US99/30095

APPLICANT: Filvaroff, Ellen
APPLICANT: Gertsen, Mary
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul
APPLICANT: Grimaldi, Christopher
APPLICANT: Gurney, Austin
APPLICANT: Hillan, Kenneth
APPLICANT: Kijavini, Ivar
APPLICANT: Napier, Mary
APPLICANT: Roy, Margaret
APPLICANT: Tuma, Daniel
APPLICANT: Wood, William
TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
FILE REFERENCE: P2548P1C1
CURRENT APPLICATION NUMBER: US/09/944,396
CURRENT FILING DATE: 2001-09-26
PRIOR APPLICATION NUMBER: 09/866,128
PRIOR FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: 60/067,411
PRIOR FILING DATE: December 3, 1997
PRIOR APPLICATION NUMBER: 60/069,334
PRIOR FILING DATE: December 11, 1997
PRIOR APPLICATION NUMBER: 60/069,335
PRIOR FILING DATE: December 11, 1997
PRIOR APPLICATION NUMBER: 60/069,278
PRIOR FILING DATE: December 11, 1997
PRIOR APPLICATION NUMBER: 60/069,425
PRIOR FILING DATE: December 12, 1997
PRIOR APPLICATION NUMBER: 60/069,696
PRIOR FILING DATE: December 16, 1997
PRIOR APPLICATION NUMBER: 60/069,694
PRIOR FILING DATE: December 16, 1997
PRIOR APPLICATION NUMBER: 60/069,702
PRIOR FILING DATE: December 16, 1997
PRIOR APPLICATION NUMBER: 60/069,870
PRIOR FILING DATE: December 17, 1997
PRIOR APPLICATION NUMBER: 60/069,873
PRIOR FILING DATE: December 17, 1997
PRIOR APPLICATION NUMBER: 60/068,017
PRIOR FILING DATE: December 18, 1997
PRIOR APPLICATION NUMBER: 60/070,440
PRIOR FILING DATE: January 5, 1998
PRIOR APPLICATION NUMBER: 60/074,086
PRIOR FILING DATE: February 9, 1998
PRIOR APPLICATION NUMBER: 60/074,092
PRIOR FILING DATE: February 9, 1998
PRIOR APPLICATION NUMBER: 60/075,945
PRIOR FILING DATE: February 25, 1998
PRIOR APPLICATION NUMBER: 60/112,850
PRIOR FILING DATE: December 16, 1998
PRIOR APPLICATION NUMBER: 60/113,296
PRIOR FILING DATE: December 22, 1998
PRIOR APPLICATION NUMBER: 60/146,222
PRIOR FILING DATE: July 28, 1999
PRIOR APPLICATION NUMBER: PCT/US98/19330
PRIOR FILING DATE: September 16, 1998
PRIOR APPLICATION NUMBER: PCT/US98/125108
PRIOR FILING DATE: December 1, 1998
PRIOR APPLICATION NUMBER: 09/216,021
PRIOR FILING DATE: December 16, 1998
PRIOR APPLICATION NUMBER: 09/218,517
PRIOR FILING DATE: December 22, 1998
PRIOR APPLICATION NUMBER: 09/254,111
PRIOR FILING DATE: March 3, 1999
PRIOR APPLICATION NUMBER: PCT/US99/12252
PRIOR FILING DATE: June 22, 1999
PRIOR APPLICATION NUMBER: PCT/US99/21090
PRIOR FILING DATE: September 15, 1999
PRIOR APPLICATION NUMBER: PCT/US99/28409
PRIOR FILING DATE: No. US20020132961a1ember 30, 1999
PRIOR APPLICATION NUMBER: PCT/US99/28313
PRIOR FILING DATE: No. US20020132961a1ember 30, 1999

```

PCT/US99/28301
PRIOR APPLICATION NUMBER: PCT/US99/28301
PRIOR FILING DATE: December 1, 1999
PRIOR APPLICATION NUMBER: PCT/US99/30095
PRIOR FILING DATE: December 16, 1999
PRIOR APPLICATION NUMBER: PCT/US00/00365
PRIOR FILING DATE: February 11, 2000
PRIOR APPLICATION NUMBER: PCT/US00/04414
PRIOR FILING DATE: February 22, 2000
PRIOR APPLICATION NUMBER: PCT/US00/05941
PRIOR FILING DATE: March 2, 2000
PRIOR APPLICATION NUMBER: PCT/US00/08439
PRIOR FILING DATE: March 30, 2000
PRIOR APPLICATION NUMBER: PCT/US00/14042
PRIOR FILING DATE: May 22, 2000
PRIOR APPLICATION NUMBER: PCT/US00/20710
PRIOR FILING DATE: July 28, 2000
PRIOR APPLICATION NUMBER: PCT/US00/32678
PRIOR FILING DATE: December 1, 2000
PRIOR APPLICATION NUMBER: PCT/US01/06520
PRIOR FILING DATE: February 28, 2001
NUMBER OF SEQ ID NOS: 120
SEQ ID NO 31
LENGTH: 1790
TYPE: DNA
ORGANISM: Homo Sapien
US-09-944-396-31

```

Query Match	Similarity	75.6%	Score 1572.4	DB 9	Length 1790
Match	Local Similarity	99.7%	Pred. No. 0		
Matches 1586	Conservative	0	Mismatches	1	Indels 3, Gaps 1
Qy	490	GC	GC	GC	GC
Db	96	GC	GC	GC	GC
Qy	550	CG	CG	CG	CG
Db	156	CG	CG	CG	CG
Qy	607	GAG	GAG	GAG	GAG
Db	216	GAG	GAG	GAG	GAG
Qy	667	GCT	GCT	GCT	GCT
Db	276	GCT	GCT	GCT	GCT
Qy	727	GCT	GCT	GCT	GCT
Db	336	GCT	GCT	GCT	GCT
Qy	787	CCT	CCT	CCT	CCT
Db	396	CCT	CCT	CCT	CCT
Qy	847	ACC	ACC	ACC	ACC
Db	456	ACC	ACC	ACC	ACC
Qy	907	TG	TG	TG	TG
Db	516	TG	TG	TG	TG
Qy	967	GC	GC	GC	GC
Db	576	GC	GC	GC	GC
Qy	1027	ACA	ACA	ACA	ACA
Db	636	ACA	ACA	ACA	ACA
Qy	1087	ACT	ACT	ACT	ACT

696 ACTCTGCAACATCCCCAAGAAAGCTGCTCTTTTACGCCCTTATGAGATCTGGGTGAGG 755
1147 CCACCAACCGCCCTGGGCTCTGCCCGCTCCGATGTACTCAAGCTGTGATCTCTGAGATGTG 1206
756 CCACCAACCGCCCTGGGCTCTGCCCGCTCCGATGTACTCAAGCTGTGATCTCTGAGATGTG 815
1207 TGACCAAGAACCCCGCCGAGAGTGTGACAGTGTGAGCCGCTGAGGAGCTTGTGAGAGCAG 1266
816 TGACCAAGAACCCCGCCGAGAGTGTGACAGTGTGAGCCGCTGAGGAGCTTGTGAGAGCAG 875
1267 TGAGCGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTG 1326
876 TGAGCGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTG 935
1327 AGATCCGCTACCGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTG 1386
936 AGATCCGCTACCGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTG 995
1387 AGATCTCTGCGCGCTGCGCGCTGCGCGCTGCGCGCGCTGCGCGCGCTGCGCGCGCTGCGCG 1446
996 AGATCTCTGCGCGCTGCGCGCTGCGCGCTGCGCGCGCTGCGCGCGCTGCGCGCGCTGCGCG 1055
1447 GCACCCCTTTGGATCTATGTGCTCAAGAAAGCCGAGATCTGAGTGTGAGTGTGAGTGTG 1506
1056 GCACCCCTTTGGATCTATGTGCTCAAGAAAGCCGAGATCTGAGTGTGAGTGTGAGTGTG 1115
1507 CCACCAACCGCCCTGGGCTCTGCCCGCTCCGATGTACTCAAGCTGTGATCTCTGAGATGTG 1566
1116 CCACCAACCGCCCTGGGCTCTGCCCGCTCCGATGTACTCAAGCTGTGATCTCTGAGATGTG 1175
1567 CGCGGGGCGGAGAGCCGAGCTCGGGGCGGGGCGGGGCGGGGCGGGGCGGGGCGGGGCGGG 1626
1176 CGCGGGGCGGAGAGCCGAGCTCGGGGCGGGGCGGGGCGGGGCGGGGCGGGGCGGGGCGGG 1235
1627 GGTCTAAGAAAGCAAGCTGTGCTCAAGCTGTGCTGCTGTGAGTGTGAGTGTGAGTGTG 1686
1236 GGTCTAAGAAAGCAAGCTGTGCTCAAGCTGTGCTGCTGTGAGTGTGAGTGTGAGTGTG 1295
1687 CCGTGAATGCAAGTGTGCAAGAACCGCAAGCAAGCAAGCAAGCAAGCAAGCAAGCAAGCAAG 1746
1296 CCGTGAATGCAAGTGTGCAAGAACCGCAAGCAAGCAAGCAAGCAAGCAAGCAAGCAAGCAAG 1355
1747 GACGGGGGCGGAGAGCTGTGCAAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAG 1806
1356 GACGGGGGCGGAGAGCTGTGCAAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAG 1415
1807 CCAAGTGTGAGAGCGCAAGAGCCGAACCCAACTGGGGCACTCTGTGACCTTCACTTCAAG 1866
1416 CCAAGTGTGAGAGCGCAAGAGCCGAACCCAACTGGGGCACTCTGTGACCTTCACTTCAAG 1475
1867 GCAACCTGAGAGCCCTCAGAGAGAGCTGGGGTGGCCCTGAGCTCCAAAGCCCAATTAACAG 1926
1476 GCAACCTGAGAGCCCTCAGAGAGAGCTGGGGTGGCCCTGAGCTCCAAAGCCCAATTAACAG 1535
1927 CTCTGACTCCACGTAAGAGCCCTTTGGGTGCAACCCAGTGTGAGTGTGAGTGTGAGTGTG 1986
1536 CTCTGACTCCACGTAAGAGCCCTTTGGGTGCAACCCAGTGTGAGTGTGAGTGTGAGTGTG 1595
1987 AGGTTGTGTGAGTGTGCTTGAACCCCTGTGCAAGGGGTGTGAGAGGGAGTCAATTA 2046
1596 AGGTTGTGTGAGTGTGCTTGAACCCCTGTGCAAGGGGTGTGAGAGGGAGTCAATTA 1655
2047 CTCCCAATTAAGAGGGCCCTTCAAAAGA 2076
1656 CTCCCAATTAAGAGGGCCCTTCAAAAGA 1685

RESULT 13
US-09-944-432-31
Sequence 31, Application US/09944432
Patent No. US20020142419A1
GENERAL INFORMATION:
APPLICANT: Baker, Kevin

APPLICANT: Botstein, David
APPLICANT: Eaton, Dan
APPLICANT: Ferrara, Napoleone
APPLICANT: Filvaroff, Ellen
APPLICANT: Gerstlisen, Mary
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul
APPLICANT: Grimaldi, Christopher
APPLICANT: Gurney, Austin
APPLICANT: Hillen, Kenneth
APPLICANT: Kljavin, Ivar
APPLICANT: Napier, Mary
APPLICANT: Roy, Margaret
APPLICANT: Tumas, Daniel
APPLICANT: Wood, William
TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
FILE REFERENCE: P2548P1C1
CURRENT APPLICATION NUMBER: US/09/944,432
CURRENT FILING DATE: 2001-09-26
PRIOR APPLICATION NUMBER: 09/866,028
PRIOR FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: 60/067,411
PRIOR FILING DATE: December 3, 1997
PRIOR APPLICATION NUMBER: 60/069,334
PRIOR FILING DATE: December 11, 1997
PRIOR APPLICATION NUMBER: 60/069,335
PRIOR FILING DATE: December 11, 1997
PRIOR APPLICATION NUMBER: 60/069,278
PRIOR FILING DATE: December 11, 1997
PRIOR APPLICATION NUMBER: 60/069,425
PRIOR FILING DATE: December 12, 1997
PRIOR APPLICATION NUMBER: 60/069,696
PRIOR FILING DATE: December 15, 1997
PRIOR APPLICATION NUMBER: 60/069,694
PRIOR FILING DATE: December 16, 1997
PRIOR APPLICATION NUMBER: 60/069,702
PRIOR FILING DATE: December 16, 1997
PRIOR APPLICATION NUMBER: 60/069,870
PRIOR FILING DATE: December 17, 1997
PRIOR APPLICATION NUMBER: 60/069,873
PRIOR FILING DATE: December 17, 1997
PRIOR APPLICATION NUMBER: 60/068,017
PRIOR FILING DATE: December 18, 1997
PRIOR APPLICATION NUMBER: 60/070,440
PRIOR FILING DATE: January 5, 1998
PRIOR APPLICATION NUMBER: 60/074,086
PRIOR FILING DATE: February 9, 1998
PRIOR APPLICATION NUMBER: 60/074,092
PRIOR FILING DATE: February 9, 1998
PRIOR APPLICATION NUMBER: 60/075,945
PRIOR FILING DATE: February 25, 1998
PRIOR APPLICATION NUMBER: 60/112,850
PRIOR FILING DATE: December 16, 1998
PRIOR APPLICATION NUMBER: 60/113,296
PRIOR FILING DATE: December 22, 1998
PRIOR APPLICATION NUMBER: 60/146,222
PRIOR FILING DATE: July 28, 1999
PRIOR APPLICATION NUMBER: PCT/US98/19330
PRIOR FILING DATE: September 16, 1998
PRIOR APPLICATION NUMBER: PCT/US98/25108
PRIOR FILING DATE: December 1, 1998
PRIOR APPLICATION NUMBER: 09/216,021
PRIOR FILING DATE: December 15, 1998
PRIOR APPLICATION NUMBER: 09/218,517
PRIOR FILING DATE: December 22, 1998
PRIOR APPLICATION NUMBER: 09/254,311
PRIOR FILING DATE: March 3, 1999
PRIOR APPLICATION NUMBER: PCT/US99/12252
PRIOR FILING DATE: June 22, 1999
PRIOR APPLICATION NUMBER: PCT/US99/21090
PRIOR FILING DATE: September 15, 1999
PRIOR APPLICATION NUMBER: PCT/US99/28409


```

1 Patent No.US20020142958A1
2 GENERAL INFORMATION:
3 APPLICANT: Baker, Kevin
4 APPLICANT: Botstein, David
5 APPLICANT: Baton, Dan
6 APPLICANT: Ferrara, Napoleone
7 APPLICANT: Filvaroff, Ellen
8 APPLICANT: Gerritsen, Mary
9 APPLICANT: Goddard, Audrey
10 APPLICANT: Godowski, Paul
11 APPLICANT: Grimaldi, Christopher
12 APPLICANT: Gurney, Austin
13 APPLICANT: Hillan, Kenneth
14 APPLICANT: Kljavin, Ivar
15 APPLICANT: Napier, Mary
16 APPLICANT: Roy, Margaret
17 APPLICANT: Tamas, Daniel
18 APPLICANT: Tamas, William
19 TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
20 FILE REFERENCE: P2548P1C1
21 CURRENT APPLICATION NUMBER: US/09/943,762
22 CURRENT FILING DATE: 2001-09-26
23 PRIOR APPLICATION NUMBER: 09/866,028
24 PRIOR FILING DATE: 2001-05-25
25 PRIOR APPLICATION NUMBER: 60/067,411
26 PRIOR FILING DATE: December 3, 1997
27 PRIOR APPLICATION NUMBER: 60/069,334
28 PRIOR FILING DATE: December 11, 1997
29 PRIOR APPLICATION NUMBER: 60/069,335
30 PRIOR FILING DATE: December 11, 1997
31 PRIOR APPLICATION NUMBER: 60/069,278
32 PRIOR FILING DATE: December 11, 1997
33 PRIOR APPLICATION NUMBER: 60/069,425
34 PRIOR FILING DATE: December 12, 1997
35 PRIOR APPLICATION NUMBER: 60/069,696
36 PRIOR FILING DATE: December 16, 1997
37 PRIOR APPLICATION NUMBER: 60/069,694
38 PRIOR FILING DATE: December 16, 1997
39 PRIOR APPLICATION NUMBER: 60/069,702
40 PRIOR FILING DATE: December 16, 1997
41 PRIOR APPLICATION NUMBER: 60/069,870
42 PRIOR FILING DATE: December 17, 1997
43 PRIOR APPLICATION NUMBER: 60/069,873
44 PRIOR FILING DATE: December 17, 1997
45 PRIOR APPLICATION NUMBER: 60/068,017
46 PRIOR FILING DATE: December 18, 1997
47 PRIOR APPLICATION NUMBER: 60/070,440
48 PRIOR FILING DATE: January 5, 1998
49 PRIOR APPLICATION NUMBER: 60/074,086
50 PRIOR FILING DATE: February 9, 1998
51 PRIOR APPLICATION NUMBER: 60/074,092
52 PRIOR FILING DATE: February 9, 1998
53 PRIOR APPLICATION NUMBER: 60/075,945
54 PRIOR FILING DATE: February 25, 1998
55 PRIOR APPLICATION NUMBER: 60/112,850
56 PRIOR FILING DATE: December 16, 1998
57 PRIOR APPLICATION NUMBER: 60/113,296
58 PRIOR FILING DATE: December 22, 1998
59 PRIOR APPLICATION NUMBER: 60/146,222
60 PRIOR FILING DATE: July 28, 1999
61 PRIOR APPLICATION NUMBER: PCT/US96/19330
62 PRIOR FILING DATE: September 16, 1998
63 PRIOR APPLICATION NUMBER: PCT/US96/25108
64 PRIOR FILING DATE: December 1, 1998
65 PRIOR APPLICATION NUMBER: 09/216,021
66 PRIOR FILING DATE: December 16, 1998
67 PRIOR APPLICATION NUMBER: 09/218,517
68 PRIOR FILING DATE: December 22, 1998
69 PRIOR APPLICATION NUMBER: 09/254,311
70 PRIOR FILING DATE: March 3, 1999
71 PRIOR APPLICATION NUMBER: PCT/US99/12252
72 PRIOR FILING DATE: June 22, 1999

```

QY 1027 ACAAGCTTAGGTGATAGCCAGAGCAACATGTGAGAGTACACAGTGGGGCCC 1086
DB 636 ACAAGCTTAGGTGATAGCCAGAGCAACATGTGAGAGTACACAGTGGGGCCC 695
QY 1087 ACTCTGCGCACATCTCCCAAGAGCTGGCTCTTTACGCCCTATGAGATCTGGGTGAGG 1146
DB 696 ACTCTGCGCACATCTCCCAAGAGCTGGCTCTTTACGCCCTATGAGATCTGGGTGAGG 755
QY 1147 CCAACCAAGCGGCTGGGGCTGGCCGCTCCATGTACTCAGCGCTGAGATATCTGGATGTGG 1206
DB 756 CCAACCAAGCGGCTGGGGCTGGCCGCTCCATGTACTCAGCGCTGAGATATCTGGATGTGG 815
QY 1207 TGAACACGAGACCCCGCCGACGATGACGTCGAGCCGCTCGAGGGGCTGAGAGACGAGC 1266
DB 816 TGAACACGAGACCCCGCCGACGATGACGTCGAGCCGCTCGAGGGGCTGAGAGACGAGC 875
QY 1267 TGAAGCGTGGCTGGGTGTGGCCACCCGCGCTCAAGAGATTTCTCTTTCAAGCCAAATACC 1326
DB 876 TGAAGCGTGGCTGGGTGTGGCCACCCGCGCTCAAGAGATTTCTCTTTCAAGCCAAATACC 935
QY 1327 AGATCCGCTACCGAGTGAAGAGACATGTGACCTGGAAGGTGTGGAAGATGTAGAGCAAC 1386
DB 936 AGATCCGCTACCGAGTGAAGAGACATGTGACCTGGAAGGTGTGGAAGATGTAGAGCAAC 995
QY 1387 AGACCTCTGCGCTGGCGCTGGAGCCGAGCAACCGGCTGATCTTGTGCAAGTGGCT 1446
DB 996 AGACCTCTGCGCTGGCGCTGGAGCCGAGCAACCGGCTGATCTTGTGCAAGTGGCT 1055
QY 1447 GCAACCCCTTTGGCATCTATGTGCTCAAGAAAGCCGGGATCTGAGATGAGTGAAGCCACC 1506
DB 1056 GCAACCCCTTTGGCATCTATGTGCTCAAGAAAGCCGGGATCTGAGATGAGTGAAGCCACC 1115
QY 1507 CCAACCGGCTCTCACTCCCCGAGTGAAGGCCCCGGGCGGGGGGGGGGGGGGGGCAAC 1566
DB 1116 CCAACCGGCTCTCACTCCCCGAGTGAAGGCCCCGGGCGGGGGGGGGGGGGGGGCAAC 1175
QY 1567 CGCGGGGCGGAGAGCCGAGCTCGGGGCGGGTGCGGCGGAGCTCAAGCAGTTCTTGGGCT 1626
DB 1176 CGCGGGGCGGAGAGCCGAGCTCGGGGCGGGTGCGGCGGAGCTCAAGCAGTTCTTGGGCT 1235
QY 1627 GGGTCAAGAGACCGGCTACTGTCTCAACCTCAGCTTCGCGCTTACGACCAAGTGGGAG 1686
DB 1236 GGGTCAAGAGACCGGCTACTGTCTCAACCTCAGCTTCGCGCTTACGACCAAGTGGGAG 1295
QY 1687 CTTGATGACGAGTGTGCAACAGCCGCAACCAAGACAGGAGGATCTGCTCCGAGCA 1746
DB 1296 CTTGATGACGAGTGTGCAACAGCCGCAACCAAGACAGGAGGATCTGCTCCGAGCA 1355
QY 1747 GACGGGAGCAGGAGAGGTCTGCGCAGATAGCTGTAAGGGGCTCAGGCCACCTCCCTG 1806
DB 1356 GACGGGAGCAGGAGAGGTCTGCGCAGATAGCTGTAAGGGGCTCAGGCCACCTCCCTG 1415
QY 1807 CCAAGTGAAGACGCAAGGCGCAACCCAACTGAGGCGCACCTCTGTACCTCACTTCAGG 1866
DB 1416 CCAAGTGAAGACGCAAGGCGCAACCCAACTGAGGCGCACCTCTGTACCTCACTTCAGG 1475
QY 1867 GCACTGAGAGCACCTCTCAGAGAGGCTGGGCTGAGCTCCAGCCGCAATACAG 1926
DB 1476 GCACTGAGAGCACCTCTCAGAGAGGCTGGGCTGAGCTCCAGCCGCAATACAG 1535
QY 1927 CTTGATCCCAAGTGAAGCCCTTTGGGTGACCCCAATGGGTGTGTGTGTGTG 1986
DB 1536 CTTGATCCCAAGTGAAGCCCTTTGGGTGACCCCAATGGGTGTGTGTGTGTG 1595
QY 1987 AGGGTGTGTTGAGTTGCTTGAAGACCCCTGCGCAGGGCTGAGGAGGAGGAGTCAATTA 2046
DB 1596 AGGGTGTGTTGAGTTGCTTGAAGACCCCTGCGCAGGGCTGAGGAGGAGGAGTCAATTA 1555
QY 2047 CTCCTCATTAACCTTAAGGGGCGGCTCCAAAGA 2076
DB 1656 CTCCTCATTAACCTTAAGGGGCGGCTCCAAAGA 1685

RESULT 15
US-09-944-654-31
Sequence 31. Application US/09944654
Patent No. US20020142959A1
GENERAL INFORMATION:
APPLICANT: Baker, Kevin
APPLICANT: Botstein, David
APPLICANT: Baton, Dan
APPLICANT: Ferrara, Napoleone
APPLICANT: Filvaroff, Ellen
APPLICANT: Geriltsen, Mary
APPLICANT: Goddard, Audrey
APPLICANT: Grimaldi, Christopher
APPLICANT: Gurney, Austin
APPLICANT: Hillan, Kenneth
APPLICANT: KJavain, Ivar
APPLICANT: Napier, Mary
APPLICANT: Roy, Margaret
APPLICANT: Tumas, Daniel
APPLICANT: Wood, William
TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
FILE REFERENCE: P2548P1C1
CURRENT APPLICATION NUMBER: US/09/944,654
CURRENT FILING DATE: 2001-09-26
PRIOR APPLICATION NUMBER: 09/866,028
PRIOR FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: 60/067,411
PRIOR FILING DATE: December 3, 1997
PRIOR APPLICATION NUMBER: 60/069,334
PRIOR FILING DATE: December 11, 1997
PRIOR APPLICATION NUMBER: 60/069,335
PRIOR FILING DATE: December 11, 1997
PRIOR APPLICATION NUMBER: 60/069,278
PRIOR FILING DATE: December 11, 1997
PRIOR APPLICATION NUMBER: 60/069,425
PRIOR FILING DATE: December 12, 1997
PRIOR APPLICATION NUMBER: 60/069,696
PRIOR FILING DATE: December 16, 1997
PRIOR APPLICATION NUMBER: 60/069,694
PRIOR FILING DATE: December 16, 1997
PRIOR APPLICATION NUMBER: 60/069,702
PRIOR FILING DATE: December 16, 1997
PRIOR APPLICATION NUMBER: 60/069,870
PRIOR FILING DATE: December 17, 1997
PRIOR APPLICATION NUMBER: 60/069,873
PRIOR FILING DATE: December 17, 1997
PRIOR APPLICATION NUMBER: 60/068,017
PRIOR FILING DATE: December 18, 1997
PRIOR APPLICATION NUMBER: 60/070,440
PRIOR FILING DATE: January 5, 1998
PRIOR APPLICATION NUMBER: 60/074,086
PRIOR FILING DATE: February 9, 1998
PRIOR APPLICATION NUMBER: 60/074,092
PRIOR FILING DATE: February 9, 1998
PRIOR APPLICATION NUMBER: 60/075,945
PRIOR FILING DATE: February 25, 1998
PRIOR APPLICATION NUMBER: 60/112,850
PRIOR FILING DATE: December 16, 1998
PRIOR APPLICATION NUMBER: 60/113,296
PRIOR FILING DATE: December 22, 1998
PRIOR APPLICATION NUMBER: 60/146,222
PRIOR FILING DATE: July 28, 1999
PRIOR APPLICATION NUMBER: PCT/US98/19330
PRIOR FILING DATE: September 16, 1998
PRIOR APPLICATION NUMBER: PCT/US98/25108
PRIOR FILING DATE: December 1, 1998
PRIOR APPLICATION NUMBER: 09/216,021
PRIOR FILING DATE: December 16, 1998
PRIOR APPLICATION NUMBER: 09/218,517
PRIOR FILING DATE: December 22, 1998
PRIOR APPLICATION NUMBER: 09/254,311

Db 1656 CTCGCCATTACTAGGGCCCCCTCCAAAGA 1685

Search completed: February 25, 2005, 18:54:50
Job time : 1108 secs

This Page Blank (uspto)